Cardiovascular disease risk profiles

American Heart Journal

121, 293-298

DOI: 10.1016/0002-8703(91)90861-b

Citation Report

#	Article	IF	Citations
1	Non-invasive methods in cardiology. American Heart Journal, 1975, 90, 813.	2.7	0
2	The Stroke Preventive Effect in Elderly Hypertensives Cannot Fully be Explained by the Reduction in Office Blood Pressureâ€“Insights from the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Blood Pressure, 1992, 1, 168-172.	1.5	25
3	Triggering of Acute Myocardial Infarction by Heavy Physical Exertion -- Protection against Triggering by Regular Exertion. New England Journal of Medicine, 1993, 329, 1677-1683.	27.0	1,300
4	Dissent â€œConsider what a long way you've comeâ€•â€”The white queen to Alice. Journal of Clinical Epidemiology, 1993, 46, 1347-1350.	5.0	1
5	Healthy People 2000. Archives of Internal Medicine, 1993, 153, 1549.	3.8	18
6	Cardiovascular risk and attitudes to lifestyle: what do patients think?. BMJ: British Medical Journal, 1993, 306, 1657-1660.	2.3	59
7	Simulation of micropopulations in epidemiology: Tutorial 3. Simulation model evaluation methods. International Journal of Bio-medical Computing, 1994, 37, 195-204.	0.5	1
8	Simulation of micropopulations in epidemiology: Tutorial 2. Analytic forms of event probabilities. International Journal of Bio-medical Computing, 1994, 37, 139-149.	0.5	3
9	Modelling different strategies to prevent coronary heart disease in primary care. Journal of Clinical Epidemiology, 1994, 47, 993-1001.	5.0	6
10	Effect of pravastatin in the prevention of coronary heart disease in patients with primary hypercholesterolemia. Current Therapeutic Research, 1994, 55, 914-924.	1.2	2
11	Estimation of CHD risk in a French working population using a modified Framingham model. Journal of Clinical Epidemiology, 1994, 47, 1353-1364.	5.0	91
12	New models for predicting cardiovascular events. Journal of Clinical Epidemiology, 1994, 47, 583-592.	5.0	33
13	Simulation of micropopulations in epidemiology: Tutorial 4. Evaluations of simulation models. International Journal of Bio-medical Computing, 1995, 39, 219-229.	0.5	0
14	Assessment of cardiovascular risk factors in the elderly: The Framingham heart study. Statistics in Medicine, 1995, 14, 1745-1756.	1.6	31
15	Development of health risk appraisal functions in the presence of multiple indicators: The Framingham Study nursing home institutionalization model. Statistics in Medicine, 1995, 14, 1757-1770.	1.6	23
16	Relationship between habitual diet and blood glucose and lipids in non-insulin dependent diabetes (NIDDM). Nutrition Research, 1995, 15, 843-857.	2.9	9
17	Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet, The, 1995, 346, 1467-1471.	13.7	121
18	HEMOSTATIC FACTORS AS TRIGGERS OF CARDIOVASCULAR EVENTS. Cardiology Clinics, 1996, 14, 239-250.	2.2	17

#	Article	IF	Citations
19	Metabolic risk factors for cardiovascular disease in a working population: A retrospective cohort study. Journal of Clinical Epidemiology, 1996, 49, 267-271.	5.0	8
20	Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. Lancet, The, 1996, 347, 466-469.	13.7	5
22	Lipid-Lowering for Prevention of Coronary Heart Disease: What Policy Now?. Clinical Science, 1996, 91, 399-413.	4.3	75
23	DOWN-REGULATION OF ANGIOTENSIN II RECEPTORS IN HYPERTROPHIED HUMAN MYOCARDIUM. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 514-518.	1.9	13
24	Prospective Study of Vascular Events and Cerebral Perfusional Chang Following Transient Ischemic Attacks. Angiology, 1996, 47, 215-224.	1.8	5
25	Triggering Myocardial Infarction by Sexual Activity. JAMA - Journal of the American Medical Association, 1996, 275, 1405.	7.4	255
26	Early Detection of Undiagnosed Nonâ€"Insulin-Dependent Diabetes Mellitus. JAMA - Journal of the American Medical Association, 1996, 276, 1261.	7.4	24
27	Angina in patients with an active lifestyle. European Heart Journal, 1996, 17, 30-35.	2.2	19
28	Patient-Specific Decisions About Hormone Replacement Therapy in Postmenopausal Women. JAMA - Journal of the American Medical Association, 1997, 277, 1140.	7.4	176
29	The absolute risk as a guide to influence the treatment decision-making process in mild hypertension. Journal of Hypertension, 1997, 15, 217-219.	0.5	17
30	A Predictive Model of the Health Benefits and Cost Effectiveness of Celiprolol and Atenolol in Primary Prevention of Cardiovascular Disease in Hypertensive Patients. Pharmacoeconomics, 1997, 12, 384-408.	3.3	4
31	THE COST-EFFECTIVENESS OF INTENSIVE THERAPY FOR DIABETES MELLITUS. Endocrinology and Metabolism Clinics of North America, 1997, 26, 679-695.	3.2	38
32	The impact of cardiovascular disease on people with diabetes: the potential for prevention. Lancet, The, 1997, 350, S29-S32.	13.7	49
33	Baseline Risk Factors and their Association With Outcome in the West of Scotland Coronary Prevention Study. American Journal of Cardiology, 1997, 79, 756-762.	1.6	115
34	Treatment challenges in hypercholesterolemia. , 1998, 12, 325-337.		4
36	Prevention of Heart Disease: Is LDL Reduction the Outcome of Choice? No, There Is More. Value in Health, 1998, 1, 120-124.	0.3	4
37	Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation, 1998, 97, 1837-1847.	1.6	8,099
38	Impact of Multiple Risk Factor Profiles on Determining Cardiovascular Disease Risk. Preventive Medicine, 1998, 27, 1-9.	3.4	217

#	Article	IF	Citations
39	Can we afford to treat hyperlipidaemia as we should?. Atherosclerosis, 1998, 139, 1-5.	0.8	57
40	A systematic review of the use of computers in the management of hypertension. Journal of Epidemiology and Community Health, 1998, 52, 520-525.	3.7	39
41	Problems on the Pathway From Risk Assessment to Risk Reduction. Circulation, 1998, 97, 1761-1762.	1.6	36
42	Individualizing Aspirin Therapy for Prevention of Cardiovascular Events. JAMA - Journal of the American Medical Association, 1998, 280, 1949.	7.4	29
43	Lipids in Hypertensive Patients. American Journal of Hypertension, 1998, 11, 887-889.	2.0	2
44	Estimating the Benefits of Modifying Risk Factors of Cardiovascular Disease. Archives of Internal Medicine, 1998, 158, 655.	3.8	131
45	Maximizing the Cost-effectiveness of Lipid-Lowering Therapy. Archives of Internal Medicine, 1998, 158, 1977.	3.8	69
46	Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. QJM - Monthly Journal of the Association of Physicians, 1999, 92, 379-385.	0.5	40
47	Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women. Archives of Internal Medicine, 1999, 159, 1458.	3.8	56
48	Should smoking be an indication for lipidâ€lowering therapy?. Medical Journal of Australia, 1999, 170, 240-240.	1.7	2
49	Strategies for Individualizing Patient Decisions About Hormone Therapy. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1799-1802.	3.6	2
50	Aortic Pulse Wave Velocity as a Marker of Cardiovascular Risk in Hypertensive Patients. Hypertension, 1999, 33, 1111-1117.	2.7	1,335
51	Cortisol Effects on Body Mass, Blood Pressure, and Cholesterol in the General Population. Hypertension, 1999, 33, 1364-1368.	2.7	322
52	Adding Behavioral Therapy to Medication for Smoking Cessation. JAMA - Journal of the American Medical Association, 1999, 281, 1983.	7.4	6
53	Coronary Calcium Does Not Accurately Predict Near-Term Future Coronary Events in High-Risk Adults. Circulation, 1999, 99, 2633-2638.	1.6	344
55	Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart, 1999, 81, 40-46.	2.9	178
56	The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-94. Diabetic Medicine, 1999, 16, 35-40.	2.3	53
57	Developing risk stratification charts for diabetic and nondiabetic subjects. Diabetic Medicine, 1999, 16, 219-227.	2.3	49

#	Article	IF	Citations
58	Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic. Diabetic Medicine, 1999, 16, 697-701.	2.3	14
59	Lipoproteins, atherogenicity, age and risk of myocardial infarction. Australian and New Zealand Journal of Public Health, 1999, 23, 174-178.	1.8	4
60	Lipoproteins, atherogenicity, age and risk of myocardial infarction. Australian and New Zealand Journal of Public Health, 1999, 23, 441-442.	1.8	0
61	Sexual activity as a trigger for cardiovascular events: what is the risk?. American Journal of Cardiology, 1999, 84, 2-5.	1.6	43
62	Update on Hypertension Management. Geriatric Nursing, 1999, 20, 218-219.	1.9	5
63	SCREENING FOR CARDIOVASCULAR DISEASE. Medical Clinics of North America, 1999, 83, 1339-1373.	2.5	7
64	Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet, The, 1999, 353, 278-281.	13.7	94
65	Short-term reproducibility of total homocysteine determinations in stable renal transplant recipients. Transplantation Proceedings, 1999, 31, 2121-2123.	0.6	3
66	Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis, 1999, 142, 105-112.	0.8	383
67	A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ: British Medical Journal, 1999, 318, 101-105.	2.3	100
68	Can echocardiography identify mildly hypertensive patients at high risk, left untreated based on current guidelines?. Journal of Hypertension, 1999, 17, 817-824.	0.5	29
69	Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management. Journal of Hypertension, 1999, 17, 1641-1646.	0.5	1
70	Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients. Archives of Internal Medicine, 2000, 160, 1277.	3.8	56
71	Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ: British Medical Journal, 2000, 320, 671-676.	2.3	159
72	Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ: British Medical Journal, 2000, 321, 1322-1325.	2.3	138
73	The impact of multiple predictors on generalist physicians' care of underserved populations. American Journal of Public Health, 2000, 90, 1225-1228.	2.7	179
74	Stiffness of Carotid Artery Wall Material and Blood Pressure in Humans. Stroke, 2000, 31, 782-790.	2.0	126
75	Lipid-lowering drug therapy: more knowledge leads to more problems for composers of guidelines. Current Opinion in Lipidology, 2000, 11, 345-349.	2.7	4

#	Article	IF	Citations
76	A Comparison of Algorithms for Initiation of Lipid Lowering Therapy in Primary Prevention of Coronary Heart Disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2000, 7, 63-71.	2.8	26
77	Guidelines on preventing cardiovascular disease in clinical practice. BMJ: British Medical Journal, 2000, 320, 659-661.	2.3	103
78	Therapeutic studies and arterial stiffness in hypertension. Journal of Hypertension, 2000, 18, 1527-1535.	0.5	179
79	Debate: at what level of coronary heart disease risk should a statin be prescribed?. Current Opinion in Lipidology, 2000, 11, 357-361.	2.7	7
80	Cost-effectiveness of statins. Current Opinion in Lipidology, 2000, 11, 351-356.	2.7	9
81	At what level of coronary heart disease risk should a statin be prescribed?. Current Opinion in Lipidology, 2000, 11, 363-367.	2.7	12
82	South Asians with diabetes mellitus do not receive lipid-lowering treatment despite an identical calculated risk of coronary heart disease compared with Caucasians. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 77-80.	0.2	4
83	Ethnicity and risk factors for coronary heart disease in diabetes mellitus. Diabetes, Obesity and Metabolism, 2000, 2, 91-97.	4.4	28
84	The influence of cholesterol on mortality after transplantation is age dependent. Transplant International, 2000, 13, S117-S119.	1.6	1
85	Planning treatment of ischemic heart disease with partially observable Markov decision processes. Artificial Intelligence in Medicine, 2000, 18, 221-244.	6.5	107
86	Triggering of cardiac events by sexual activity: findings from a caseâ€“crossover analysis. American Journal of Cardiology, 2000, 86, 14-18.	1.6	52
87	Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents. Current Hypertension Reports, 2000, 2, 525-529.	3.5	5
88	The cost-effectiveness of different management strategies for Type I diabetes: a Swiss perspective. Diabetologia, 2000, 43, 13-26.	6.3	87
89	Estimating cardiovascular risk for primary prevention: outstanding questions for primary care. BMJ: British Medical Journal, 2000, 320, 702-704.	2.3	28
90	Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ: British Medical Journal, 2000, 320, 709-710.	2.3	191
91	Pharmacoeconomics: Economic Evaluation of Pharmaceuticals. , 0, , 573-601.		0
92	What is the optimal age for starting lipid lowering treatment? A mathematical model. BMJ: British Medical Journal, 2000, 320, 1134-1140.	2.3	34
93	Stent treatment for pseudocoarctation and refractory hypertension in an elderly patient with Takayasu's arteritis. Nephrology Dialysis Transplantation, 2000, 15, 536-538.	0.7	7

#	Article	IF	Citations
94	Cardiovascular risk in uraemic patientsâ€"is it fully explained by classical risk factors?. Nephrology Dialysis Transplantation, 2000, 15, 454-457.	0.7	135
95	Feasibility and Reliability of Ankle/Arm Blood Pressure Index in Preventive Medicine. Angiology, 2000, 51, 463-471.	1.8	10
96	Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet, The, 2000, 355, 675-687.	13.7	819
97	The global diabetes model: user friendly version 3.0. Diabetes Research and Clinical Practice, 2000, 50, S15-S46.	2.8	76
98	Outline of a diabetes disease management model: principles and applications. Diabetes Research and Clinical Practice, 2000, 50, S47-S56.	2.8	29
99	The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Research and Clinical Practice, 2000, 50, S57-S64.	2.8	54
100	Cholesterol-lowering therapy for smokers and non-smokers: a life-table analysis. Lancet, The, 2000, 356, 2004-2006.	13.7	10
101	Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet, The, 2000, 356, 2119-2125.	13.7	790
102	EFFICACY, SAFETY AND PATIENT ACCEPTANCE OF SILDENAFIL CITRATE AS TREATMENT FOR ERECTILE DYSFUNCTION. Journal of Urology, 2000, 164, 1192-1196.	0.4	121
103	Risks associated with renal dysfunction in patients in the coronary care unit. Journal of the American College of Cardiology, 2000, 36, 679-684.	2.8	226
104	Effect of computerized coronary heart disease risk assessment on the use of lipid-lowering therapy in general practice patients. Coronary Health Care, 2001, 5, 4-8.	0.4	6
105	Do conventional risk factors predict subclinical coronary artery disease? Results from the Prospective Army Coronary Calcium Project. American Heart Journal, 2001, 141, 463-468.	2.7	130
106	A computer simulation model for costâ€"effectiveness analysis of mass screening for Type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2001, 54, 37-42.	2.8	32
107	Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass. American Journal of Hypertension, 2001, 14, 357-363.	2.0	41
108	Clinical impact and health economic consequences of posttransplant type 2 diabetes mellitus. Transplantation Proceedings, 2001, 33, S32-S39.	0.6	7
109	Economics of drug treatment: for which patients is it costeffective to lower cholesterol?. Lancet, The, 2001, 358, 1251-1256.	13.7	25
110	Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. British Heart Journal, 2001, 85, 265-271.	2.1	347
111	Identification of Patients at High Cardiovascular Risk: a Critical Appraisal of Applicability of Statistical Risk Prediction Models. Methods of Information in Medicine, 2001, 40, 6-11.	1.2	2

#	Article	IF	Citations
112	Improved Hypertension Management and Control. Hypertension, 2001, 38, 827-832.	2.7	232
113	Elaboration and Formalization of Current Scientific Knowledge of Risks and Preventive Measures Illustrated by Colorectal Cancer. Methods of Information in Medicine, 2001, 40, 323-330.	1.2	1
114	Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?. Cardiovascular Research, 2001, 52, 199-207.	3.8	44
115	Intra-left atrial invasive mass extended via the pulmonary vein. British Heart Journal, 2001, 85, 271-271.	2.1	16
116	Laboratory-based Calculation of Coronary Heart Disease Risk. Clinical Chemistry, 2001, 47, 589-591.	3.2	6
117	Epidemiology of cardiovascular diseases in Europe. Public Health Nutrition, 2001, 4, 441-457.	2.2	76
118	Social inequalities and the burden of food-related ill-health. Public Health Nutrition, 2001, 4, 1371-3.	2.2	23
119	Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validation. Journal of Hypertension, 2001, 19, 691-696.	0.5	11
120	History of Treatment for Depression: Risk Factor for Myocardial Infarction in Hypertensive Patients. Psychosomatic Medicine, 2001, 63, 203-209.	2.0	48
121	Lipid-lowering trials in diabetes. Current Opinion in Lipidology, 2001, 12, 619-623.	2.7	10
122	Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors. Current Opinion in Nephrology and Hypertension, 2001, 10, 257-261.	2.0	185
123	A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ: British Medical Journal, 2001, 323, 75-81.	2.3	216
124	The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clinical Science, 2001, 101, 671-679.	4.3	734
125	The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clinical Science, 2001, 101, 671.	4.3	695
126	Quality improvement report: A laboratory based intervention to improve appropriateness of lipid tests and audit cholesterol lowering in primary care. BMJ: British Medical Journal, 2001, 323, 1224-1227.	2.3	17
127	Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clinical Endocrinology, 2001, 55, 209-216.	2.4	96
128	Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. Diabetes, Obesity and Metabolism, 2001, 3, 279-286.	4.4	17
129	Coronary heart disease risk assessment in diabetes mellitusâ€“â€¢a comparison of PROCAM and Framingham risk assessment functions. Diabetic Medicine, 2001, 18, 355-359.	2.3	40

#	Article	IF	Citations
130	Predicting CHD risk in patients with diabetes mellitus. Diabetic Medicine, 2001, 18, 341-344.	2.3	56
131	Modeling Medical Prognosis: Survival Analysis Techniques. Journal of Biomedical Informatics, 2001, 34, 428-439.	4.3	102
132	Family history and the risk of coronary heart disease: comparing predictive models. European Journal of Epidemiology, 2001, 17, 609-620.	5.7	12
133	Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. , 2001, 4, 269-279.		2
134	Cardiovascular Monitoring and Therapy for HIVâ€Infected Patients. Annals of the New York Academy of Sciences, 2001, 946, 236-273.	3.8	17
135	Usefulness of the Framingham risk score and body mass index to predict early coronary artery calcium in young adults (Muscatine Study). American Journal of Cardiology, 2001, 88, 509-515.	1.6	53
136	Global risk assessment in the presymptomatic patient. American Journal of Cardiology, 2001, 88, 17-22.	1.6	8
137	Cardiovascular Chronobiology: Do You Know What Time It Is?. Progress in Cardiovascular Nursing, 2001, 16, 65-79.	0.4	3
138	Randomized trial evaluating the framing of cardiovascular risk and its impact on blood pressure control [ISRCTN87597585]. BMC Health Services Research, 2001, 1, 10.	2.2	3
139	Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey. British Heart Journal, 2001, 86, 289-295.	2.1	7
140	Absolute, attributable, and relative risk in the management of coronary heart disease. British Heart Journal, 2001, 85, 491-492.	2.1	9
141	Shared decision making in hypertension: the impact of patient preferences on treatment choice. Family Practice, 2001, 18, 309-313.	1.9	70
142	Highly active antiretroviral therapy and coronary heart disease: the need for perspective. Aids, 2001, 15, S193-S201.	2.2	25
143	At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?. European Heart Journal, 2001, 22, 919-925.	2.2	57
144	Frozen-thawed embryo transfer: influence of clinical factors on implantation rate and risk of multiple conception. Human Reproduction, 2001, 16, 2316-2319.	0.9	94
145	Pulse Pressure, Arterial Stiffness, and Drug Treatment of Hypertension. Hypertension, 2001, 38, 914-921.	2.7	210
146	Comparative accuracy of cardiovascular risk prediction methods in primary care patients. British Heart Journal, 2001, 85, 37-43.	2.1	60
147	Methods for the prediction of coronary heart disease risk. British Heart Journal, 2001, 85, 489-490.	2.1	5

#	Article	IF	Citations
148	Ethnic Variation in C-Reactive Protein: UK Resident Indo-Asians Compared with Caucasians. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 139-141.	2.8	9
149	Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. BMJ: British Medical Journal, 2002, 324, 459-464.	2.3	58
150	Coronary Risk Versus Cardiovascular Risk for Treatment Decisions in Mild Hypertension. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 275-280.	2.8	1
151	A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. International Journal of Epidemiology, 2002, 31, 817-822.	1.9	159
152	Accuracy of Cardiovascular Risk Estimation for Primary Prevention in Patients Without Diabetes. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 183-190.	2.8	33
153	Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used?. British Heart Journal, 2002, 87, 423-427.	2.1	8
154	CARDIOVASCULAR AND CORONARY RISK ESTIMATION IN HYPERTENSION MANAGEMENT. British Heart Journal, 2002, 88, 306-312.	2.1	20
155	Predicting cardiovascular risk in the elderly in different European countries. European Heart Journal, 2002, 23, 294-300.	2.2	45
156	Diabetes, Insulin Resistance and Vascular Disease Among Indian Asians and Europeans. Seminars in Vascular Medicine, 2002, 2, 199-214.	2.1	19
157	Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2002, 287, 2542.	7.4	467
158	UKPDS 60. Stroke, 2002, 33, 1776-1781.	2.0	391
159	Aspirin Use and Counseling About Aspirin Among Patients With Diabetes. Diabetes Care, 2002, 25, 965-970.	8.6	38
160	The Anatomy of a Clinical Trial. Medical Principles and Practice, 2002, 11, 17-30.	2.4	3
161	Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. European Heart Journal, 2002, 23, 1922-1930.	2.2	42
162	Commentary: The prediction of coronary heart disease risk in individualsâ€" an imprecise science. International Journal of Epidemiology, 2002, 31, 822-824.	1.9	3
164	Comparative evaluation of the new Sheffield table and the modified joint British societies coronary risk prediction chart against a laboratory based risk score calculation. Postgraduate Medical Journal, 2002, 78, 269-272.	1.8	9
165	Heritability of Coronary Artery Calcium Quantity Measured by Electron Beam Computed Tomography in Asymptomatic Adults. Circulation, 2002, 106, 304-308.	1.6	121
166	Cardiovascular risk assessment in patients with retinal vein occlusion. British Journal of Ophthalmology, 2002, 86, 774-776.	3.9	66

#	Article	IF	Citations
167	Endothelial Damage, Asymmetric Dimethylarginine and Cardiovascular Risk in End-Stage Renal Disease. Blood Purification, 2002, 20, 469-472.	1.8	29
168	Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals. Blood Coagulation and Fibrinolysis, 2002, 13, 513-518.	1.0	33
169	Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods. Journal of Hypertension, 2002, 20, 2173-2182.	0.5	19
170	1999 WHO/ISH Guidelines applied to a 1999 MONICA sample from northern Sweden. Journal of Hypertension, 2002, 20, 29-35.	0.5	36
171	Pharmacotherapy of obesity: lessons from clinical trials in hypertension. Journal of Hypertension, 2002, 20, 1731-1735.	0.5	3
172	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 139-141.	1.5	16
173	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 183-190.	1.5	65
174	Cardiovascular risk evaluation. Journal of Hypertension, 2002, 20, 2127-2130.	0.5	12
175	Prognostic significance of arterial stiffness measurements in end-stage renal disease patients. Current Opinion in Nephrology and Hypertension, 2002, 11, 629-634.	2.0	63
176	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 275-280.	1.5	3
177	The Framingham prediction rule is not valid in a European population of treated hypertensive patients. Journal of Hypertension, 2002, 20, 1973-1980.	0.5	74
178	Mechanical factors predicting cardiovascular risk and drug treatment of hypertension. Journal of Hypertension, 2002, 20, 349-352.	0.5	3
179	Calculation of coronary risk in Type II diabetes: another cause for concern. Clinical Science, 2002, 103, 217-217.	4.3	1
180	Calculation of coronary risk in Type II diabetes: anothercause for concern: authorsâ€™ reply. Clinical Science, 2002, 103, 217-219.	4.3	1
181	Calculation of coronary risk in Type II diabetes: another cause for concern. Clinical Science, 2002, 103, 217.	4.3	0
182	Calculation of coronary risk in Type II diabetes: another cause for concern: author's reply. Clinical Science, 2002, 103, 217.	4.3	0
183	Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ: British Medical Journal, 2002, 325, 1271-1271.	2.3	119
184	Ethnic Differences in Total and HDL Cholesterol Concentrations: Caucasians Compared with Predominantly Punjabi Sikh Indo-Asians. Annals of Clinical Biochemistry, 2002, 39, 609-611.	1.6	23

#	Article	IF	Citations
185	Should we treat high-normal blood pressure?. Journal of Hypertension, 2002, 20, 2057-2062.	0.5	8
186	Some Thoughts on the Adult Treatment Panel III Report. Preventive Cardiology, 2002, 5, 87-91.	1.1	3
187	Bedside quantification of atherosclerosis severity for cardiovascular risk stratification: a prospective cohort study. Journal of the American College of Cardiology, 2002, 39, 702-709.	2.8	10
188	Homocysteine is the only plasma thiol associated with carotid artery remodeling. Atherosclerosis, 2002, 165, 167-174.	0.8	25
189	Cardiovascular risk assessment using ultrasound: the value of arterial wall changes including the presence, severity and character of plaques. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 367-370.	0.3	21
190	EvaluaciÃ³n del riesgo cardiovascular global en la prÃ¡ctica clÃ¬nica. EMC - Tratado De Medicina, 2002, 6, 1-3.	0.0	0
191	Implementing national guidelines on risk prediction and primary prevention of coronary heart disease in a cardiology information system. , 0, , .		6
192	HDL in risk prediction and its direct and indirect involvement in atherogenesis. Atherosclerosis Supplements, 2002, 3, 3-12.	1.2	19
193	Insulin resistance and atherosclerosis in diabetes mellitus. Metabolism: Clinical and Experimental, 2002, 51, 941-948.	3.4	7
194	A comparison of the Framingham and European society of cardiology coronary heart disease risk prediction models in the normative aging study. American Heart Journal, 2002, 144, 95-100.	2.7	55
195	Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. American Heart Journal, 2002, 144, 226-232.	2.7	195
198	Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 821-826.	0.5	15
199	HDL-cholesterol and cardiac disease: which table to use?. Annals of Clinical Biochemistry, 2002, 39, 12-21.	1.6	3
200	Effects of Sirolimus on Lipids in Renal Allograft Recipients: An Analysis Using the Framingham Risk Model. American Journal of Transplantation, 2002, 2, 551-559.	4.7	83
202	Cardiovascular risk management in primary care. Diabetes, Obesity and Metabolism, 2002, 4, 362-367.	4.4	1
203	Reproducibility of individualized coronary heart disease risk calculations in patients with diabetes mellitus. Diabetic Medicine, 2002, 19, 514-517.	2.3	3
204	High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. International Journal of Impotence Research, 2002, 14, 533-538.	1.8	52
205	Archimedes: A trial-validated model of diabetes. Diabetes Care, 2003, 26, 3093-3101.	8.6	229

#	Article	IF	Citations
207	Sexual activity and cardiovascular disease. American Journal of Cardiology, 2003, 92, 3-8.	1.6	18
208	A practical approach to risk assessment to prevent coronary artery disease and its complications. American Journal of Cardiology, 2003, 92, 19-26.	1.6	72
209	The evaluation of disease prevention and treatment using simulation models. European Journal of Operational Research, 2003, 150, 53-66.	5.7	43
210	Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Journal of Internal Medicine, 2003, 253, 81-91.	6.0	23
211	Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. Journal of Internal Medicine, 2003, 253, 553-562.	6.0	42
212	Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney International, 2003, 63, 1852-1860.	5.2	446
213	Comparison of current guidelines for primary prevention of coronary heart disease. Journal of General Internal Medicine, 2003, 18, 190-195.	2.6	30
214	Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Medicine, 2003, 4, 1-10.	2.2	114
215	Undertreatment of hypercholesterolaemia: a population-based study. British Journal of Clinical Pharmacology, 2003, 55, 389-397.	2.4	37
216	Framingham-based tools to calculate the global risk of coronary heart disease. Journal of General Internal Medicine, 2003, 18, 1039-1052.	2.6	149
217	Tratamiento farmacolÃ³gico del riesgo cardiovascular metabÃ³lico. Medicine, 2003, 8, 6382-6395.	0.0	0
219	Efecto del tratamiento antihipertensivo con irbesartÃ¡n sobre el riesgo cardiovascular absoluto. Revista Clinica Espanola, 2003, 203, 183-188.	0.6	2
220	The prevalence and severity of coronaryartery calcification on coronary arterycomputed tomography in black and white subjects. Journal of the American College of Cardiology, 2003, 41, 39-44.	2.8	153
221	Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. American Journal of Medicine, 2003, 114, 485-494.	1.5	44
222	Should the Patient With Coronary Artery Disease Use Sildenafil?. Preventive Cardiology, 2003, 6, 161-165.	1.1	12
223	Why target sedentary adults in primary health care? Baseline results from the Waikato Heart, Health, and Activity Study. Preventive Medicine, 2003, 37, 342-348.	3.4	31
224	Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet, The, 2003, 361, 717-725.	13.7	499
225	Measurement of plasma small-dense LDL concentration by a simplified ultracentrifugation procedure and immunoassay of apolipoprotein B. Clinica Chimica Acta, 2003, 334, 95-106.	1.1	22

#	Article	IF	Citations
226	Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field. Health Policy, 2003, 64, 311-324.	3.0	15
227	A note on the effect of unemployment on mortality. Journal of Health Economics, 2003, 22, 505-518.	2.7	184
228	Youth characteristics and contextual variables influencing physical activity in young adolescents of parents with premature coronary heart disease. Journal of Pediatric Nursing, 2003, 18, 159-168.	1.5	11
229	Effectiveness of counselling patients on physical activity in general practice: cluster randomised controlled trial. BMJ: British Medical Journal, 2003, 326, 793-793.	2.3	445
230	Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. American Journal of Hypertension, 2003, 16, 11-20.	2.0	127
231	Framingham risk function overestimates risk of coronary heart disease in men and women from Germanyâ€"results from the MONICA Augsburg and the PROCAM cohorts. European Heart Journal, 2003, 24, 937-945.	2.2	301
232	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1772-1778.	1.6	1,562
233	Financial and Health Costs of Uncontrolled Blood Pressure in the United Kingdom. Pharmacoeconomics, 2003, 21, 33-41.	3.3	30
234	Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting. Pharmacoeconomics, 2003, 21, 61-74.	3.3	18
235	Transductive support vector machines and applications in bioinformatics for promoter recognition. , 2003, , .		27
236	Blood Pressure Indices and Cardiovascular Disease in the Asia Pacific Region. Hypertension, 2003, 42, 69-75.	2.7	155
237	Major Risk Factors for Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2003, 290, 947.	7.4	97
238	The applicability of the Framingham coronary heart disease prediction function to black and minority ethnic groups in the UK. British Heart Journal, 2003, 89, 785-786.	2.1	20
239	Detecting Occult Coronary Disease in a High-Risk Asymptomatic Population. Circulation, 2003, 107, 702-707.	1.6	50
240	Low-Density Lipoprotein Subfractions and Cardiovascular Risk in Hypertension. Hypertension, 2003, 41, 528-533.	2.7	31
241	Risk Factors for Coronary Heart Disease in Patients Treated for Human Immunodeficiency Virus Infection Compared with the General Population. Clinical Infectious Diseases, 2003, 37, 292-298.	5.8	364
242	Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score. Circulation, 2003, 108, 161-165.	1.6	240
243	Sex, Diabetes, and Stroke After Carotid Endarterectomy. Diabetes Care, 2003, 26, 1641-1641.	8.6	36

#	Article	IF	Citations
244	Accuracy of Cardiovascular Risk Estimation. Clinical Chemistry, 2003, 49, 706-707.	3.2	0
245	Management of Uncontrolled Hypertension in a Nurse-Led Clinic Compared With Conventional Care for Patients with Type 2 Diabetes. Diabetes Care, 2003, 26, 2256-2260.	8.6	134
246	Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ: British Medical Journal, 2003, 327, 1267-0.	2.3	415
248	Cardiovascular disease prediction using support vector machines. , 0, , .		12
249	Carotid intimaâ€“media thickness and carotid and/or iliofemoral plaques. Journal of Hypertension, 2003, 21, 739-746.	0.5	19
250	DESIGN AND DEVELOPMENT OF A CORONARY HEART DISEASE DECISION SUPPORT TOOL. International Journal of Technology Assessment in Health Care, 2003, 19, 555-558.	0.5	2
251	The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension. Journal of Hypertension, 2003, 21, 1753-1759.	0.5	70
252	Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. Aids, 2003, 17, S96-S122.	2.2	31
253	A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension. Blood Coagulation and Fibrinolysis, 2003, 14, 425-431.	1.0	59
254	Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. Journal of Hypertension, 2003, 21, 1089-1095.	0.5	14
255	Population-based cardiovascular risk prediction. European Heart Journal, 2003, 24, 1796.	2.2	0
256	The Discrepancy between Observational Studies and Randomized Trials of Menopausal Hormone Therapy: Did Expectations Shape Experience?. Annals of Internal Medicine, 2003, 139, 923.	3.9	46
257	Untreated hypertension among Australian adults: the 1999â€“2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Medical Journal of Australia, 2003, 179, 135-139.	1.7	117
258	Cardiovascular risk among urban Aboriginal people. Medical Journal of Australia, 2003, 179, 557-557.	1.7	0
259	Cardiovascular risk among urban Aboriginal people. Medical Journal of Australia, 2003, 179, 557-557.	1.7	3
260	Complications of type 2 diabetes. Practice Nursing, 2003, 14, 455-458.	0.1	1
261	Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. Medical Journal of Australia, 2003, 178, 113-116.	1.7	48
262	Impact of Electron Beam Tomography, With or Without Case Management, on Motivation, Behavioral Change, and Cardiovascular Risk Profile. JAMA - Journal of the American Medical Association, 2003, 289, 2215.	7.4	163

#	Article	IF	Citations
263	Plasma von Willebrand Factor and the Development of the Metabolic Syndrome in Patients with Hypertension. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5377-5381.	3.6	33
264	Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease. Annals of the Rheumatic Diseases, 2004, 63, 420-425.	0.9	16
265	Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK. Quality and Safety in Health Care, 2004, 13, 191-197.	2.5	50
266	Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes. Diabetes Care, 2004, 27, 201-207.	8.6	254
267	Updated Risk Factor Values and the Ability of the Multivariable Risk Score to Predict Coronary Heart Disease. American Journal of Epidemiology, 2004, 160, 707-716.	3.4	42
268	How general practitioners perceive and grade the cardiovascular risk of their patients. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 233-238.	2.8	15
269	Lipid levels and the use of lipid-lowering agents in England and Scotland. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 484-488.	2.8	6
270	Predictive Value for the Chinese Population of the Framingham CHD Risk Assessment Tool Compared With the Chinese Multi-provincial Cohort Study. JAMA - Journal of the American Medical Association, 2004, 291, 2591.	7.4	560
271	Aortic pulse wave velocity as an independent marker of coronary artery disease. Blood Pressure, 2004, 13, 369-375.	1.5	51
272	Observations, predictions and decisions--assessing cardiovascular risk assessment. International Journal of Epidemiology, 2004, 33, 235-239.	1.9	36
273	Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). Current Medical Research and Opinion, 2004, 20, 765-772.	1.9	13
274	Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate.. Diabetes, Obesity and Metabolism, 2004, 6, 299-307.	4.4	5
275	Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine, 2004, 21, 238-245.	2.3	59
276	Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabetic Medicine, 2004, 21, 318-323.	2.3	85
277	General description and methods. Diabetic Medicine, 2004, 21, 20-21.	2.3	0
279	What's new in the journals?. Diabetic Medicine, 2004, 21, 2-6.	2.3	7
281	The Polypill and Type 2 diabetes. Diabetic Medicine, 2004, 21, 8-10.	2.3	14
282	Structured education programmes and Type 2 diabetes. Diabetic Medicine, 2004, 21, 10-12.	2.3	6

#	Article	IF	Citations
283	End-stage renal failure and management of diabetes. Diabetic Medicine, 2004, 21, 12-14.	2.3	11
284	Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabetic Medicine, 2004, 21, 15-18.	2.3	14
285	Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of Type 2 diabetes. Diabetic Medicine, 2004, 21, 18-20.	2.3	25
286	Metaâ€analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. British Journal of Clinical Pharmacology, 2004, 57, 640-651.	2.4	259
287	Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk. Clinical Endocrinology, 2004, 61, 387-393.	2.4	34
288	Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with type 2 diabetes and additional atherogenic risk factors. Journal of General Internal Medicine, 2004, 19, 1181-1191.	2.6	31
289	Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?. Eye, 2004, 18, 821-825.	2.1	14
290	Should pulse pressure become part of the Framingham risk score?. Journal of Human Hypertension, 2004, 18, 279-286.	2.2	28
291	Adult Obesity and the Burden of Disability throughout Life. Obesity, 2004, 12, 1145-1151.	4.0	103
292	ED: Efficacy and Safety of Daily Tadalafil in Men with Erectile Dysfunction Previously Unresponsive to Onâ€demand Tadalafil. Journal of Sexual Medicine, 2004, 1, 292-300.	0.6	120
293	HMG-CoA Reductase Inhibitors and the Risk of Vertebral Fracture. Journal of Bone and Mineral Research, 2004, 19, 1525-1530.	2.8	58
294	Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 625-30.	2.9	101
295	Cardiovascular risk factors in Turkish immigrants with type 2 diabetes mellitus: Comparison with Dutch patients. European Journal of Epidemiology, 2004, 19, 923-929.	5.7	10
296	A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 2004, 47, 1747-1759.	6.3	516
298	Perceptions of cardiovascular risk among patients with hypertension or diabetes. Patient Education and Counseling, 2004, 52, 47-53.	2.2	101
299	The development and preliminary evaluation of a decision aid based on decision analysis for two treatment conditions: Benign Prostatic Hyperplasia and Hypertension. Patient Education and Counseling, 2004, 52, 209-215.	2.2	9
300	Decision analysis for newly diagnosed hypertensive patients: a qualitative investigation. Patient Education and Counseling, 2004, 53, 197-203.	2.2	12
301	SAS macros for confidence interval estimation for CHD risk prediction by different survival models. Computational Statistics and Data Analysis, 2004, 46, 571-592.	1.2	3

#	Article	IF	Citations
302	Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. Pharmacoeconomics Italian Research Articles, 2004, 6, 81-93.	0.2	15
303	Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. British Journal of Rheumatology, 2004, 43, 924-929.	2.3	161
304	Current lipid management and low cholesterol goal attainment in common daily practice in Spain. Pharmacoeconomics, 2004, 22, 1-12.	3.3	52
305	Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics, 2004, 22, 37-48.	3.3	21
306	Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal. Pharmacoeconomics, 2004, 22, 49-61.	3.3	26
307	Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective. Pharmacoeconomics, 2004, 22, 321-341.	3.3	25
308	Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. Current Medical Research and Opinion, 2004, 20, 811-818.	1.9	24
309	Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scandinavian Journal of Rheumatology, 2004, 33, 293-299.	1.1	53
310	Erectile Dysfunction and Cardiovascular Disease. Mayo Clinic Proceedings, 2004, 79, 782-794.	3.0	24
311	Aterosclerosis: Â¿mantequilla en las arterias?. EMC - Tratado De Medicina, 2004, 8, 1-6.	0.0	0
313	Beyond hypertension*Toward guidelines for cardiovascular risk reduction*. American Journal of Hypertension, 2004, 17, 1068-1074.	2.0	23
315	Cardiovascular disease: different strategies for primary and secondary prevention?. Heart, 2004, 90, 1217-1223.	2.9	73
316	Hypertension Treatment and Control in Five European Countries, Canada, and the United States. Hypertension, 2004, 43, 10-17.	2.7	944
317	Recognition of patients with cardiovascular disease by artificial neural networks. Annals of Medicine, 2004, 36, 630-640.	3.8	19
318	Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinology and Metabolism Clinics of North America, 2004, 33, 467-481.	3.2	49
319	Beyond hypertension toward guidelines for cardiovascular risk reduction. American Journal of Hypertension, 2004, 17, 1068-1074.	2.0	48
320	Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. American Journal of Medicine, 2004, 116, 621-629.	1.5	19
321	Heart to Heart: A Computerized Decision Aid for Assessment of Coronary Heart Disease Risk and the Impact of Risk-Reduction Interventions for Primary Prevention. Preventive Cardiology, 2004, 7, 26-33.	1.1	23

#	Article	IF	Citations
322	Trends in Self-reported Multiple Cardiovascular Disease Risk Factors Among Adults in the United States, 1991-1999. Archives of Internal Medicine, 2004, 164, 181.	3.8	76
323	The Relationship Between Health Risks and Work Productivity. Journal of Occupational and Environmental Medicine, 2004, 46, 737-745.	1.7	276
324	Statin policy and target populations: evidence-based or evidence-biased?. Current Opinion in Lipidology, 2004, 15, 381-386.	2.7	2
325	Is there disparity between risk and incidence of cardiovascular disease after liver transplant?. Transplantation, 2004, 77, 93-99.	1.0	95
326	Change in Health Risks and Work Productivity Over Time. Journal of Occupational and Environmental Medicine, 2004, 46, 746-754.	1.7	117
327	Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. European Heart Journal, 2004, 25, 484-491.	2.2	190
328	Residual coronary risk in men aged 50â€“59 years treated for hypertension and hyperlipidaemia in the population. Journal of Hypertension, 2004, 22, 415-423.	0.5	25
329	Erectile Dysfunction and Cardiovascular Disease. Mayo Clinic Proceedings, 2004, 79, 782-794.	3.0	54
330	Cardiovascular risk factors and endothelial dysfunction. Clinical Science, 2004, 107, 609-615.	4.3	31
331	Varieties of Causal Intervention. Lecture Notes in Computer Science, 2004, , 322-331.	1.3	45
332	Chronic Renal Dysfunction as an Independent Risk Factor for the Development of Cardiovascular Disease. Cardiology in Review, 2005, 13, 98-107.	1.4	41
333	May subclinical arterial disease help to better detect and treat high-risk asymptomatic individuals?. Journal of Hypertension, 2005, 23, 1939-1945.	0.5	38
334	Arguing about the evidence: readers, writers and inscription devices in coronary heart disease risk assessment. Sociology of Health and Illness, 2005, 27, 780-801.	2.1	26
335	Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes, Obesity and Metabolism, 2005, 7, 254-262.	4.4	64
336	Predicting vascular risk in Type 1 diabetes: stratification in a hospital based population in Scotland. Diabetic Medicine, 2005, 22, 164-171.	2.3	15
337	Regarding the use of HOMA to aid drug selection. Diabetic Medicine, 2005, 22, 225-225.	2.3	0
338	Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone. Diabetic Medicine, 2005, 22, 225-226.	2.3	1
339	A deletion polymorphism of the alpha2B-adrenergic receptor gene is not associated with late complications in Type 1 diabetic patients. Diabetic Medicine, 2005, 22, 226-228.	2.3	3

#	Article	IF	Citations
340	Framingham risk equations underestimate coronary heart disease risk in diabetes. Diabetic Medicine, 2005, 22, 228-228.	2.3	15
341	Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabetic Medicine, 2005, 22, 554-562.	2.3	156
342	Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden. International Journal of Clinical Practice, 2005, 59, 1143-1152.	1.7	16
343	Intraclass correlation coefficients from three cluster randomised controlled trials in primary and residential health care. Australian and New Zealand Journal of Public Health, 2005, 29, 461-467.	1.8	41
344	Prevalence and treatment of cardiovascular disease and traditional risk factors in Australian adults with renal insufficiency. Nephrology, 2005, 10, 40-47.	1.6	15
345	Evaluating national guidelines for prevention of cardiovascular disease in primary care. Journal of Evaluation in Clinical Practice, 2005, 11, 452-461.	1.8	11
346	The effect of atorvastatin on serum lipoproteins in acromegaly. Clinical Endocrinology, 2005, 62, 650-655.	2.4	12
347	Factors predicting the development of metabolic syndrome and type II diabetes against a background of hypertension. European Journal of Clinical Investigation, 2005, 35, 324-329.	3.4	21
348	Obesity-related correlation between C-reactive protein and the calculated 10-y Framingham Coronary Heart Disease Risk Score. International Journal of Obesity, 2005, 29, 772-777.	3.4	21
349	Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. Journal of Human Hypertension, 2005, 19, 301-307.	2.2	33
350	Changing from CHD to CVD risk-based guidelines for the management of mild uncomplicated hypertension in different ethnic groups: implications for primary care. Journal of Human Hypertension, 2005, 19, 321-324.	2.2	2
351	The impact of implementing national hypertension guidelines on prevalence and workload in primary care: a population-based survey of older people. Journal of Human Hypertension, 2005, 19, 683-689.	2.2	4
352	Relation Between Coronary Artery Calcium and Incident Chest Pain in a Community-Dwelling Screening Population. American Journal of Cardiology, 2005, 96, 61-63.	1.6	5
353	Evaluation of Acute Risk for Myocardial Infarction in Men Treated With Sildenafil Citrate. American Journal of Cardiology, 2005, 96, 443-446.	1.6	58
354	Sexual Activity and Cardiac Risk. American Journal of Cardiology, 2005, 96, 24-28.	1.6	35
355	Comparison of Efficacy, Safety, and Tolerability of Onâ€Demand Tadalafil and Daily Dosed Tadalafil for the Treatment of Erectile Dysfunction. Journal of Sexual Medicine, 2005, 2, 415-427.	0.6	98
356	Some highlights of a 47ï¿½year career in research. Cellular and Molecular Life Sciences, 2005, 62, 1-3.	5.4	30
357	Validation of a decision model for preventive pharmacological strategies in postmenopausal women. European Journal of Epidemiology, 2005, 20, 89-101.	5.7	8

#	Article	IF	Citations
358	The Blood Pressure "Uncertainty Range" â€“ a pragmatic approach to overcome current diagnostic uncertainties (II). Current Controlled Trials in Cardiovascular Medicine, 2005, 6, 5.	1.5	19
360	Is the Framingham coronary heart disease absolute risk function applicable to Aboriginal people?. Medical Journal of Australia, 2005, 182, 66-69.	1.7	91
361	By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart, 2005, 92, 307-310.	2.9	69
362	Large artery stiffness and pulse wave reflection: Results of a populationâ€based study. Blood Pressure, 2005, 14, 45-52.	1.5	45
363	Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa. Circulation, 2005, 112, 3569-3576.	1.6	123
364	Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart, 2005, 93, 172-176.	2.9	513
365	Building prediction models for coronary heart disease by synthesizing multiple longitudinal research findings. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 459-464.	2.8	12
367	The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed. Cmaj, 2005, 172, 1027-1031.	2.0	16
368	Multi-targeted and Aggressive Treatment of Patients with Type 2 Diabetes at High Risk: What Are We Waiting For?. Hormone and Metabolic Research, 2005, 37, 76-82.	1.5	18
369	Large Artery Stiffness and Antihypertensive Agents. Current Pharmaceutical Design, 2005, 11, 3317-3326.	1.9	21
370	Prevalence of cardiovascular diseases and associated risk factors in a rural black population of South Africa. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 347-354.	2.8	110
371	Aspirin for everyone older than 50?. BMJ: British Medical Journal, 2005, 330, 1440-1441.	2.3	40
372	Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. Journal of Public Health, 2005, 27, 93-100.	1.8	125
373	Specialist Nurse-Led Clinics to Improve Control of Hypertension and Hyperlipidemia in Diabetes: Economic analysis of the SPLINT trial. Diabetes Care, 2005, 28, 40-46.	8.6	59
374	Predicting coronary risk in UK South Asians: an adjustment method for Framingham-based tools. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 46-51.	2.8	15
375	Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. International Journal of Epidemiology, 2005, 34, 413-421.	1.9	187
376	Risk Modeling: Applying Evidence-Based Risk Assessment in Oncology Nursing Practice. Oncology Nursing Forum, 2005, 32, 49-56.	1.2	8
377	Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk. Heart, 2005, 92, 741-745.	2.9	14

#	Article	IF	Citations
378	Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. BMJ: British Medical Journal, 2005, 331, 869.	2.3	115
379	Control of hypertension in patients at high risk of cardiovascular disease. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 581-588.	0.5	12
380	EvaluaciÃ³n del riesgo cardiovascular y nuevos factores de riesgo de aterosclerosis. Hipertension, 2005, 22, 195-203.	0.0	2
381	Epidemiology of the metabolic syndrome in 2045 French military personnel (EPIMIL study). Diabetes and Metabolism, 2005, 31, 353-359.	2.9	40
382	Correlation of parentsâ€™ longevity with carotid intimaâ€“media thickness in patients attending a Lipid Clinic. Atherosclerosis, 2005, 179, 111-117.	0.8	7
383	Projected coronary heart disease risk benefit with ezetimibe. Atherosclerosis, 2005, 179, 375-378.	0.8	10
385	Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 529-535.	3.3	67
386	Cost Effectiveness of Treating Low HDL-Cholesterol in the Primary Prevention of Coronary Heart Disease. Pharmacoeconomics, 2005, 23, 133-141.	3.3	28
387	A Novel Molecule of the Angiotensin II Receptor Blocker Class. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 79-89.	2.2	1
388	What Should We Expect from the Next Guidelines on Hypertension?. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 199-202.	2.2	0
389	How to Manage Metabolic Syndrome. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 231-238.	2.2	2
390	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart, 2005, 91, v1-v52.	2.9	731
391	A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 442-450.	2.8	61
392	Differences between statins on clinical endpoints: a population-based cohort study. Current Medical Research and Opinion, 2005, 21, 1461-1468.	1.9	20
393	Effect of antibiotics as cholesterol-lowering agents. Metabolism: Clinical and Experimental, 2005, 54, 103-112.	3.4	26
394	A risk score predicted coronary heart disease and stroke in a Chinese cohort. Journal of Clinical Epidemiology, 2005, 58, 951-958.	5.0	74
395	Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-label pilot study. Current Therapeutic Research, 2005, 66, 613-629.	1.2	3
396	Brisk walking, fitness, and cardiovascular risk: A randomized controlled trial in primary care. Preventive Medicine, 2005, 41, 622-628.	3.4	126

#	Article	IF	Citations
397	Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 426-440.	2.6	47
398	Large-artery stiffness, hypertension and cardiovascular risk in older patients. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 450-455.	3.3	97
399	Coronary Calcium Independently Predicts Incident Premature Coronary Heart Disease Over Measured Cardiovascular Risk Factors. Journal of the American College of Cardiology, 2005, 46, 807-814.	2.8	580
400	Towards Consistency Between Guidelines and Policy: Lipid Managementâ€"2005. Heart Lung and Circulation, 2005, 14, 237-238.	0.4	15
401	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Heart Lung and Circulation, 2005, 14, 275-291.	0.4	115
402	NFI: a neuro-fuzzy inference method for transductive reasoning. IEEE Transactions on Fuzzy Systems, 2005, 13, 799-808.	9.8	44
403	Management of hypertension and hypercholesterolaemia in primary care in the Netherlands. Current Medical Research and Opinion, 2005, 21, 839-848.	1.9	15
404	Current treatment strategies for obesity. Therapy: Open Access in Clinical Medicine, 2005, 2, 955-967.	0.2	0
405	Evolving Intelligent Systems: Methods, Learning, & Applications. , 2006, , .		38
406	Drug Costs Associated with Non-Adherence to Cholesterol Management Guidelines for Primary Prevention of Cardiovascular Disease in an Elderly Population. Drugs and Aging, 2006, 23, 733-741.	2.7	7
407	Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus. Pharmacoeconomics, 2006, 24, 425-441.	3.3	42
408	Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada. Pharmacoeconomics, 2006, 24, 815-830.	3.3	18
411	Controversies in stable coronary artery disease. Lancet, The, 2006, 367, 69-78.	13.7	56
412	Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis, 2006, 186, 345-353.	0.8	84
413	Relationship between premenopausal dietary intake and postmenopausal subclinical atherosclerosis. Atherosclerosis, 2006, 186, 420-427.	0.8	18
414	Stress Echocardiography in the Identification of Left Anterior Descending Coronary Artery Disease in Patients With Inferior Myocardial Infarction and a Positive Exercise Electrocardiography Result. Revista Espanola De Cardiologia (English Ed), 2006, 59, 545-552.	0.6	1
415	Cardiovascular Risk in Patients with HIV Infection. Drugs, 2006, 66, 1971-1987.	10.9	54
416	Coronary Heart Disease and Stroke with Aromatase Inhibitor, Tamoxifen, and Menopausal Hormone Therapy Use. Clinical Breast Cancer, 2006, 6, S58-S64.	2.4	26

#	Article	IF	Citations
418	Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart, 2006, 92, 1752-1759.	2.9	359
419	CardioVision 2020. American Journal of Preventive Medicine, 2006, 30, 137-143.	3.0	11
420	Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. American Heart Journal, 2006, 152, 997-1003.	2.7	49
421	Conventional, Emerging, Heredity, Lifestyle, and Psychosocial Coronary Risk Factors: Relationships to Subclinical Atherosclerosis. Preventive Cardiology, 2006, 9, 25-32.	1.1	21
422	Incremental Risk-Factor Reduction Improves Overall Cardiovascular Benefit: Is It Time to Abandon the Silos?. Journal of Clinical Hypertension, 2006, 8, 686-688.	2.0	5
423	Current possibilities for detecting high risk of cardiovascular disease. International Journal of Cardiology, 2006, 110, 146-152.	1.7	10
424	Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year periodâ€"a pilot study. Public Health, 2006, 120, 1140-1148.	2.9	23
425	ConsÃ©quences cliniques etÂÃ©pidÃ©miologiques duÂvieillissement artÃ©riel. Revue De Medecine Interne, 2006, 27, S46.	1.0	0
426	Cardiovascular prevention in the Hartslag Limburg project: Effects of a high-risk approach on behavioral risk factors in a general practice population. Preventive Medicine, 2006, 43, 372-378.	3.4	17
427	Cytoprotective Gene HO-1 and Chronic Rejection in Heart Transplantation. Transplantation Proceedings, 2006, 38, 3259-3262.	0.6	20
429	Use of orlistat in obese, dyslipidemic patients. Future Lipidology, 2006, 1, 267-273.	0.5	1
430	Secular Changes in Shuttle-Run Performance: A 23-Year Retrospective Comparison of 9- to 11-Year-Old Children. Pediatric Exercise Science, 2006, 18, 364-373.	1.0	7
431	Reductionism and holism in coronary heart disease and cardiac nursing. British Journal of Nursing, 2006, 15, 1017-1020.	0.7	1
432	Acarbose for the Prevention of Diabetes, Hypertension, and Cardiovascular Disease in Subjects with Impaired Glucose Tolerance: The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (Stop-Niddm) Trial. Endocrine Practice, 2006, 12, 25-30.	2.1	95
433	Antihypertensive therapy and cerebrovascular protection. Current Opinion in Nephrology and Hypertension, 2006, 15, 498-504.	2.0	9
434	Classification of Aortic Stiffness From Eigendecomposition of the Digital Volume Pulse Waveform. , 0, , .		1
435	Risk prediction and finding new independent prognostic factors. Journal of Hypertension, 2006, 24, 643-645.	0.5	14
438	Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenetics and Genomics, 2006, 16, 139-147.	1.5	13

#	Article	IF	Citations
439	Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention ??? the HIV polypill study. Current Opinion in HIV and AIDS, 2006, 1, 482-487.	3.8	4
440	Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. The Cochrane Library, 2006, , CD005061.	2.8	66
441	Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Current Opinion in Nephrology and Hypertension, 2006, 15, 105-110.	2.0	67
442	Risk scoring in the assessment of cardiovascular risk. Current Opinion in Lipidology, 2006, 17, 375-386.	2.7	46
443	Improvement in hypertension management in England: results from the Health Survey for England 2003. Journal of Hypertension, 2006, 24, 1187-1192.	0.5	126
444	Are guidelines on cardiovascular risk prevention comprehensive enough? Focus on the 2005 Joint British Societiesâ€™ Guidelines. Therapy: Open Access in Clinical Medicine, 2006, 3, 687-690.	0.2	0
445	Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Costâ€“Utility Analysis. Annals of Internal Medicine, 2006, 144, 326.	3.9	168
446	Protocol for the 'e-Nudge trial': a randomised controlled trial of electronic feedback to reduce the cardiovascular risk of individuals in general practice [ISRCTN64828380]. Trials, 2006, 7, 11.	1.6	9
447	A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance. International Journal of Clinical Practice, 2006, 60, 847-855.	1.7	12
448	The use of the Framingham equation to predict myocardial infarctions in HIVâ€infected patients: comparison with observed events in the D:A:D Study. HIV Medicine, 2006, 7, 218-230.	2.2	296
449	Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. International Journal of Clinical Practice, 2006, 60, 1129-1137.	1.7	8
450	Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clinical Endocrinology, 2006, 64, 292-298.	2.4	38
451	Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999). British Journal of Clinical Pharmacology, 2006, 61, 592-600.	2.4	8
452	Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines. Journal of Human Hypertension, 2006, 20, 641-645.	2.2	22
453	TWNFI â€” a transductive neuro-fuzzy inference system with weighted data normalization for personalized modeling. Neural Networks, 2006, 19, 1591-1596.	5.9	57
454	Patientsâ€™ opinions on health counseling in the Hartslag Limburg cardiovascular prevention project: Perceived quality, satisfaction, and normative concerns. Patient Education and Counseling, 2006, 61, 142-151.	2.2	15
455	Birth Size and Coronary Heart Disease Risk Score in Young Adulthood. The Atherosclerosis Risk in Young Adults (ARYA) Study. European Journal of Epidemiology, 2006, 21, 33-38.	5.7	41
456	Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction. European Journal of Health Economics, 2006, 7, 247-254.	2.8	16

#	Article	IF	Citations
457	Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Womenâ€™s Heart and Health Study. Diabetologia, 2006, 49, 41-48.	6.3	137
458	Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia, 2006, 49, 49-55.	6.3	94
459	Treating the Cardiometabolic Syndrome: An Opportunity to Provide Comprehensive Cardiovascular Risk Reduction. Journal of the Cardiometabolic Syndrome, 2006, 1, 358-361.	1.7	7
460	Integrating regression formulas and kernel functions into locally adaptive knowledge-based neural networks: A case study on renal function evaluation. Artificial Intelligence in Medicine, 2006, 36, 235-244.	6.5	5
461	Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Medicine, 2006, 4, 22.	5.5	157
462	Metabolic syndrome: a fata morgana?. Nephrology Dialysis Transplantation, 2006, 22, 15-20.	0.7	30
465	Longitudinal Change in Coronary Heart Disease Risk Factors in Older Runners. Age and Ageing, 2006, 36, 57-62.	1.6	17
466	Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart, 2006, 92, 1595-1602.	2.9	76
467	Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women's Heart and Health prospective cohort study. Heart, 2006, 92, 1396-1401.	2.9	74
468	Non-cardiac determinants of NT-proBNP levels in the elderly: Relevance of haematocrit and hepatic steatosis. European Journal of Heart Failure, 2006, 8, 468-476.	7.1	24
469	Traditional Risk Factors for Coronary Atherosclerosis in Indo Asians: The Need for a Reappraisal. Current Pharmaceutical Design, 2006, 12, 1611-1621.	1.9	18
470	Consequences of using different methods to assess cardiovascular risk in primary care. Family Practice, 2006, 23, 28-33.	1.9	33
471	Toward Targeted Hypertension Screening Guidelines. Medical Decision Making, 2006, 26, 145-153.	2.4	5
472	The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 523-528.	2.8	7
473	A Computerised Guidance Tree (Decision Aid) for Hypertension, Based on Decision Analysis: Development and Preliminary Evaluation. European Journal of Cardiovascular Nursing, 2006, 5, 146-149.	0.9	20
474	A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 515-522.	2.8	11
475	The polypill: at what price would it become cost effective?. Journal of Epidemiology and Community Health, 2006, 60, 213-217.	3.7	17
476	Derivation and Validation of a Prediction Score for Major Coronary Heart Disease Events in a U.K. Type 2 Diabetic Population. Diabetes Care, 2006, 29, 1231-1236.	8.6	69

#	Article	IF	Citations
477	Circulating Leukocyte-Derived Microparticles Predict Subclinical Atherosclerosis Burden in Asymptomatic Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2775-2780.	2.4	173
478	Using Individualized Predictive Disease Modeling to Identify Patients with the Potential to Benefit from a Disease Management Program for Diabetes Mellitus. Disease Management: DM, 2006, 9, 242-256.	1.0	18
479	Arterial Stiffness, Isolated Systolic Hypertension, and Cardiovascular Risk in the Elderly. The American Journal of Geriatric Cardiology, 2006, 15, 178-184.	0.6	19
480	Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Current Medical Research and Opinion, 2006, 22, 121-129.	1.9	69
481	American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. Heart, 2006, 92, 1213-1218.	2.9	24
482	Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Heart, 2007, 94, 1331-1332.	2.9	254
483	Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment?. European Heart Journal, 2007, 28, 929-940.	2.2	23
484	Awareness, treatment and control of hypertension: the â€˜rule of halvesâ€™ in an era of risk-based treatment of hypertension. Journal of Human Hypertension, 2007, 21, 99-106.	2.2	73
485	The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 501-507.	2.8	43
486	Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Rheumatology, 2007, 46, 1133-1139.	1.9	76
487	Association of Kidney Function and Albuminuria With Cardiovascular Mortality in Older vs Younger Individuals. Archives of Internal Medicine, 2007, 167, 2490.	3.8	241
488	Associations between high-density lipoprotein cholesterol and both stroke and coronary heart disease in the Asia Pacific region. European Heart Journal, 2007, 28, 2653-2660.	2.2	53
489	Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. Journal of Human Hypertension, 2007, 21, 183-211.	2.2	113
490	Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ: British Medical Journal, 2007, 335, 136.	2.3	751
491	Use of predictive markers to improve cardiovascular protection. Future Cardiology, 2007, 3, 447-456.	1.2	2
492	Aspirin for the Primary Prevention of Cardiovascular Disease in Women. Archives of Internal Medicine, 2007, 167, 290.	3.8	65
493	Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Review of Cardiovascular Therapy, 2007, 5, 767-776.	1.5	14
494	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 rgBT /Ov	2.8	978

#	Article	IF	Citations
495	Fasting Plasma Glucose Predicts Survival And Angiographic Progression in High-Risk Postmenopausal Women with Coronary Artery Disease. Journal of Women's Health, 2007, 16, 228-234.	3.3	1
496	Prediction Is Difficult, Particularly About the Future. Archives of Internal Medicine, 2007, 167, 2286.	3.8	11
497	The Value Of Coronary Heart Disease Care For The Elderly: 1987â€“2002. Health Affairs, 2007, 26, 111-123.	5.2	19
498	Better Management of Cardiovascular Diseases by Pulse Wave Velocity: Combining Clinical Practice with Clinical Research using Evidence-Based Medicine. Clinical Medicine and Research, 2007, 5, 45-52.	0.8	51
499	Prevention of coronary heart disease with statins in UK South Asians and Caucasians. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 333-339.	2.8	5
500	Combining Population Health and Baseline Risk Strategy by Determining an Age Cutoff for Initiating Statins in Patients With Diabetes: A population-based study. Diabetes Care, 2007, 30, 2025-2029.	8.6	7
501	Coronary Artery Calcification Progression Is Heritable. Circulation, 2007, 116, 25-31.	1.6	43
502	The Value Of Antihypertensive Drugs: A Perspective On Medical Innovation. Health Affairs, 2007, 26, 97-110.	5.2	104
503	Can the Risk of Cardiovascular Disease in HIV-Infected Patients Be Estimated from Conventional Risk Prediction Tools?. Clinical Infectious Diseases, 2007, 45, 1082-1084.	5.8	29
504	Evolving Connectionist Systems. , 2007, , .		11
505	Arterial Stiffness: Determinants and Relationship to the Metabolic Syndrome. Angiology, 2007, 58, 11-20.	1.8	29
506	Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension. Current Hypertension Reviews, 2007, 3, 196-202.	0.9	0
507	Framingham, SCORE, and DECODE Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes. Diabetes Care, 2007, 30, 1292-1293.	8.6	158
508	Cardiovascular risk prediction tools for populations in Asia. Journal of Epidemiology and Community Health, 2007, 61, 115-121.	3.7	147
509	Does consideration of either psychological or material disadvantage improve coronary risk prediction? Prospective observational study of Scottish men. Journal of Epidemiology and Community Health, 2007, 61, 833-837.	3.7	11
510	Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. British Journal of Psychiatry, 2007, 191, 23-29.	2.8	118
511	Ischemic Heart Disease and Ambient Air Pollution of Particulate Matter 2.5 in 51 Counties in the U.S.. Public Health Reports, 2007, 122, 626-633.	2.5	29
512	Inflammation/Oxidation in Chronic Rejection: Apolipoprotein A-I Mimetic Peptide Reduces Chronic Rejection of Transplanted Hearts. Transplantation, 2007, 84, 238-243.	1.0	27

#	Article	IF	Citations
513	Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. Aids, 2007, 21, 2445-2453.	2.2	163
514	Spousal Caregivers of Patients With Alzheimer's Disease Show Longitudinal Increases in Plasma Level of Tissue-Type Plasminogen Activator Antigen. Psychosomatic Medicine, 2007, 69, 816-822.	2.0	28
515	Circulating Endothelial Cells, Arterial Stiffness, and Cardiovascular Risk Stratification in Hypertension. Chest, 2007, 132, 1540-1547.	0.8	26
517	Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. Journal of Medical Economics, 2007, 10, 239-254.	2.1	20
518	Primary prevention of cardiovascular disease: Cost-effectiveness comparison. International Journal of Technology Assessment in Health Care, 2007, 23, 71-79.	0.5	39
519	Comparison of methods to identify individuals at increased risk of cardiovascular disease in Italian cohorts. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 311-318.	2.6	9
520	Prediction of first coronary events with the Framingham score: A systematic review. American Heart Journal, 2007, 153, 722-731.e8.	2.7	174
521	Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. American Heart Journal, 2007, 154, 554-560.	2.7	24
522	Increased Pulse Pressure Amplification in Treated Hypertensive Subjects With Metabolic Syndrome. American Journal of Hypertension, 2007, 20, 127-133.	2.0	45
523	Rationale, design, and methods for the risk evaluation and communication health outcomes and utilization trial (REACH OUT). Contemporary Clinical Trials, 2007, 28, 662-673.	1.8	11
524	A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy, 2007, 83, 257-267.	3.0	31
525	Associations of apolipoprotein B with pulse pressure and glucose in Chinese families with familial combined hyperlipidemia. International Journal of Cardiology, 2007, 115, 293-296.	1.7	7
526	Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: Factors influencing on international application of evidence-based guidelines. International Journal of Cardiology, 2007, 118, 88-96.	1.7	25
527	Decreased number of circulating CD34+KDR+ cells in asymptomatic subjects with preclinical atherosclerosis. Atherosclerosis, 2007, 191, 115-120.	0.8	78
528	Gender influence on metabolic syndrome's effects on arterial stiffness and pressure wave reflections in treated hypertensive subjects. Atherosclerosis, 2007, 193, 151-158.	0.8	52
529	Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet, The, 2007, 370, 2054-2062.	13.7	293
530	Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis. Arthritis Research and Therapy, 2007, 9, R39.	3.5	13
531	Aortic Pulse Wave Velocity: An Independent Marker of Cardiovascular Risk. The American Journal of Geriatric Cardiology, 2007, 11, 295-304.	0.6	76

#	Article	IF	Citations
532	Agreement of Two Metabolic Syndrome Definitions and Their Association with Subclinical Atherosclerosis: Multi-Ethnic Study of Atherosclerosis Cross Sectional Study. Metabolic Syndrome and Related Disorders, 2007, 5, 343-352.	1.3	9
533	High Blood Pressure & Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 1-3.	2.2	2
534	Angiotensin II Receptor Antagonists. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 39-47.	2.2	0
535	Industry Pulse. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 111-112.	2.2	0
536	Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events. Pharmacoeconomics, 2007, 25, 1063-1082.	3.3	21
537	Is estimated cardiovascular risk higher in HIV-infected patients than in the general population?. Scandinavian Journal of Infectious Diseases, 2007, 39, 805-812.	1.5	39
538	Valutazione economica di rosuvastatina nel trattamento di prevenzione delle malattie cardiovascolari: una revisione sistematica della letteratura. Pharmacoeconomics Italian Research Articles, 2007, 9, 45-58.	0.2	0
539	Indices of angiogenesis, platelet activation, and endothelial damage/dysfunction in relation to ethnicity and coronary artery disease: Differences in central versus peripheral levels. Annals of Medicine, 2007, 39, 628-633.	3.8	6
540	Anthropometric measures and absolute cardiovascular risk estimates in the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 740-745.	2.8	37
541	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 rgBT /Ove	2.3	2,331
542	The Beneficial Effect of<scp>l</scp>-Thyroxine on Cardiovascular Risk Factors, Endothelial Function, and Quality of Life in Subclinical Hypothyroidism: Randomized, Crossover Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1715-1723.	3.6	369
543	Prise en compte par les malades des facteurs de risque de la maladie vasculaire pÃ©riphÃ©rique. Annales De Chirurgie Vasculaire, 2007, 21, 36-41.	0.0	0
544	Patient Awareness of Risk Factors for Peripheral Vascular Disease. Annals of Vascular Surgery, 2007, 21, 433-437.	0.9	9
545	A 10-Year Follow-Up of Ischemic Heart Disease Risk Factors in Military Pilots. Military Medicine, 2007, 172, 214-219.	0.8	11
546	Generation of knowledge for clinical decision support. , 2007, , 227-248.		5
547	An application of the patient rule-induction method for evaluating the contribution of theApolipoprotein E andLipoprotein Lipase genes to predicting ischemic heart disease. Genetic Epidemiology, 2007, 31, 515-527.	1.3	14
548	Nurse-led management of uncontrolled hypertension in those with diabetes and high vascular risk. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 92-96.	0.2	3
549	Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nature Medicine, 2007, 13, 1176-1184.	30.7	601

#	Article	IF	Citations
550	Economic Burden and Risk of Cardiovascular Disease and Diabetes in Patients with Different Cardiometabolic Risk Profiles. Value in Health, 2007, 10, S12-S20.	0.3	19
551	Development, Validation, and Application of a Microsimulation Model to Predict Stroke and Mortality in Medically Managed Asymptomatic Patients with Significant Carotid Artery Stenosis. Value in Health, 2007, 10, 489-497.	0.3	12
552	Quality as well as quantity? Beyond low-density lipoprotein-cholesterol - the role of particle size*. International Journal of Clinical Practice, 2007, 61, 1780-1782.	1.7	11
553	Total Cardiovascular Risk Management. American Journal of Cardiology, 2007, 100, S53-S60.	1.6	22
554	Predicting Arterial Stiffness From the Digital Volume Pulse Waveform. IEEE Transactions on Biomedical Engineering, 2007, 54, 2268-2275.	4.2	143
555	The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2007, 21, 297-309.	2.6	49
556	Subsets of SNPs define rare genotype classes that predict ischemic heart disease. Human Genetics, 2007, 120, 865-877.	3.8	17
558	Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of Cancer Survivorship, 2008, 2, 128-137.	2.9	40
559	Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 Diabetes Mellitus. Cardiovascular Diabetology, 2008, 7, 9.	6.8	52
560	O313 Relation between adverse effects of ARV treatment and underlying risk in number needed to treat to harm (NNTH) â€“ myocardial infarction and abacavir use. Journal of the International AIDS Society, 2008, 11, O29.	3.0	0
561	Adaptive modeling and discovery in bioinformatics: The evolving connectionist approach. International Journal of Intelligent Systems, 2008, 23, 545-555.	5.7	4
562	Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis and Rheumatism, 2008, 59, 1105-1111.	6.7	22
563	Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study. Journal of Infection, 2008, 57, 33-40.	3.3	49
564	The value of a specialist lipid clinic. International Journal of Clinical Practice, 2008, 62, 961-966.	1.7	9
565	Estimated 10-year cardiovascular risk in a British population: results of a national screening project. International Journal of Clinical Practice, 2008, 62, 1322-1331.	1.7	15
566	Cardiovascular risk estimation - making sense of the numbers. International Journal of Clinical Practice, 2008, 62, 1300-1303.	1.7	4
567	Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. International Journal of Obesity, 2008, 32, 1752-1763.	3.4	40
568	Uncertainty in Decision-Making: Value of Additional Information in the Cost-Effectiveness of Lifestyle Intervention in Overweight and Obese People. Value in Health, 2008, 11, 424-434.	0.3	14

#	Article	IF	Citations
569	Lipid Testing among Patients Beginning Statin Therapy in General Practice in the United Kingdom. Value in Health, 2008, 11, 933-938.	0.3	2
570	The Relative Merits of Populationâ€Based and Targeted Prevention Strategies. Milbank Quarterly, 2008, 86, 557-580.	4.4	83
571	UKPDSâ€"modelling of cardiovascular risk assessment and lifetime simulation of outcomes. Diabetic Medicine, 2008, 25, 41-46.	2.3	28
572	Secular changes in cardiovascular risk factors and attack rate of myocardial infarction among men aged 50 in Gothenburg, Sweden. Accurate prediction using risk models. Journal of Internal Medicine, 2008, 263, 636-643.	6.0	46
573	Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?. Journal of Internal Medicine, 2008, 264, 481-492.	6.0	36
574	Healthy Hearts â€“ A community-based primary prevention programme to reduce coronary heart disease. BMC Cardiovascular Disorders, 2008, 8, 18.	1.7	42
575	Identification of patients for clinical risk assessment by prediction of cardiovascular risk using default risk factor values. BMC Public Health, 2008, 8, 25.	2.9	22
576	The Sandwell Project: A controlled evaluation of a programme of targeted screening for prevention of cardiovascular disease in primary care. BMC Public Health, 2008, 8, 73.	2.9	21
577	Construction of an odds model of coronary heart disease using published information: the Cardiovascular Health Improvement Model (CHIME). BMC Medical Informatics and Decision Making, 2008, 8, 49.	3.0	4
578	Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: Lessons learned from a health care services study. BMC Health Services Research, 2008, 8, 148.	2.2	12
579	Physical health in schizophrenia and related disorders. Psychiatry (Abingdon, England), 2008, 7, 472-476.	0.2	4
580	Scientific Rationale for Combination of a Calcium Channel Antagonist and an HMG-CoA Reductase Inhibitor. Drugs, 2008, 68, 885-900.	10.9	6
581	Stroke Risk Screening of Adults with Hypertension. Clinical Drug Investigation, 2008, 28, 281-289.	2.2	15
584	Risk Functions and the Primary Prevention of Cardiovascular Disease. Revista Espanola De Cardiologia (English Ed), 2008, 61, 404-416.	0.6	7
585	Global Preventive Policies. Strategies at European and Worldwide Level. Revista Espanola De Cardiologia (English Ed), 2008, 61, 960-970.	0.6	1
586	Comparison of Cardiovascular Risk Factors in Young Spanish Men Between the 1980s and After the Year 2000. Data From the AGEMZA Study. Revista Espanola De Cardiologia (English Ed), 2008, 61, 1260-1266.	0.6	6
587	An Italian Chart for Cardiovascular Risk Estimate Including High-Density Lipoprotein-Cholesterol. Disease Management and Health Outcomes, 2008, 16, 183-197.	0.4	2
588	Risk assessment for prevention of morbidity and mortality: Lessons for pressure ulcer prevention. Journal of Tissue Viability, 2008, 17, 115-120.	2.0	10

#	Article	IF	Citations
589	Cardiovascular risk management of different ethnic groups with type 2 diabetes in primary care in New Zealand. Diabetes Research and Clinical Practice, 2008, 79, 468-473.	2.8	21
590	Back to the futureâ€"Do IGT and IFG have value as clinical entities?. Diabetes Research and Clinical Practice, 2008, 81, 131-133.	2.8	8
591	Characteristics and cardiovascular risk of new cases of type 2 diabetes in Otago, New Zealand, 1998â€“2004. Diabetes Research and Clinical Practice, 2008, 82, 396-401.	2.8	4
593	Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet, The, 2008, 371, 923-931.	13.7	283
594	Laboratory-based versus non-laboratory-based CVD risk analysis â€“ Authors' reply. Lancet, The, 2008, 371, 2082-2083.	13.7	0
596	How many cardiovascular events can be prevented with optimal management of high-risk Canadians?. Canadian Journal of Cardiology, 2008, 24, 363-368.	1.7	6
597	Â¿Existen diferencias en el cribado de la hipertensiÃ³n arterial entre la poblaciÃ³n inmigrante y la autÃ³ctona?. Hipertension Y Riesgo Vascular, 2008, 25, 47-51.	0.6	2
598	Cardiovascular Risk Management in Clinical Practice. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 9-16.	2.2	4
599	2008 White Paper for Implementing Strategies and Interventions for Cardiovascular Prevention in Italy. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 63-73.	2.2	4
600	Cost-Utility Analysis of Antihypertensive Combination Therapy in Japan by a Monte Carlo Simulation Model. Hypertension Research, 2008, 31, 1373-1383.	2.7	22
601	General Cardiovascular Risk Profile for Use in Primary Care. Circulation, 2008, 117, 743-753.	1.6	5,601
602	Making sense of congenital cardiac disease with a research database: The Congenital Heart Surgeonsâ€™ Society Data Center. Cardiology in the Young, 2008, 18, 152-162.	0.8	17
603	Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocrine-Related Cancer, 2008, 15, 597-607.	3.1	38
604	The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal, 2008, 29, 923-931.	2.2	27
605	Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy. Current Medical Research and Opinion, 2008, 24, 2703-2709.	1.9	5
606	Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 562-566.	2.8	36
607	Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ: British Medical Journal, 2008, 336, 1475-1482.	2.3	1,175
608	Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart, 2008, 94, 34-39.	2.9	185

#	Article	IF	Citations
609	Risk Prediction of Cardiovascular Disease in Type 2 Diabetes. Diabetes Care, 2008, 31, 2038-2043.	8.6	141
610	General practitionersâ€™ coronary risk assessments and lipid-lowering treatment decisions in primary prevention: comparison between two European areas with different cardiovascular risk levels. Primary Health Care Research and Development, 2008, 9, 248.	1.2	3
611	Ankle Brachial Index Combined With Framingham Risk Score to Predict Cardiovascular Events and Mortality. JAMA - Journal of the American Medical Association, 2008, 300, 197.	7.4	1,553
612	Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. International Journal of Impotence Research, 2008, 20, 92-99.	1.8	134
613	Managing cardiovascular risk: the need for change. Journal of Human Hypertension, 2008, 22, 154-157.	2.2	23
614	Lipid external quality assessment: commutability between external quality assessment and clinical specimens. Annals of Clinical Biochemistry, 2008, 45, 260-265.	1.6	7
615	HDL-cholesterol modulation and its impact on the management of cardiovascular risk. Annals of Clinical Biochemistry, 2008, 45, 122-128.	1.6	9
616	Electronic Alerts Versus On-Demand Decision Support to Improve Dyslipidemia Treatment. Circulation, 2008, 117, 371-378.	1.6	107
617	Patients' acceptance of antihypertensive therapy to prevent cardiovascular disease: a comparison between South Asians and Caucasians in the United Kingdom. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 59-66.	2.8	8
618	Transfacet screw placement for posterior fixation of C-7. Journal of Neurosurgery: Spine, 2008, 9, 200-206.	1.7	24
619	Targeted versus global approaches to the management of hypercholesterolaemia. Perspectives in Public Health, 2008, 128, 248-254.	0.4	6
620	Co-occurrence of risk factors for cardiovascular disease by social class: 1958 British birth cohort. Journal of Epidemiology and Community Health, 2008, 62, 1030-1035.	3.7	17
621	Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk. Circulation, 2008, 117, 2875-2883.	1.6	89
623	Abnormal lipids in high-risk patients achieving cholesterol targets: a cross-sectional study of routinely collected UK general practice data. Current Medical Research and Opinion, 2008, 24, 2551-2560.	1.9	10
624	What are the effects of patient age and blood pressure on the cholesterol-related risk of vascular mortality?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 310-311.	3.3	0
625	Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, S10-S14.	3.3	18
626	Patients with diabetesâ€”to whom should one offer statin treatment?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 16-17.	2.8	0
627	Economic evaluation of treatment with orlistat in Italian obese patients. Current Medical Research and Opinion, 2008, 24, 63-74.	1.9	17

#	Article	IF	Citations
628	Age threshold for vascular prophylaxis by aspirin in patients without diabetes. Heart, 2008, 94, 1429-1432.	2.9	16
629	Chapter 5 Biomarkers Related To Aging In Human Populations. Advances in Clinical Chemistry, 2008, 46, 161-216.	3.7	126
630	Evaluation of a workplace health program to reduce coronary risk factors. Clinical Governance, 2008, 13, 95-105.	0.3	11
632	Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ: British Medical Journal, 2008, 336, 1246-1248.	2.3	81
633	Identifying individuals for primary cardiovascular disease prevention in UK general practice: priorities and resource implications. British Journal of General Practice, 2008, 58, 495-498.	1.4	8
634	Ethnicity and cardiovascular disease prevention: practical clinical considerations. Current Opinion in Cardiology, 2008, 23, 465-470.	1.8	4
635	Detection of small dense LDL-cholesterol: is it necessary to determine particle size?. Future Lipidology, 2008, 3, 23-25.	0.5	1
636	Cardiovascular Disease Knowledge and Risk Perception Among Underserved Individuals at Increased Risk of Cardiovascular Disease. Journal of Cardiovascular Nursing, 2008, 23, 332-337.	1.1	103
637	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. Journal of Hypertension, 2008, 26, 1244-1249.	0.5	25
638	Impact of shear stimulus, risk factor burden and early atherosclerosis on the time-course of brachial artery flow-mediated vasodilation. Journal of Hypertension, 2008, 26, 508-515.	0.5	21
639	The Effect of Comorbid Illness and Functional Status on the Expected Benefits of Intensive Glucose Control in Older Patients with Type 2 Diabetes: A Decision Analysis. Annals of Internal Medicine, 2008, 149, 11.	3.9	138
640	O escore de risco de Framingham para doenÃ§as cardiovasculares. , 2008, 87, 232.	0.1	10
641	Military Community: A Privileged Site for Clinical Research: Epidemiological Study of Metabolic Syndrome Risk Factors in the Military Environment. Military Medicine, 2008, 173, 960-967.	0.8	10
642	Lipid-Lowering Effects of Time-Released Garlic Powder Tablets in Double-Blinded Placebo-Controlled Randomized Study. Journal of Atherosclerosis and Thrombosis, 2008, 15, 334-338.	2.0	68
643	Smoking-induced long-lasting modifications of human platelet serotonin catabolism through a MAO epigenetic regulation. Nature Precedings, 2008, , .	0.1	0
644	Development of Risk Simulation Software for Outcome Prediction and Economic Assessment of Diabetes Mellitus. Asian Pacific Journal of Disease Management, 2008, 2, 111-118.	0.3	0
645	How do the Australian guidelines for lipidâ€lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999â€“2000. Medical Journal of Australia, 2008, 189, 319-322.	1.7	15
646	Assessing cardiovascular risk in the individual. British Journal of Cardiac Nursing, 2008, 3, 358-362.	0.1	4

#	Article	IF	Citations
647	Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians. Vascular Health and Risk Management, 0, Volume 4, 199-211.	2.3	3
648	Maximising the effectiveness and costâ€effectiveness of cardiovascular disease prevention in the general population. Medical Journal of Australia, 2009, 191, 300-302.	1.7	7
649	Cardiovascular disease risk management for Aboriginal and Torres Strait Islander peoples in primary health care settings: findings from the Kanyini Audit. Medical Journal of Australia, 2009, 191, 304-309.	1.7	62
650	Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2â€‰diabetes from the Fremantle Diabetes Study. Medical Journal of Australia, 2009, 190, 180-184.	1.7	45
651	Gaps in cardiovascular disease risk management in Australian general practice. Medical Journal of Australia, 2009, 191, 324-329.	1.7	107
652	Treatment of Renovascular Disease. , 2009, , 391-396.		0
653	Clinical Effects of Calcium Channel Blocker and Angiotensin Converting Enzyme Inhibitor on Endothelial Function and Arterial Stiffness in Patients with Angina Pectoris. Journal of Korean Medical Science, 2009, 24, 223.	2.5	29
654	Selenium Status and Cardiovascular Risk Profile in Healthy Adult Saudi Males. Molecules, 2009, 14, 141-159.	3.8	13
655	Ten-Year Mortality and Cardiovascular Morbidity in the Finnish Diabetes Prevention Studyâ€"Secondary Analysis of the Randomized Trial. PLoS ONE, 2009, 4, e5656.	2.5	158
656	Recalibration of a Framingham risk equation for a rural population in India. Journal of Epidemiology and Community Health, 2009, 63, 379-385.	3.7	41
657	Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ: British Medical Journal, 2009, 338, a3083-a3083.	2.3	274
658	Optimizing the Start Time of Statin Therapy for Patients with Diabetes. Medical Decision Making, 2009, 29, 351-367.	2.4	71
659	Effects of Categorizing Continuous Variables in Decision-Analytic Models. Medical Decision Making, 2009, 29, 549-556.	2.4	11
660	Smoking Induces Long-Lasting Effects through a Monoamine-Oxidase Epigenetic Regulation. PLoS ONE, 2009, 4, e7959.	2.5	115
661	Continued Improvement in Hypertension Management in England. Hypertension, 2009, 53, 480-486.	2.7	190
662	Should the first priority in cardiovascular risk management be those with prior cardiovascular disease?. Heart, 2009, 95, 125-129.	2.9	72
663	Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. European Heart Journal, 2009, 30, 3048-3054.	2.2	62
664	Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes. Family Practice, 2009, 26, 351-358.	1.9	13

#	Article	IF	Citations
665	Framingham Stroke Risk Function in a Large Population-Based Cohort of Elderly People. Stroke, 2009, 40, 1564-1570.	2.0	41
666	Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels. HIV Clinical Trials, 2009, 10, 1-12.	2.0	48
667	An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ: British Medical Journal, 2009, 339, b2584-b2584.	2.3	148
668	Risk assessment in asthma and COPD: a potential role for biomarkers?. Thorax, 2009, 64, 261-264.	5.6	26
669	Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 562-570.	2.8	34
670	The Role of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 34-40.	2.0	42
671	Cardiovascular risk: who should we treat, and how much should we stratify?. Heart, 2009, 95, 783-784.	2.9	0
672	Ethnic inequalities in access to and outcomes of healthcare: analysis of the Health Survey for England. Journal of Epidemiology and Community Health, 2009, 63, 1022-1027.	3.7	74
673	Information Theory and Statistical Learning. , 2009, , .		14
675	Coronary Heart Disease Risk Reduction Intervention Among Overweight Smokers with a Psychotic Disorder: Pilot Trial. Australian and New Zealand Journal of Psychiatry, 2009, 43, 129-135.	2.3	31
676	The metabolic syndrome is not a sensible tool for predicting the risk of coronary heart disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 210-214.	2.8	16
677	An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome. International Journal of Technology Assessment in Health Care, 2009, 25, 26-34.	0.5	39
678	QRISK or Framingham for predicting cardiovascular risk?. BMJ: British Medical Journal, 2009, 339, b2673-b2673.	2.3	22
679	Coronary Heart Disease and Dyslipidemia: A Crossâ€Sectional Evaluation of Prevalence, Current Treatment, and Clinical Control in a Large Cohort of Spanish Highâ€Risk Patients: The PRINCEPS Study. Preventive Cardiology, 2009, 12, 65-71.	1.1	9
680	National Cholesterol Education Panel Î™Î™Î™ Guidelines Performance Role in Preventing Myocardial Infarction in a Large Cohort Without a History of Coronary Artery Disease: Korea Acute Myocardial Infarction Registry Study. Preventive Cardiology, 2009, 12, 109-113.	1.1	8
681	Costâ€Effectiveness of Treating Resistant Hypertension With an Implantable Carotid Body Stimulator. Journal of Clinical Hypertension, 2009, 11, 555-563.	2.0	28
682	Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Clinical Therapeutics, 2009, 31, 862-879.	2.5	9
683	Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clinical Therapeutics, 2009, 31, 2189-2203.	2.5	14

#	Article	IF	Citations
684	Central Obesity and Multivariable Cardiovascular Risk as Assessed by the Framingham Prediction Scores. American Journal of Cardiology, 2009, 103, 1403-1407.	1.6	83
685	A Comparison of the Prevalence of the MS and Its Complications Using Three Proposed Definitions in Korean Subjects. American Journal of Cardiology, 2009, 103, 1732-1735.	1.6	16
686	Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapyâ€â€Conflicts of interest: Drs. Nichols and Brown are employees of Kaiser Permanente Northwest. Drs. Ambegaonkar and Sazonov are employees of Merck & Company, Inc. Drs. Nichols and Brown have received research support from Amgen, Inc., Thousand Oaks, California; Novo Nordisk A/S, BagsvÃ¦rd, Denmark; Novartis Pharmaceuticals Corporation, Eas. American Journal of Cardiology, 2009, 104, 1689-1694.	1.6	29
687	A model to predict the costâ€effectiveness of disease management programs. Health Economics (United) Tj ETQq1 1 0.784314 rgBT	1.7	12
688	Cardiovascular risk status and primary prevention in postmenopausal women: the MENOCARD study. Wiener Klinische Wochenschrift, 2009, 121, 202-208.	1.9	7
691	Development of an evidence-based checklist for the detection of drug related problems in type 2 diabetes. International Journal of Clinical Pharmacy, 2009, 31, 580-595.	1.4	33
692	Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoeaâ€“hypopnoea. Sleep and Breathing, 2009, 13, 241-252.	1.7	36
693	Stress single photon emission computed tomography for detection of coronary artery disease and risk stratification of asymptomatic patients at moderate risk. Journal of Nuclear Cardiology, 2009, 16, 516-523.	2.1	22
694	Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia, 2009, 52, 2001-2014.	6.3	139
695	Current European guidelines for management of arterial hypertension: Are they adequate for use in primary care? Modelling study based on the Norwegian HUNT 2 population. BMC Family Practice, 2009, 10, 70.	2.9	23
696	Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Effectiveness and Resource Allocation, 2009, 7, 4.	1.5	37
697	Does fibrinogen add to prediction of cardiovascular disease? Results from the Scottish Heart Health Extended Cohort Study. British Journal of Haematology, 2009, 146, 442-446.	2.5	21
698	High density lipoproteinâ€cholesterol levels increase with age in American women but not in Hong Kong Chinese women. Clinical Endocrinology, 2009, 70, 561-568.	2.4	11
699	Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology, 2009, 70, 815-828.	2.4	69
700	Can individuals with a significant risk for cardiovascular disease be adequately identified by combination of several risk factors? Modelling study based on the Norwegian HUNT 2 population. Journal of Evaluation in Clinical Practice, 2009, 15, 103-109.	1.8	15
701	Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nature Genetics, 2009, 41, 47-55.	21.4	776
702	Vascular risk screening: possible or too much, too soon?. International Journal of Clinical Practice, 2009, 63, 989-996.	1.7	6
703	Impact on clinical practice of the Joint British Societiesâ€™ cardiovascular risk assessment tools. International Journal of Clinical Practice, 2009, 63, 1683-1692.	1.7	13

#	Article	IF	Citations
704	Targeting treatment using calculated cardiovascular disease risk: Effective? A shot in the dark? Or is it time to change the paradigm?. International Journal of Clinical Practice, 2009, 63, 1785-1791.	1.7	2
705	Aspirin for primary prevention: do potential benefits outweigh the risks?. Internal Medicine Journal, 2009, 39, 401-407.	0.8	2
706	Skeletal muscle microvascular exchange capacity is associated with hyperglycaemia in subjects with central obesity. Diabetic Medicine, 2009, 26, 1112-1119.	2.3	10
707	Coronary risk estimates and decisions on lipid-lowering treatment in primary prevention. European Journal of Internal Medicine, 2009, 20, 601-606.	2.2	2
708	Central obesity and cigarette smoking are key determinants of cardiovascular disease deaths in Australia: A public health perspective. Preventive Medicine, 2009, 49, 153-157.	3.4	19
709	Prediction of 10-year coronary heart disease risk in Caribbean type 2 diabetic patients using the UKPDS risk engine. International Journal of Cardiology, 2009, 132, 348-353.	1.7	8
710	Overview of Risk Prediction Models in Cardiovascular Disease Research. Annals of Epidemiology, 2009, 19, 711-717.	1.9	39
711	Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk. Journal of the American College of Cardiology, 2009, 54, 1209-1227.	2.8	347
713	Where on the Healthcare Continuum Should We Invest? The Case for Primary Care?. Heart Lung and Circulation, 2009, 18, 108-113.	0.4	5
714	SCORE should be preferred to Framingham to predict cardiovascular death in French population. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 609-615.	2.8	17
715	Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. Journal of Lipid Research, 2009, 50, 1967-1975.	4.2	81
716	Statin Therapy in Rheumatoid Arthritis. Pharmacoeconomics, 2009, 27, 25-37.	3.3	26
717	Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis, 2009, 202, 225-233.	0.8	22
718	The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis, 2009, 203, 581-586.	0.8	106
719	Magnetic resonance of carotid artery ageing in healthy subjects. Atherosclerosis, 2009, 205, 168-173.	0.8	11
720	How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgraduate Medical Journal, 2009, 85, 538-545.	1.8	121
721	Risk Scores for Prediction of Coronary Heart Disease: An Update. Endocrinology and Metabolism Clinics of North America, 2009, 38, 33-44.	3.2	18
722	Hypertension, Systolic Blood Pressure, and Large Arteries. Medical Clinics of North America, 2009, 93, 605-619.	2.5	5

#	Article	IF	Citations
723	Predicting the 30-Year Risk of Cardiovascular Disease. Circulation, 2009, 119, 3078-3084.	1.6	688
724	The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the General Practice Research Database. Journal of Hypertension, 2009, 27, 1485-1492.	0.5	21
725	Statins and hypertension. Journal of Hypertension, 2009, 27, 662-665.	0.5	4
726	Deprivation-based risk scores: the re-emergence of postcode prescribing in the UK?. Journal of Cardiovascular Medicine, 2009, 10, 157-160.	1.5	6
727	A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutrition, 2009, 12, 455.	2.2	47
728	Risk Charts Illustrating the 10-year Risk of Myocardial Infarction among Residents of Japanese Rural Communities: The JMS Cohort Study. Journal of Epidemiology, 2009, 19, 94-100.	2.4	18
729	Risk Charts Illustrating the 10-year Risk of Stroke among Residents of Japanese Rural Communities: The JMS Cohort Study. Journal of Epidemiology, 2009, 19, 101-106.	2.4	19
731	Diagnostic efficacy of a low-dose 32-projection SPECT 99mTc-sestamibi myocardial perfusion imaging protocol in routine practice. Nuclear Medicine Communications, 2009, 30, 140-147.	1.1	7
732	A System Dynamics Model for Planning Cardiovascular Disease Interventions. American Journal of Public Health, 2010, 100, 616-622.	2.7	92
733	New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?. Recent Patents on Cardiovascular Drug Discovery, 2010, 5, 69-81.	1.5	4
734	Economic model system of chronic diseases in Australia: a novel approach initially focusing on diabetes and cardiovascular disease. International Journal of Simulation and Process Modelling, 2010, 6, 137.	0.2	6
735	Premature onset of cardiovascular disease in HIV-infected individuals: the drugs and the virus. HIV Therapy, 2010, 4, 675-692.	0.6	4
736	The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia, 2010, 53, 821-831.	6.3	112
737	Assessment of Cardiovascular Risk. Current Hypertension Reports, 2010, 12, 384-393.	3.5	13
738	Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study. European Journal of Epidemiology, 2010, 25, 789-798.	5.7	84
739	A Health Policy Model of CKD: 1. Model Construction, Assumptions, and Validation of Health Consequences. American Journal of Kidney Diseases, 2010, 55, 452-462.	1.9	75
740	Comparison of the Prevalence and Mortality Risk of CKD in Australia Using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR Estimating Equations: The AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. American Journal of Kidney Diseases, 2010, 55, 660-670.	1.9	231
741	The Framingham Study, Diabetes Mellitus and Cardiovascular Disease: Turning Back the Clock. Progress in Cardiovascular Diseases, 2010, 53, 45-51.	3.1	43

#	Article	IF	Citations
742	The Framingham Heart Study's Impact on Global Risk Assessment. Progress in Cardiovascular Diseases, 2010, 53, 68-78.	3.1	110
743	Absolute risk representation in cardiovascular disease prevention: comprehension and preferences of health care consumers and general practitioners involved in a focus group study. BMC Public Health, 2010, 10, 108.	2.9	53
744	Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk. BMC Public Health, 2010, 10, 458.	2.9	33
745	Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). BMC Public Health, 2010, 10, 737.	2.9	10
746	Engaging community pharmacists in the primary prevention of cardiovascular disease: protocol for the Pharmacist Assessment of Adherence, Risk and Treatment in Cardiovascular Disease (PAART CVD) pilot study. BMC Health Services Research, 2010, 10, 264.	2.2	21
747	Relation Between the Framingham Risk Score, Coronary Calcium, and Incident Coronary Heart Disease Among Low-Risk Men. American Journal of Cardiology, 2010, 106, 47-50.	1.6	26
748	A Multi-Disciplinary Lifestyle Intervention Program Decreases Cardiovascular Disease Risk in Adults after 100 Days of Treatment. Journal of the American Dietetic Association, 2010, 110, A89.	1.1	0
749	Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: A controlled cardiac magnetic resonance imaging study. Arthritis and Rheumatism, 2010, 62, 2093-2100.	6.7	43
750	The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clinical Biochemistry, 2010, 43, 1399-1404.	1.9	50
751	Assessing risk prediction models in caseâ€“control studies using semiparametric and nonparametric methods. Statistics in Medicine, 2010, 29, 1391-1410.	1.6	39
752	Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIVâ€1â€infected patients treated with abacavir. HIV Medicine, 2010, 11, 200-208.	2.2	13
753	Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study. Value in Health, 2010, 13, 726-734.	0.3	20
754	Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. International Journal of Clinical Practice, 2010, 64, 1252-1259.	1.7	45
755	Comparison of the metabolic and economic consequences of longâ€term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a costâ€effectiveness analysis. Journal of Evaluation in Clinical Practice, 2010, 16, 744-755.	1.8	23
756	SAS macros for point and interval estimation of area under the receiver operating characteristic curve for non-proportional and proportional hazards Weibull models. Journal of Evaluation in Clinical Practice, 2010, 16, 756-770.	1.8	2
757	Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clinical and Experimental Immunology, 2010, 159, 281-291.	2.6	139
758	Tracking of Noninvasive Ultrasound Measurements of Subclinical Atherosclerosis in Adulthood: Findings from the Cardiovascular Risk in Young Finns Study. Ultrasound in Medicine and Biology, 2010, 36, 1237-1244.	1.5	10
759	Impact of personalized cardiovascular disease risk estimates on physical activity-a randomized controlled trial. Diabetic Medicine, 2010, 28, no-no.	2.3	19

#	Article	IF	Citations
760	A guide to lipid modification. British Journal of Cardiac Nursing, 2010, 5, 410-416.	0.1	0
761	Comparative Effects of the Leaves of <i>Gongronema latifolium</i> and <i>Vernonia amygdalina</i> Incorporated Diets on the Lipid Profiles of Rats. Biokemistri, 2010, 21, .	0.1	2
762	Perceptions of risk: understanding cardiovascular disease. Risk Management and Healthcare Policy, 2010, 3, 49.	2.5	91
764	Use of the Joint British Society cardiovascular risk calculator before initiating statins for primary prevention in hospital medicine: experience from a large university teaching hospital. International Journal of General Medicine, 2010, 3, 379.	1.8	2
765	Diastolic function is strongly and independently associated with cardiorespiratory fitness in central obesity. Journal of Applied Physiology, 2010, 108, 1568-1574.	2.5	11
766	Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 549-555.	2.8	18
767	Cardiovascular risk perception and evidenceâ€“practice gaps in Australian general practice (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	1.7	118
768	Evaluation of cardiovascular risk predicted by different SCORE equations: The Netherlands as an example. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 244-249.	2.8	53
769	The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. Journal of Psychopharmacology, 2010, 24, 867-873.	4.0	61
770	'Your Heart Forecast': a new approach for describing and communicating cardiovascular risk?. Heart, 2010, 96, 708-713.	2.9	56
771	Community Programs for the Prevention of Cardiovascular Disease: A Systematic Review. American Journal of Epidemiology, 2010, 172, 501-516.	3.4	106
772	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 491-501.	2.8	309
773	Testicular Cancer Survivorship: Research Strategies and Recommendations. Journal of the National Cancer Institute, 2010, 102, 1114-1130.	6.3	260
774	Cardiovascular Risk Factors and Estimated 10-Year Risk of Fatal Cardiovascular Events Using Various Equations in Greeks With Metabolic Syndrome. Angiology, 2010, 61, 49-57.	1.8	14
775	Prediction of Cardiovascular Death in Racial/Ethnic Minorities Using Framingham Risk Factors. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 181-187.	2.2	47
776	Prediction of Cardiovascular Events in Subjects in the Second Australian National Blood Pressure Study. Hypertension, 2010, 56, 44-48.	2.7	10
777	Framingham risk prediction equations for incidence of cardiovascular disease using detailed measures for smoking. Heart International, 2010, 5, e11.	1.4	25
778	Physiciansâ€™ gender is associated with risk factor control in patients on antihypertensive and lipid lowering treatment. Blood Pressure, 2010, 19, 240-248.	1.5	24

#	Article	IF	Citations
779	Derivation and Validation of a New Cardiovascular Risk Score for People With Type 2 Diabetes. Diabetes Care, 2010, 33, 1347-1352.	8.6	72
780	Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. Journal of Epidemiology and Community Health, 2010, 64, 109-113.	3.7	35
781	Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Current Medical Research and Opinion, 2010, 26, 25-36.	1.9	27
782	Evaluation of a cardiovascular disease opportunistic risk assessment pilot ('Heart MOT' service) in community pharmacies. Journal of Public Health, 2010, 32, 110-116.	1.8	54
783	Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology, 2010, 75, 864-873.	1.1	176
784	Measuring hsCRPâ€"An Important Part of a Comprehensive Risk Profile or a Clinically Redundant Practice?. PLoS Medicine, 2010, 7, e1000196.	8.4	15
785	Aging and HIV Infection: A Comparison Between Older HIV-Infected Persons and the General Population. HIV Clinical Trials, 2010, 11, 100-109.	2.0	153
786	Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 464-471.	2.1	17
787	Do inflammatory biomarkers add to the discrimination of cardiovascular disease after allowing for social deprivation? Results from a 10-year cohort study in Glasgow, Scotland. European Heart Journal, 2010, 31, 2669-2675.	2.2	19
788	Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 727-739.	0.5	80
789	The effect of blood pressure and cholesterol variability on the precision of Framingham cardiovascular risk estimation: a simulation study. Journal of Human Hypertension, 2010, 24, 631-638.	2.2	6
790	Improving the accuracy of predicting cardiovascular risk. BMJ: British Medical Journal, 2010, 340, c2334-c2334.	2.3	3
791	An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ: British Medical Journal, 2010, 340, c2442-c2442.	2.3	199
792	Potential economic impact of increasing low dose aspirin usage on CVD in the US. Current Medical Research and Opinion, 2010, 26, 2365-2373.	1.9	7
793	Raising highly desirable lipoprotein versus lowering deleterious lipoprotein. Expert Review of Clinical Pharmacology, 2010, 3, 173-176.	3.1	0
794	First evaluation using a validated scale of the risk of congestive heart failure among hypertensive patients treated by general practitioners (O-PREDICT survey). Archives of Cardiovascular Diseases, 2010, 103, 176-183.	1.6	0
795	Oral session 2. International Journal of Pharmacy Practice, 2010, 15, B13-B19.	0.6	0
796	Cardiovascular Risk-Estimation Systems in Primary Prevention. Circulation, 2010, 122, 300-310.	1.6	196

#	Article	IF	Citations
797	Plasma indices of angiogenesis in rheumatoid disease: Relationship to cardiovascular risk factors and cardiac function. International Journal of Cardiology, 2010, 145, e105-e108.	1.7	4
798	Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitusâ€"The STOP-NIDDM risk-score. Diabetes Research and Clinical Practice, 2010, 87, 267-274.	2.8	35
799	Randomised controlled trial of additional lifestyle support for the reduction of cardiovascular disease risk through primary care in Stoke-on-Trent, UK. Contemporary Clinical Trials, 2010, 31, 345-354.	1.8	8
800	Evolution of Causes of Mortality in Renal Transplantation in the Last 10 Years. Transplantation Proceedings, 2010, 42, 1077-1079.	0.6	9
801	Association Between Abnormal Contrast Sensitivity and Mortality Among People With Acquired Immunodeficiency Syndrome. American Journal of Ophthalmology, 2010, 149, 807-816.	3.3	23
803	Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart, 2010, 96, 1985-1989.	2.9	96
804	Cost Effectiveness of Angiotensin Receptor Blocker Monotherapy in Patients with Hypertension in the Netherlands. American Journal of Cardiovascular Drugs, 2010, 10, 49-54.	2.2	12
805	A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment. Pharmacoeconomics, 2010, 28, 255-277.	3.3	48
806	Cost Estimation of Cardiovascular Disease Events in the US. Pharmacoeconomics, 2011, 29, 693-704.	3.3	74
807	Prediction of Cardiovascular Disease Events. Cardiology Clinics, 2011, 29, 1-13.	2.2	10
809	Parental History and Myocardial Infarction Risk Across the World. Journal of the American College of Cardiology, 2011, 57, 619-627.	2.8	116
811	Exercise Guidelines in Pregnancy. Sports Medicine, 2011, 41, 345-360.	6.5	95
812	Effect of a Diabetes Counseling Programme on Knowledge, Attitude and Practice among Diabetic Patients in Erode District of South India. Journal of Young Pharmacists, 2011, 3, 65-72.	0.2	62
813	Differential Improvements in Lipid Profiles and Framingham Recurrent Risk Score in Patients With and Without Diabetes Mellitus Undergoing Long-Term Cardiac Rehabilitation. Archives of Physical Medicine and Rehabilitation, 2011, 92, 1382-1387.	0.9	17
814	The effectiveness of personalized coronary heart disease and stroke risk communication. American Heart Journal, 2011, 161, 673-680.	2.7	51
815	Training providers in hypertension guidelines: Cost-effectiveness evaluation of a continuing medical education program in South Carolina. American Heart Journal, 2011, 162, 786-793.e1.	2.7	12
816	Weight Loss and Lifetime Medical Expenditures. American Journal of Preventive Medicine, 2011, 40, 338-344.	3.0	12
817	Cardiovascular diseases and genome-wide association studies. Clinica Chimica Acta, 2011, 412, 1697-1701.	1.1	22

#	Article	IF	Citations
818	The Challenges and Benefits of Cardiovascular Risk Assessment in Clinical Practice. Canadian Journal of Cardiology, 2011, 27, 481-487.	1.7	16
819	Myocardial Blood Flow and Fibrosis in Hypertrophic Cardiomyopathy. Journal of Cardiac Failure, 2011, 17, 384-391.	1.7	14
820	Rationale and design for a cardiovascular screening and prevention study with tele-cardiology in Mediterranean Italy: The CAPITAL study (CArdiovascular Prevention wIth Telecardiology in ApuLia). International Journal of Cardiology, 2011, 149, 130-133.	1.7	12
821	Lipid metabolism and osteoarthritis: Lessons from atherosclerosis. Progress in Lipid Research, 2011, 50, 133-140.	11.6	131
822	Management of hypertension: summary of NICE guidance. BMJ: British Medical Journal, 2011, 343, d4891-d4891.	2.3	427
823	Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand. International Journal of Pharmacy Practice, 2011, 19, 129-135.	0.6	8
825	Most of the patients presenting myocardial infarction would not be eligible for intensive lipid-lowering based on clinical algorithms or plasma C-reactive protein. Atherosclerosis, 2011, 214, 148-150.	0.8	16
826	Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet, The, 2011, 378, 1219-1230.	13.7	296
827	Platelet, Fatty Acids, Membrane Viscosity, Depression and Ischemic Heart Disease - Biological-Molecular Path, with Medical-Anthropology Insights. , 0, , .		1
828	Metabolic Alterations of HIV Infection. , 2011, , .		0
829	Management of High Blood Pressure in Those without Overt Cardiovascular Disease Utilising Absolute Risk Scores. International Journal of Hypertension, 2011, 2011, 1-3.	1.3	1
830	Socio-medical Characteristics of Coronary Disease in Bosnia and Herzegovina and the World. Materia Socio-medica, 2011, 23, 171.	0.7	22
831	Reducing CVD Risk with Lipid ManagementThis article was first published in British Journal of Cardiac Nursing Vol. 5 No. 9, pp. 410â€“16. Practice Nursing, 2011, 22, 93-97.	0.1	0
832	Layperson-Oriented versus Clinical-Based Models for Assessing 10-Year Incidence of Coronary Heart Disease: National FINRISK Study. International Journal of Vascular Medicine, 2011, 2011, 1-9.	1.0	0
833	Diagnosis of diabetes mellitus as a cardiovascular risk equivalent or risk factor and implications in drug therapy management. Diabetes Management, 2011, 1, 615-626.	0.5	0
834	Effects of a multifaceted educational program on blood pressure and cardiovascular risk in hypertensive patients. Journal of Hypertension, 2011, 29, 2024-2030.	0.5	14
835	Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women. Current Vascular Pharmacology, 2011, 9, 647-657.	1.7	44
836	Association among basal serum BDNF, cardiorespiratory fitness and cardiovascular disease risk factors in untrained healthy Korean men. Yearbook of Sports Medicine, 2011, 2011, 204-206.	0.0	1

#	Article	IF	Citations
837	An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. Yearbook of Sports Medicine, 2011, 2011, 202-204.	0.0	0
838	Validation of two Framingham cardiovascular risk prediction algorithms in an Australian population: the â€˜oldâ€™ versus the â€˜newâ€™ Framingham equation. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 115-120.	2.8	30
839	A new model for 5-year risk of cardiovascular disease in Typeâ€ƒ1 diabetes; from the Swedish National Diabetes Register (NDR). Diabetic Medicine, 2011, 28, 1213-1220.	2.3	67
840	Role of echocardiographic left ventricular mass and carotid intimaâ€media thickness in the cardiovascular risk assessment of asymptomatic patients with type 2 diabetes mellitus. Internal Medicine Journal, 2011, 41, 391-398.	0.8	5
841	Improving lipid profiles and increasing use of lipid-lowering therapy in England: results from a national cross-sectional survey - 2006. Clinical Endocrinology, 2011, 75, 621-627.	2.4	10
842	Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naÃ¯ve HIV-1-infected patients (the ARTEN study). HIV Medicine, 2011, 12, 374-382.	2.2	30
843	Effects on blood pressure and cardiovascular risk of variations in patientsâ€™ adherence to prescribed antihypertensive drugs: role of duration of drug action. International Journal of Clinical Practice, 2011, 65, 41-53.	1.7	35
844	Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. International Journal of Clinical Practice, 2011, 65, 127-133.	1.7	23
845	Functional Dilator Capacity is Independently Associated with Insulin Sensitivity and Age in Central Obesity and is not Improved by High Dose Statin Treatment. Microcirculation, 2011, 18, 74-84.	1.8	21
846	Classical risk factors of cardiovascular disease among Chinese male steel workers: a prospective cohort study for 20 years. BMC Public Health, 2011, 11, 497.	2.9	13
847	Intima-Media Thickness and Carotid Plaques in Cardiovascular Risk Assessment. , 2011, , 397-418.		0
848	Plasma Osteoprotegerin Levels and Longâ€Term Prognosis in Patients With Intermediate Coronary Artery Lesions. Clinical Cardiology, 2011, 34, 447-453.	1.8	14
849	Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk. Diabetologia, 2011, 54, 291-299.	6.3	14
850	Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. Diabetologia, 2011, 54, 2544-2551.	6.3	19
851	Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observational study. BMC Public Health, 2011, 11, 144.	2.9	4
852	Metabolic syndrome and dietary components are associated with coronary artery disease risk score in free-living adults: a cross-sectional study. Diabetology and Metabolic Syndrome, 2011, 3, 7.	2.7	27
853	On the Câ€statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Statistics in Medicine, 2011, 30, 1105-1117.	1.6	972
854	Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normality. Statistics in Medicine, 2011, 30, 1410-1418.	1.6	29

#	Article	IF	Citations
855	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care and Research, 2011, 63, 588-596.	3.4	147
856	Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention. Archives of Internal Medicine, 2011, 171, 218.	3.8	45
857	Investigating mixed hyperlipidaemia. BMJ: British Medical Journal, 2011, 343, d5146-d5146.	2.3	2
858	Increased Risk of Myocardial Infarction Associated With Angiotensin-Converting Enzyme Gene Polymorphism Is Age Dependent. Journal of Clinical Pharmacology, 2011, 51, 1286-1292.	2.0	20
859	Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naÃ¯ve human immunodeficiency virus-1 patients in Sweden. Scandinavian Journal of Infectious Diseases, 2011, 43, 304-312.	1.5	6
860	Gender disparities in the assessment and management of cardiovascular risk in primary care: the AusHEART study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 498-503.	2.8	22
861	Screening for cardiovascular disease: Concerns with a Norwegian proposal. Journal of Medical Screening, 2011, 18, 165-166.	2.3	1
862	Estimated GFR Associates with Cardiovascular Risk Factors Independently of Measured GFR. Journal of the American Society of Nephrology: JASN, 2011, 22, 927-937.	6.1	104
863	Comparing costs associated with risk stratification rules for t-year survival. Biostatistics, 2011, 12, 597-609.	1.5	4
864	Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease. Circulation, 2011, 124, 2056-2064.	1.6	122
865	Performance of the ASSIGN cardiovascular disease risk score on a UK cohort of patients from general practice. Heart, 2011, 97, 491-499.	2.9	35
866	Young Women Have Poorer Outcomes than Men after Stroke. Cerebrovascular Diseases, 2011, 31, 455-463.	1.7	35
867	Palmitic acid in the sn-2 position of triacylglycerols acutely influences postprandial lipid metabolism. American Journal of Clinical Nutrition, 2011, 94, 1433-1441.	4.7	63
868	Diets high in palmitic acid (16:0), lauric and myristic acids (12:0 + 14:0), or oleic acid (18:1) do not alter postprandial or fasting plasma homocysteine and inflammatory markers in healthy Malaysian adults. American Journal of Clinical Nutrition, 2011, 94, 1451-1457.	4.7	106
869	Individual and Population Benefits of Daily Aspirin Therapy. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 268-275.	2.2	30
870	Traditional Risk Factors for Incident Cardiovascular Events Have Limited Importance in Later Life Compared With the Health in Men Study Cardiovascular Risk Score. Stroke, 2011, 42, 952-959.	2.0	24
871	Prediction of coronary heart disease risk by Framingham and SCORE risk assessments varies by socioeconomic position: results from a study in British men. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 186-193.	2.8	26
872	The structure of optimal statin initiation policies for patients with Type 2 diabetes. IIE Transactions on Healthcare Systems Engineering, 2011, 1, 49-65.	0.8	33

#	Article	IF	Citations
873	Cardiovascular Risk and Risk Scores: ASSIGN, Framingham, QRISK and others: how to choose. Heart, 2011, 97, 442-444.	2.9	44
874	Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 393-398.	2.8	127
875	Health behaviour risk factors for coronary heart disease (CHD) in smokers with a psychotic disorder: baseline results. Mental Health and Substance Use: Dual Diagnosis, 2011, 4, 158-171.	0.5	16
876	Risk Prediction for Early In-Hospital Mortality Following Heart Transplantation in the United States. Circulation: Heart Failure, 2012, 5, 259-266.	3.9	47
877	Being at risk for cardiovascular disease: Perceptions and preventive behavior in people with and without a known genetic predisposition. Psychology, Health and Medicine, 2012, 17, 511-521.	2.4	38
878	Cardiovascular screening for men at high risk in Heart of Birmingham Teaching Primary Care Trust: the 'Deadly Trio' programme. Journal of Public Health, 2012, 34, 73-82.	1.8	25
879	Soluble Vascular Adhesion Protein-1 Correlates With Cardiovascular Risk Factors and Early Atherosclerotic Manifestations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 523-532.	2.4	49
880	A comparative effect of atorvastatin with other statins in patients of hyperlipidemia. Indian Journal of Pharmacology, 2012, 44, 261.	0.7	15
881	Causes of Resistant Hypertension Detected by a Standardized Algorithm. International Journal of Hypertension, 2012, 2012, 1-5.	1.3	3
882	A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention. European Journal of Preventive Cardiology, 2012, 19, 42-53.	1.8	6
883	Risk Estimation Versus Screening Performance: A Comparison of Six Risk Algorithms for Cardiovascular Disease. Journal of Medical Screening, 2012, 19, 201-205.	2.3	20
884	Principles of health economic evaluations of lipid-lowering strategies. Current Opinion in Lipidology, 2012, 23, 271-281.	2.7	5
885	Inclusion of Stroke in Cardiovascular Risk Prediction Instruments. Stroke, 2012, 43, 1998-2027.	2.0	125
886	Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ, The, 2012, 344, e3318-e3318.	6.0	238
887	Are reference equations for spirometry an appropriate criterion for diagnosing disease and predicting prognosis?. Thorax, 2012, 67, 85-87.	5.6	25
888	A Pilot Study Evaluating Multiple Risk Factor Interventions by Community Pharmacists to Prevent Cardiovascular Disease: The PAART CVD Pilot Project. Annals of Pharmacotherapy, 2012, 46, 183-191.	1.9	20
889	Simulation Of Quitting Smoking In The Military Shows Higher Lifetime Medical Spending More Than Offset By Productivity Gains. Health Affairs, 2012, 31, 2717-2726.	5.2	6
890	Association of C-Reactive Protein With Cardiovascular Disease Mortality According to Diabetes Status. Diabetes Care, 2012, 35, 396-403.	8.6	90

#	Article	IF	Citations
891	The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model. BMJ, The, 2012, 344, e3657-e3657.	6.0	39
892	Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ, The, 2012, 344, e4181-e4181.	6.0	195
893	Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ, The, 2012, 345, e4535-e4535.	6.0	55
894	A Score for the Prediction of Cardiovascular Events in the Hypertensive Aged. American Journal of Hypertension, 2012, 25, 190-194.	2.0	6
896	Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain. Journal of Medical Economics, 2012, 15, 45-54.	2.1	11
897	Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart, 2012, 98, 360-369.	2.9	184
898	Associations of Glycemic Index and Load With Coronary Heart Disease Events: A Systematic Review and Metaâ€Analysis of Prospective Cohorts. Journal of the American Heart Association, 2012, 1, e000752.	3.7	123
899	Nutrition and the HIV-associated lipodystrophy syndrome. Nutrition Research Reviews, 2012, 25, 267-287.	4.1	31
900	Primary prevention of cardiovascular disease using validated risk scores: A systematic review. Journal of the Royal Society of Medicine, 2012, 105, 348-356.	2.0	31
901	Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. Heart, 2012, 98, 988-994.	2.9	151
902	Methods for assessing cardiovascular disease risk in a UK black population. Heart, 2012, 98, 1373-1377.	2.9	11
903	Carotid intimaâ€“media thickness and the prediction of vascular events. Vascular Medicine, 2012, 17, 239-248.	1.5	47
904	Patient and Other Factors Influencing the Prescribing of Cardiovascular Prevention Therapy in the General Practice Setting With and Without Nurse Assessment. Medical Decision Making, 2012, 32, 498-506.	2.4	16
905	Cardiovascular Risk Estimation in 2012: Lessons Learned and Applicability to the HIV Population. Journal of Infectious Diseases, 2012, 205, S362-S367.	4.0	62
906	Starting and staying on preventive medication for cardiovascular disease. Current Opinion in Cardiology, 2012, 27, 533-541.	1.8	5
907	Synergistic Effects of HIV Infection and Older Age on Daily Functioning. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 341-348.	2.1	116
908	Development and Validation of a Coronary Risk Prediction Model for Older U.S. and European Persons in the Cardiovascular Health Study and the Rotterdam Study. Annals of Internal Medicine, 2012, 157, 389.	3.9	58
910	Screening for Future Coronary Heart Disease in Oilfield Personnel by Using Risk Factor Categories. , 2012, , .		0

#	Article	IF	Citations
911	Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?. Current Cardiology Reviews, 2012, 8, 86-97.	1.5	16
912	Cardiovascular Risk Score and Cardiovascular Events Among Airline Pilots: A Case-Control Study. Aviation, Space, and Environmental Medicine, 2012, 83, 465-471.	0.5	11
913	Estimation of cardiovascular risk using 10-year risk metric. Current Opinion in Lipidology, 2012, 23, 402-403.	2.7	0
915	On the Applications of Heart Disease Risk Classification and Hand-written Character Recognition using Support Vector Machines. , 2012, , 213-253.		2
916	Cardiovascular Risk Management After a Hypertensive Disorder of Pregnancy. Hypertension, 2012, 60, 1368-1373.	2.7	72
917	Cardiovascular risk. British Journal of Clinical Pharmacology, 2012, 74, 396-410.	2.4	53
918	ProtÃ©ine C rÃ©active, homocystÃ©ine et risque cardiovasculaire. Revue Francophone Des Laboratoires, 2012, 2012, 27-31.	0.0	0
919	Apolipoprotein E genotype and the cardiovascular disease risk phenotype: Impact of sex and adiposity (the FINGEN study). Atherosclerosis, 2012, 221, 467-470.	0.8	32
920	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68.	0.8	414
921	Impact of country of birth on arterial function in subjects living in France. Journal of the American Society of Hypertension, 2012, 6, 405-413.	2.3	7
923	Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes. American Journal of Kidney Diseases, 2012, 60, 770-778.	1.9	110
924	Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 513-520.	1.3	32
925	Risques cardiovasculaires et mÃ©dicaments. Medecine Des Maladies Metaboliques, 2012, 6, 11-13.	0.1	0
926	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	2.2	5,247
929	Prognostic models in the clinical arena. Aging Clinical and Experimental Research, 2012, 24, 300-304.	2.9	4
930	Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. European Journal of Epidemiology, 2012, 27, 657-665.	5.7	73
931	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Journal of Preventive Cardiology, 2012, 19, 585-667.	1.8	359
932	Risk prediction models: II. External validation, model updating, and impact assessment. Heart, 2012, 98, 691-698.	2.9	845

#	Article	IF	Citations
933	Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. Journal of Medical Economics, 2012, 15, 253-260.	2.1	4
934	The association between the Framingham risk score and sleep: A SÃ£o Paulo epidemiological sleep study. Sleep Medicine, 2012, 13, 577-582.	1.6	17
935	People living with psychotic illness in 2010: The second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry, 2012, 46, 735-752.	2.3	405
936	An International Model to Predict Recurrent Cardiovascular Disease. American Journal of Medicine, 2012, 125, 695-703.e1.	1.5	184
937	The relationship between subclinical atherosclerosis, nonâ€“high-density lipoprotein cholesterol, exercise, andÂdiet among male participants of the PACC Project. Journal of Clinical Lipidology, 2012, 6, 174-179.	1.5	11
938	Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 98, 83-90.	2.8	18
939	Carotid circumferential wall stress homeostasis in early remodeling: Theoretical approach and clinical application. Journal of Clinical Ultrasound, 2012, 40, 486-494.	0.8	4
940	Mixed methods evaluation of targeted case finding for cardiovascular disease prevention using a stepped wedged cluster RCT. BMC Public Health, 2012, 12, 908.	2.9	13
941	NHS health checks through general practice: randomised trial of population cardiovascular risk reduction. BMC Public Health, 2012, 12, 944.	2.9	56
942	Assessing cardiovascular risk in regional areas: the Healthy Hearts â€“ Beyond City Limits program. BMC Health Services Research, 2012, 12, 296.	2.2	10
943	Lifestyle Educational Program Strongly Increases Compliance to Nonpharmacologic Intervention in Hypertensive Patients: A 2â€Year Followâ€Up Study. Journal of Clinical Hypertension, 2012, 14, 767-772.	2.0	16
944	Multi-Ethnic Study of Atherosclerosis Arterial Age Versus Framingham 10-Year or Lifetime Cardiovascular Risk. American Journal of Cardiology, 2012, 110, 1627-1630.	1.6	22
946	Metabolic syndrome and vascular risk estimation in a Mediterranean non-diabetic population without cardiovascular disease. European Journal of Internal Medicine, 2012, 23, 558-563.	2.2	10
947	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine, 2012, 19, 403-488.	1.7	224
948	GuÃa europea sobre prevenciÃ³n de la enfermedad cardiovascular en la prÃ¡ctica clÃnica (versiÃ³n 2012). Revista Espanola De Cardiologia, 2012, 65, 937.e1-937.e66.	1.2	30
949	Changes to the Statin Prescribing Policy in Belgium. American Journal of Cardiovascular Drugs, 2012, 12, 225-232.	2.2	5
950	Prevention of Type 2 Diabetes. , 2012, , .		1
951	Decreasing Postprandial Plasma Glucose Using an Î±-Glucosidase Inhibitor in Subjects with IGT for the Prevention of Type 2 Diabetes Mellitus: The STOP-NIDDM Trial. , 2012, , 167-187.		1

#	Article	IF	Citations
952	Health- related quality of life in diabetic people with different vascular risk. BMC Public Health, 2012, 12, 812.	2.9	27
953	Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health, 2012, 12, 398.	2.9	58
954	The effect of a patient-oriented treatment decision aid for risk factor management in patients with diabetes (PORTDA-diab): study protocol for a randomised controlled trial. Trials, 2012, 13, 219.	1.6	12
955	Angiotensin Converting Enzyme Inhibitor and HMG-CoA Reductase Inhibitor as Adjunct Treatment for Persons with HIV Infection: A Feasibility Randomized Trial. PLoS ONE, 2012, 7, e46894.	2.5	32
956	New Zealand Diabetes Cohort Study cardiovascular risk score for people with Type 2 diabetes: validation in the PREDICT cohort. Journal of Primary Health Care, 2012, 4, 181.	0.6	9
957	Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. ClinicoEconomics and Outcomes Research, 2012, 4, 1.	1.9	19
958	Application of Total Cardiovascular Risk Estimation in The Management of A Patient with Cardiovascular Risk. University Heart Journal, 2012, 7, 28-34.	0.0	0
959	A framework for quantifying net benefits of alternative prognostic models. Statistics in Medicine, 2012, 31, 114-130.	1.6	18
960	Quantifying discrimination of Framingham risk functions with different survival C statistics. Statistics in Medicine, 2012, 31, 1543-1553.	1.6	76
961	Misuse of DeLong test to compare AUCs for nested models. Statistics in Medicine, 2012, 31, 2577-2587.	1.6	192
962	Attainment of Normal Lipid Levels Among Patients on Lipid-Modifying Therapy in Hong Kong. Advances in Therapy, 2012, 29, 427-441.	2.9	6
963	The partially observable Markov decision processes in healthcare: an application to patients with ischemic heart disease (IHD). Operational Research, 2012, 12, 3-14.	2.0	7
964	Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany. European Journal of Health Economics, 2012, 13, 365-374.	2.8	9
965	<scp>B</scp>ritish <scp>HIV A</scp>ssociation guidelines for the routine investigation and monitoring of adult <scp>HIV</scp>â€‰â€infected individuals 2011. HIV Medicine, 2012, 13, 1-44.	2.2	162
966	Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study. Journal of Evaluation in Clinical Practice, 2012, 18, 159-168.	1.8	35
967	Underestimation of urinary albumin to creatinine ratio in morbidly obese subjects due to high urinary creatinine excretion. Clinical Nutrition, 2012, 31, 212-216.	5.0	10
968	New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. International Journal of Clinical Practice, 2012, 66, 622-630.	1.7	22
969	A â€˜whole of systemâ€™ approach to compare options for CVD interventions in Counties Manukau. Australian and New Zealand Journal of Public Health, 2012, 36, 263-268.	1.8	12

#	Article	IF	Citations
970	Newâ€onset hypertension in pregnancy: a review of the longâ€term maternal effects. The Obstetrician and Gynaecologist, 2012, 14, 99-105.	0.4	3
971	Outcome of smoking cessation counselling of <scp>HIV</scp>â€positive persons by <scp>HIV</scp> care physicians. HIV Medicine, 2012, 13, 387-397.	2.2	41
973	Impact of pharmacy outreach services on blood pressure management in the elderly community of Hong Kong. Geriatrics and Gerontology International, 2013, 13, 175-181.	1.5	8
974	Serum thiols and cardiovascular risk scores: a combined assessment of transsulfuration pathway components and substrate/product ratios. Journal of Translational Medicine, 2013, 11, 99.	4.4	19
975	In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study. BMC Family Practice, 2013, 14, 13.	2.9	14
976	Evaluation of a community intervention program in Japan using Framingham risk score and estimated 10-year coronary heart disease risk as outcome variables: a non-randomized controlled trial. BMC Public Health, 2013, 13, 219.	2.9	16
977	Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men. Journal of General Internal Medicine, 2013, 28, 1483-1491.	2.6	17
978	Cerebral Ischemic Stroke: is Gender Important?. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1355-1361.	4.3	125
979	Genetic neural network based data mining in prediction of heart disease using risk factors. , 2013, , .		136
980	Age- and gender-specific reference values of pulse wave velocity for African adults: preliminary results. Age, 2013, 35, 2345-2355.	3.0	17
981	Characterizing mild cognitive disorders in the youngâ€old over 8 years: Prevalence, estimated incidence, stability of diagnosis, and impact on IADLs. Alzheimer's and Dementia, 2013, 9, 640-648.	0.8	40
982	External validation of the 2008 Framingham cardiovascular risk equation for CHD and stroke events in a European population of middle-aged men. The PRIME study. Preventive Medicine, 2013, 57, 49-54.	3.4	21
983	Diabetes Modifies Effect of High-Phosphate Diet on Fibroblast Growth Factor-23 in Chronic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1901-E1908.	3.6	18
984	The Faces of Personalized Medicine: A Framework for Understanding Its Meaning and Scope. Value in Health, 2013, 16, S4-S9.	0.3	138
985	Using Benefit-Based Tailored Treatment to Improve the Use of Antihypertensive Medications. Circulation, 2013, 128, 2309-2317.	1.6	80
986	The Cost-effectiveness of Supervised Exercise for the Treatment of Intermittent Claudication. European Journal of Vascular and Endovascular Surgery, 2013, 46, 707-714.	1.5	43
987	Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk. Atherosclerosis, 2013, 226, 245-251.	0.8	23
988	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,758

#	Article	IF	Citations
989	Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations. BMC Medicine, 2013, 11, 170.	5.5	38
990	Evaluation of the performance of existing non-laboratory based cardiovascular risk assessment algorithms. BMC Cardiovascular Disorders, 2013, 13, 123.	1.7	16
991	Impact of correlation on predictive ability of biomarkers. Statistics in Medicine, 2013, 32, 4196-4210.	1.6	17
992	Predicting the Impact of Polypill Use in a Metabolic Syndrome Population: An Effectiveness and Cost-Effectiveness Analysis. American Journal of Cardiovascular Drugs, 2013, 13, 121-128.	2.2	7
993	Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States. Pharmacoeconomics, 2013, 31, 427-444.	3.3	18
994	Concise Review: Heart Regeneration and the Role of Cardiac Stem Cells. Stem Cells Translational Medicine, 2013, 2, 434-443.	3.3	69
995	Plasma <scp>YKL</scp>â€40 predicts 10â€year cardiovascular and allâ€cause mortality in individuals with type 2 diabetes. Clinical Endocrinology, 2013, 79, 185-191.	2.4	14
998	Evaluation of Framingham and Systematic Coronary Risk Evaluation Scores by Coronary Computed Tomographic Angiography in Asymptomatic Adults. American Journal of Cardiology, 2013, 111, 700-704.	1.6	13
999	Attainment of normal lipid levels among high cardiovascular risk patients: Pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada. European Journal of Internal Medicine, 2013, 24, 656-663.	2.2	7
1000	Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia. Schizophrenia Research, 2013, 147, 187-192.	2.0	29
1001	A new set of risk equations for predicting long term risk of all-cause mortality using cardiovascular risk factors. Preventive Medicine, 2013, 56, 41-45.	3.4	10
1002	Designing and implementing a comparative effectiveness study of two strategies for delivering high quality CHD prevention: Methods and participant characteristics for the Heart to Health study. Contemporary Clinical Trials, 2013, 36, 394-405.	1.8	16
1003	ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. Journal of Human Hypertension, 2013, 27, 492-496.	2.2	14
1004	Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ, The, 2013, 346, f2573-f2573.	6.0	115
1005	Personalized cardiovascular medicine: concepts and methodological considerations. Nature Reviews Cardiology, 2013, 10, 308-316.	13.7	32
1006	Effects of Transoral Gastroplasty on Glucose Homeostasis in Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1901-1910.	3.6	5
1007	High osteoporotic fracture risk and CVD risk co-exist in postmenopausal women. Bone, 2013, 52, 120-125.	2.9	15
1008	Machine Learning in Medical Imaging. Lecture Notes in Computer Science, 2013, , .	1.3	24

#	Article	IF	Citations
1009	Attainment of Goal and Normalized Lipid Levels With Lipid-Modifying Therapy in Malaysia. Clinical Therapeutics, 2013, 35, 450-460.	2.5	1
1010	Cardiovascular Disease Risk Prediction - Integration into Clinical Practice. Current Cardiovascular Risk Reports, 2013, 7, 346-353.	2.0	2
1011	Starting statins for primary prevention of cardiovascular disease. Heart, 2013, 99, 1547-1548.	2.9	4
1012	Plasma Acetylcholinesterase Activity Correlates with Intracerebral Î²-Amyloid Load. Current Alzheimer Research, 2013, 10, 48-56.	1.4	13
1013	Cost-Effectiveness of a Novel Blood-Pool Contrast Agent in the Setting of Chest Pain Evaluation in an Emergency Department. American Journal of Roentgenology, 2013, 201, 710-719.	2.2	3
1014	Cardiovascular risk assessment of South Asian populations in religious and community settings: a qualitative study. Family Practice, 2013, 30, 466-472.	1.9	10
1015	Utility of established cardiovascular disease risk score models for the 10-year prediction of disease outcomes in women. Expert Review of Cardiovascular Therapy, 2013, 11, 425-435.	1.5	10
1016	Four-Limb Blood Pressure as Predictors of Mortality in Elderly Chinese. Hypertension, 2013, 61, 1155-1160.	2.7	74
1017	Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. European Heart Journal, 2013, 34, 972-981.	2.2	33
1018	Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. BMJ, The, 2013, 347, f6048-f6048.	6.0	45
1019	The cost-effectiveness of growth hormone replacement therapy (GenotropinÂ®) in hypopituitary adults in Sweden. Cost Effectiveness and Resource Allocation, 2013, 11, 24.	1.5	10
1020	From Model to Action. Health Promotion Practice, 2013, 14, 53-61.	1.6	60
1021	Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective. Journal of Medical Economics, 2013, 16, 907-916.	2.1	5
1022	Assessing Appropriateness of Lipid Management Among Patients With Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 66-74.	2.2	24
1023	Fibrinogen and future cardiovascular disease in people with diabetes: Aetiological associations and risk prediction using individual participant data from nine community-based prospective cohort studies. Diabetes and Vascular Disease Research, 2013, 10, 143-151.	2.0	11
1024	Agreement Among Cardiovascular Disease Risk Calculators. Circulation, 2013, 127, 1948-1956.	1.6	97
1025	Cost-Effectiveness of Renin-Guided Treatment of Hypertension. American Journal of Hypertension, 2013, 26, 1303-1310.	2.0	14
1026	Cardiovascular risk factors and cognitive decline in adults aged 50 and over: a population-based cohort study. Age and Ageing, 2013, 42, 338-345.	1.6	136

#	Article	IF	Citations
1027	Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions. Circulation, 2013, 128, 1927-1995.	1.6	449
1028	Letter by Payne and Webb Regarding Article, â€œAgreement Among Cardiovascular Disease Risk Calculatorsâ€• Circulation, 2013, 128, e428.	1.6	0
1029	Aortic stiffness and cardiovascular risk in type 2 diabetes. Journal of Hypertension, 2013, 31, 1584-1592.	0.5	51
1030	Differences in Predicted Cardiovascular Risk in Sinhalese and Tamils in Sri Lanka Compared With Sri Lankans in Norway. Asia-Pacific Journal of Public Health, 2013, 25, 452-462.	1.0	3
1031	Impact of lipidâ€lowering therapy on the prevalence of dyslipidaemia in patients at highâ€risk of cardiovascular events in <scp>UK</scp> primary care â€“ a retrospective database study. International Journal of Clinical Practice, 2013, 67, 1228-1237.	1.7	13
1032	A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort. European Journal of Preventive Cardiology, 2013, 20, 98-106.	1.8	3
1033	Characteristics and Future Cardiovascular Risk of Patients With Notâ€Atâ€Goal Hypertension in General Practice in France: The <scp>AVANT</scp>'<scp>AGE</scp> Study. Journal of Clinical Hypertension, 2013, 15, 291-295.	2.0	12
1034	Does measurement of ankleâ€brachial index contribute to prediction of adverse health outcomes in older <scp>C</scp>hinese people?. Internal Medicine Journal, 2013, 43, 1017-1023.	0.8	4
1035	The Identification of Prediabetes Condition with ARIC Algorithm Predicts Long-Term CV Events in Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2013, 10, 1114-1123.	0.6	24
1036	Vascular Risk Calculators. Circulation, 2013, 127, 1929-1931.	1.6	11
1037	The TrueBlue model of collaborative care using practice nurses as case managers for depression alongside diabetes or heart disease: a randomised trial. BMJ Open, 2013, 3, e002171.	1.9	82
1038	Ethnic differences in risk factors and total risk of cardiovascular disease based on the Norwegian CONOR study. European Journal of Preventive Cardiology, 2013, 20, 1013-1021.	1.8	32
1039	Cardiovascular Risk Assessment in Diabetes Mellitus. Angiology, 2013, 64, 336-342.	1.8	20
1040	Is serum urate causally associated with incident cardiovascular disease?. Rheumatology, 2013, 52, 135-142.	1.9	17
1041	Effects of Smoking Habit on the Prevalence of Atrial Fibrillation in Japanese Patients With Special Reference to Sex Differences. Circulation Journal, 2013, 77, 2948-2953.	1.6	16
1042	Considerations for the Long-Term Management of Women Living with HIV in Europe. Antiviral Therapy, 2013, 18, 45-52.	1.0	8
1043	Microbial Translocation in HIV Infection Is Associated With Dyslipidemia, Insulin Resistance, and Risk of Myocardial Infarction. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 425-433.	2.1	73
1044	Cardiovascular Investigations of Airline Pilots with Excessive Cardiovascular Risk. Aviation, Space, and Environmental Medicine, 2013, 84, 608-612.	0.5	5

#	Article	IF	Citations
1045	Improved Cardiovascular Risk Prediction Using Nonparametric Regression and Electronic Health Record Data. Medical Care, 2013, 51, 251-258.	2.4	52
1046	The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?. Heart, 2013, 99, 1597-1602.	2.9	49
1047	Accuracy of Anthropometric Parameters in Identification of High-risk Patients Predicted With Cardiovascular Risk Models. American Journal of the Medical Sciences, 2013, 346, 26-31.	1.1	10
1048	Hemoglobin A1c Is Positively Correlated with Framingham Risk Score in Older, Apparently Healthy Nondiabetic Korean Adults. Endocrinology and Metabolism, 2013, 28, 103.	3.0	8
1049	A 50-year follow-up of the Seven Countries Study: Prevalence of cardiovascular risk factors, food and nutrient intakes among Cretans. Hormones, 2013, 12, 379-385.	1.9	14
1050	Primary prevention of cardiovascular disease: new guidelines, technologies and therapies. Medical Journal of Australia, 2013, 198, 606-610.	1.7	32
1051	Joint Prevalence of Diabetes, Impaired Glucose Regulation, Cardiovascular Disease Risk and Chronic Kidney Disease in South Asians and White Europeans. PLoS ONE, 2013, 8, e55580.	2.5	26
1052	Impact of Cardiovascular Calcifications on the Detrimental Effect of Continued Smoking on Cardiovascular Risk in Male Lung Cancer Screening Participants. PLoS ONE, 2013, 8, e66484.	2.5	8
1053	Are Lifestyle Interventions in Primary Care Cost-Effective? â€“ An Analysis Based on a Markov Model, Differences-In-Differences Approach and the Swedish BjÃ¶rknÃs Study. PLoS ONE, 2013, 8, e80672.	2.5	17
1054	Recreational Physical Activity as an Independent Predictor of Multivariable Cardiovascular Disease Risk. PLoS ONE, 2013, 8, e83435.	2.5	20
1055	Early Mortality and Primary Causes of Death in Mothers of Children with Intellectual Disability or Autism Spectrum Disorder: A Retrospective Cohort Study. PLoS ONE, 2014, 9, e113430.	2.5	21
1056	Adding multiple risk factors improves Framingham coronary heart disease risk scores. Vascular Health and Risk Management, 2014, 10, 557.	2.3	3
1057	MULTI-STATE MODELS OF HIV/AIDS BY HOMOGENEOUS SEMI-MARKOV PROCESS. American Journal of Biostatistics, 2014, 4, 21-28.	0.1	6
1058	Multidetector Computed Tomography for the Evaluation of Coronary Artery Disease; The Diagnostic Accuracy in Calcified Coronary Arteries, Comparing with IVUS Imaging. Yonsei Medical Journal, 2014, 55, 599.	2.2	5
1059	Cardiovascular disease risk score prediction models for women and its applicability to Asians. International Journal of Women's Health, 2014, 6, 259.	2.6	6
1060	Effectiveness of a team intervention in reducing modifiable cardiovascular disease risk in HIV-infected subjects on antiretroviral therapy. Journal of the International AIDS Society, 2014, 17, 19546.	3.0	4
1062	Health Track. , 2014, , .		4
1063	Ethnic group differences in cardiovascular risk assessment scores: national cross-sectional study. Ethnicity and Health, 2014, 19, 367-384.	2.5	21

#	Article	IF	Citations
1064	Using the Coronary Artery Calcium Score to Guide Statin Therapy. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 276-284.	2.2	95
1065	Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study. BMC Women's Health, 2014, 14, 118.	2.0	30
1066	Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis. European Journal of Preventive Cardiology, 2014, 21, 1517-1530.	1.8	81
1067	Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naÃ¯ve women of childbearing age. Journal of Medical Economics, 2014, 17, 250-258.	2.1	1
1068	Self-management Education by Group Care Reduces Cardiovascular Risk in Patients With Type 2 Diabetes: Analysis of the ROMEO Clinical Trial. Diabetes Care, 2014, 37, e192-e193.	8.6	6
1069	The impact of different point-of-care testing lipid analysers on cardiovascular disease risk assessment. Journal of Clinical Pathology, 2014, 67, 535-539.	2.0	12
1070	Predicted 10-year risk of cardiovascular disease is influenced by the risk equation adopted: a cross-sectional analysis. British Journal of General Practice, 2014, 64, e634-e640.	1.4	14
1071	Contribution of Individual Risk Factor Changes to Reductions in Population Absolute Cardiovascular Risk. BioMed Research International, 2014, 2014, 1-6.	1.9	6
1072	Increasing Obesity in Treated Female HIV Patients from Sub-Saharan Africa: Potential Causes and Possible Targets for Intervention. Frontiers in Immunology, 2014, 5, 507.	4.8	22
1073	Family history of premature cardiovascular disease: blood pressure control and long-term mortality outcomes in hypertensive patients. European Heart Journal, 2014, 35, 563-570.	2.2	25
1074	Anthropometric measurements of general and central obesity and the prediction of cardiovascular disease risk in women: a cross-sectional study. BMJ Open, 2014, 4, e004138.	1.9	93
1075	Ethnicity and the association between anthropometric indices of obesity and cardiovascular risk in women: a cross-sectional study. BMJ Open, 2014, 4, e004702.	1.9	25
1076	Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings. Journal of Hypertension, 2014, 32, 681-692.	0.5	24
1077	Prevalence and costs of treating uncomplicated stage 1 hypertension in primary care: a cross-sectional analysis. British Journal of General Practice, 2014, 64, e641-e648.	1.4	10
1078	Biomarkers in psychosis: an approach to early identification and individualized treatment. Biomarkers in Medicine, 2014, 8, 51-57.	1.4	11
1079	Homocysteine Levels and Treatment Effect in the Prospective Study of Pravastatin in the Elderly at Risk. Journal of the American Geriatrics Society, 2014, 62, 213-221.	2.6	24
1080	Improvement in Stroke Risk Prediction: Role of C-Reactive Protein and Lipoprotein-Associated Phospholipase A₂ in the Women's Health Initiative. International Journal of Stroke, 2014, 9, 902-909.	5.9	12
1081	Validation of the IMS CORE Diabetes Model. Value in Health, 2014, 17, 714-724.	0.3	163

#	Article	IF	Citations
1082	The Role of Aspirin in the Prevention of Cardiovascular Disease. Clinical Medicine and Research, 2014, 12, 147-154.	0.8	146
1083	Risk predictive modelling for diabetes and cardiovascular disease. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 1-12.	6.1	22
1084	Improving risk prediction performance for a better guidelines application. Journal of Hypertension, 2014, 32, 1192-1193.	0.5	0
1085	High performance of a risk calculator that includes renal function in predicting mortality of hypertensive patients in clinical application. Journal of Hypertension, 2014, 32, 1245-1254.	0.5	9
1086	The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. Current Opinion in Lipidology, 2014, 25, 239-246.	2.7	12
1087	Introducing genetic testing for cardiovascular disease in primary care: a qualitative study. British Journal of General Practice, 2014, 64, e282-e289.	1.4	12
1088	Risk Calculation Variability Over Time in Ocular Hypertensive Subjects. Journal of Glaucoma, 2014, 23, 1-4.	1.6	32
1089	Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. Aids, 2014, 28, 1171-1179.	2.2	22
1090	Comparison of cardiovascular disease risk calculators. Current Opinion in Lipidology, 2014, 25, 254-265.	2.7	39
1091	A Naturopathic Approach to the Prevention of Cardiovascular Disease. Journal of Occupational and Environmental Medicine, 2014, 56, 171-176.	1.7	20
1092	Effects of Combination Antiretroviral Therapies on the Risk of Myocardial Infarction Among HIV Patients. Epidemiology, 2014, 25, 406-417.	2.7	26
1093	Effect of Patientsâ€™ Risks and Preferences on Health Gains With Plasma Glucose Level Lowering in Type 2 Diabetes Mellitus. JAMA Internal Medicine, 2014, 174, 1227.	5.1	158
1094	A Comparison of Live Counseling With a Web-Based Lifestyle and Medication Intervention to Reduce Coronary Heart Disease Risk. JAMA Internal Medicine, 2014, 174, 1144.	5.1	64
1095	A New High-Resolution Spectral Approach to Noninvasively Evaluate Wall Deformations in Arteries. Computational and Mathematical Methods in Medicine, 2014, 2014, 1-15.	1.3	10
1096	Cardiometabolic risk and disease in Indigenous Australians: The heart of the heart study. International Journal of Cardiology, 2014, 171, 377-383.	1.7	38
1097	Economic Evaluation of Primary Prevention of Cardiovascular Diseases in Mild Hypertension: A Scenario Analysis for the Netherlands. Clinical Therapeutics, 2014, 36, 368-384.e5.	2.5	7
1098	The ACTonHEART study: rationale and design of a randomized controlled clinical trial comparing a brief intervention based on Acceptance and Commitment Therapy to usual secondary prevention care of coronary heart disease. Health and Quality of Life Outcomes, 2014, 12, 22.	2.4	29
1099	Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. European Journal of Epidemiology, 2014, 29, 119-132.	5.7	108

#	Article	IF	Citations
1100	New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. Wiener Klinische Wochenschrift, 2014, 126, 169-175.	1.9	17
1101	Findings of Cardiac Magnetic Resonance Imaging in Asymptomatic Myocardial Ischemic Disease in Takayasu Arteritis. American Journal of Cardiology, 2014, 113, 881-887.	1.6	30
1102	GuÃa de prÃ¡ctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciÃ³n con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	1.2	15
1103	Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease. Pharmacoeconomics, 2014, 32, 627-637.	3.3	5
1104	Profiling Cardiovascular Disease Event Risk through Clustering of Classification Association Rules. , 2014, , .		3
1105	Screening for hyperuricaemia and gout: a perspective and research agenda. Nature Reviews Rheumatology, 2014, 10, 752-756.	8.0	19
1106	A comparison of methods for assessing mortality risk. American Journal of Human Biology, 2014, 26, 768-776.	1.6	70
1107	Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries. International Journal of Clinical Practice, 2014, 68, 1010-1019.	1.7	7
1108	Interventions for improving modifiable risk factor control in the secondary prevention of stroke. The Cochrane Library, 2014, , CD009103.	2.8	45
1109	Standard cardiovascular disease risk algorithms underestimate the risk of cardiovascular disease in schizophrenia: Evidence from a national primary care database. Schizophrenia Research, 2014, 159, 176-181.	2.0	22
1110	Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms. European Journal of Preventive Cardiology, 2014, 21, 384-390.	1.8	13
1113	Increased risk of cardiovascular disease (<scp>CVD</scp>) with age in <scp>HIV</scp>â€positive men: a comparison of the <scp>D</scp>:<scp>A</scp>:<scp>D CVD</scp> risk equation and general population <scp>CVD</scp> risk equations. HIV Medicine, 2014, 15, 595-603.	2.2	44
1114	Cardiovascular Risk Stratification and Management in Pre-Diabetes. Current Diabetes Reports, 2014, 14, 493.	4.2	48
1115	Correlation Between Brachial-Ankle Pulse Wave Velocity, Carotid Artery Intima-Media Thickness, Ankle-Brachial Index, and the Severity of Coronary Lesions. Cell Biochemistry and Biophysics, 2014, 70, 1205-1211.	1.8	15
1116	Hypertension education and adherence in South Africa: a cost-effectiveness analysis of community health workers. BMC Public Health, 2014, 14, 240.	2.9	45
1117	IMPACT - Integrative Medicine PrimAry Care Trial: protocol for a comparative effectiveness study of the clinical and cost outcomes of an integrative primary care clinic model. BMC Complementary and Alternative Medicine, 2014, 14, 132.	3.7	19
1118	Formal and informal prediction of recurrent stroke and myocardial infarction after stroke: a systematic review and evaluation of clinical prediction models in a new cohort. BMC Medicine, 2014, 12, 58.	5.5	23
1119	Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment?. International Journal of Cardiology, 2014, 176, 980-987.	1.7	7

#	Article	IF	Citations
1120	Neurosurgery for Extracranial Carotid Disease. , 2014, , 1-22.		0
1121	Prediction of Coronary Artery Disease Severity Using CHADS2 and CHA2DS2-VASc Scores and a Newly Defined CHA2DS2-VASc-HS Score. American Journal of Cardiology, 2014, 113, 950-956.	1.6	74
1122	Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study. British Journal of General Practice, 2014, 64, e38-e46.	1.4	28
1123	More rigorous protocol adherence to intensive structured management improves blood pressure control in primary care. Journal of Hypertension, 2014, 32, 1342-1350.	0.5	10
1124	Separate prediction of intracerebral hemorrhage and ischemic stroke. Neurology, 2014, 82, 1804-1812.	1.1	20
1125	Assessing lifestyle interventions to improve cardiovascular health using an agent-based model. , 2014, , .		6
1126	Normal Myocardial Flow Reserve in HIV-Infected Patients on Stable Antiretroviral Therapy. Medicine (United States), 2015, 94, e1886.	1.0	15
1127	Intervention fidelity for a complex behaviour change intervention in community pharmacy addressing cardiovascular disease risk. Health Education Research, 2015, 30, cyv050.	1.9	8
1128	Factors associated with neurocognitive test performance at baseline: a substudy of the <scp>INSIGHT</scp> Strategic Timing of AntiRetroviral Treatment (<scp>START</scp>) trial. HIV Medicine, 2015, 16, 97-108.	2.2	69
1129	Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. Annals of Internal Medicine, 2015, 162, 55-63.	3.9	1,807
1130	How do general practitioners and patients make decisions about cardiovascular disease risk?. Health Psychology, 2015, 34, 253-261.	1.6	36
1131	Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective cohort study. BMJ Open, 2015, 5, e008503.	1.9	33
1133	Discrete event simulation of whole care pathways to estimate cost-effectiveness in Clinical Guidelines. , 2015, , .		0
1134	A novel hypothesis for atherosclerosis as a cholesterol sulfate deficiency syndrome. Theoretical Biology and Medical Modelling, 2015, 12, 9.	2.1	23
1135	Can oral vitamin D prevent the cardiovascular diseases among migrants in Australia? Provider perspective using Markov modelling. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 596-601.	1.9	3
1136	Information and Risk Modification Trial (INFORM): design of a randomised controlled trial of communicating different types of information about coronary heart disease risk, alongside lifestyle advice, to achieve change in health-related behaviour. BMC Public Health, 2015, 15, 868.	2.9	13
1137	Validation of a new predictive risk model: measuring the impact of the major modifiable risks of death for patients and populations. Population Health Metrics, 2015, 13, 27.	2.7	14
1138	Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience. Diabetology and Metabolic Syndrome, 2015, 7, 95.	2.7	16

#	Article	IF	Citations
1139	Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ, The, 2015, 350, g7594-g7594.	6.0	1,842
1140	A Naive Bayes machine learning approach to risk prediction using censored, timeâ€toâ€event data. Statistics in Medicine, 2015, 34, 2941-2957.	1.6	47
1141	The Effect of a Cardiovascular Polypill Strategy on Pill Burden. Cardiovascular Therapeutics, 2015, 33, 347-352.	2.5	25
1142	Advancing the Use of Evidence-Based Decision-Making in Local Health Departments With Systems Science Methodologies. American Journal of Public Health, 2015, 105, S217-S222.	2.7	24
1143	Strategic Planning for Chronic Disease Prevention in Rural America. Journal of Public Health Management and Practice, 2015, 21, 392-399.	1.4	12
1145	Impact of Health Insurance Expansions on Nonelderly Adults With Hypertension. Preventing Chronic Disease, 2015, 12, E105.	3.4	23
1146	Agreement between Framingham Risk Score and United Kingdom Prospective Diabetes Study Risk Engine in Identifying High Coronary Heart Disease Risk in North Indian Population. Diabetes and Metabolism Journal, 2015, 39, 321.	4.7	13
1147	Framingham Ten-Year General Cardiovascular Disease Risk: Agreement between BMI-Based and Cholesterol-Based Estimates in a South Asian Convenience Sample. PLoS ONE, 2015, 10, e0119183.	2.5	15
1148	The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease. PLoS ONE, 2015, 10, e0131707.	2.5	35
1149	Community Cardiovascular Disease Risk From Cross-Sectional General Practice Clinical Data: A Spatial Analysis. Preventing Chronic Disease, 2015, 12, E26.	3.4	19
1150	Coronary Artery Calcium Score Compared with Cardio-Ankle Vascular Index in the Prediction of Cardiovascular Events in Asymptomatic Patients with Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis, 2015, 22, 1255-1265.	2.0	52
1151	Assessment and Relevance of Carotid Intima-Media Thickness (C-IMT) in Primary and Secondary Cardiovascular Prevention. Current Pharmaceutical Design, 2015, 21, 1164-1171.	1.9	35
1152	Tests of calibration and goodnessâ€ofâ€fit in the survival setting. Statistics in Medicine, 2015, 34, 1659-1680.	1.6	216
1153	Coverage of a national cardiovascular risk assessment and management programme (NHS Health) Tj ETQq1 1 0.784314 rgBT /Overlock	3.4	44
1154	Cohort Profile: The PREDICT Cardiovascular Disease Cohort in New Zealand Primary Care (PREDICT-CVD 19). International Journal of Epidemiology, 2017, 46, dyv312.	1.9	47
1155	Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 621-630.	2.2	45
1156	Cardiovascular disease prevention via a nurse-facilitated intervention clinic in a regional setting: The Protecting Healthy Hearts Program. European Journal of Cardiovascular Nursing, 2015, 14, 352-361.	0.9	13
1157	Challenges of diabetes prevention in the real world: results and lessons from the Melbourne Diabetes Prevention Study. BMJ Open Diabetes Research and Care, 2015, 3, e000131.	2.8	22

#	Article	IF	Citations
1158	Premature atherosclerotic cardiovascular disease in childhood cancer survivors. Progress in Pediatric Cardiology, 2015, 39, 59-66.	0.4	3
1159	Imaging Biomarkers. , 2015, , 225-238.		0
1160	Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough. BMJ Open, 2015, 5, e008678.	1.9	5
1161	Type of myocardial infarction presentation in patients with chronic kidney disease. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 148-152.	2.6	4
1162	Biomarker classification derived from finite growth mixture modeling with a time-varying covariate: an example with phosphorus and glomerular filtration rate. Journal of Applied Statistics, 2015, 42, 409-427.	1.3	0
1163	Value of Lifestyle Intervention to Prevent Diabetes and Sequelae. American Journal of Preventive Medicine, 2015, 48, 271-280.	3.0	31
1164	Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD statement. Journal of Clinical Epidemiology, 2015, 68, 112-121.	5.0	283
1165	Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model. Obesity Surgery, 2015, 25, 1559-1568.	2.1	78
1166	Biostatistics and Epidemiology. , 2015, , .		11
1167	Anthropometric measures in cardiovascular disease prediction: comparison of laboratory-based versus non-laboratory-based model. Heart, 2015, 101, 377-383.	2.9	38
1168	Prediction of Cardiovascular and All-Cause Mortality at 10 Years in the Hypertensive Aged Population. American Journal of Hypertension, 2015, 28, 649-656.	2.0	16
1169	Short Communication: Lipids and Cardiovascular Risk After Switching HIV-1 Patients on Nevirapine and Emtricitabine/Tenofovir-DF to Rilpivirine/Emtricitabine/Tenofovir-DF. AIDS Research and Human Retroviruses, 2015, 31, 363-367.	1.1	7
1170	Association between smoking habits and the first-time appearance of atrial fibrillation in Japanese patients: Evidence from the Shinken Database. Journal of Cardiology, 2015, 66, 73-79.	1.9	26
1171	Assessment of cardiometabolic risk factors and its association with Framingham risk score in Indian patients with type 2 diabetes mellitus. International Journal of Diabetes in Developing Countries, 2015, 35, 340-345.	0.8	1
1172	HIV infection and arterial inflammation assessed by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET): A prospective cross-sectional study. Journal of Nuclear Cardiology, 2015, 22, 372-380.	2.1	24
1173	Diabetes Status and Race are Associated With Cardiovascular Risk Markers in Obese Adolescents. Endocrine Practice, 2015, 21, 165-173.	2.1	2
1175	Association of Frailty and Cardiometabolic Risk Among Community-Dwelling Middle-Aged and Older People: Results from the I-Lan Longitudinal Aging Study. Rejuvenation Research, 2015, 18, 564-572.	1.8	36
1176	Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy. Croatian Medical Journal, 2015, 56, 14-23.	0.7	20

#	Article	IF	Citations
1177	Risk Prediction for Early CKD in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1371-1379.	4.5	97
1178	Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2015, 314, 142.	7.4	205
1179	Risk factors for a recurrence of low back pain. Spine Journal, 2015, 15, 2360-2368.	1.3	55
1180	Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea. Medical Decision Making, 2015, 35, 671-682.	2.4	9
1181	Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement. British Journal of Surgery, 2015, 102, 148-158.	0.3	582
1182	Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD). Circulation, 2015, 131, 211-219.	1.6	432
1183	Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (<scp>TRIPOD</scp>): the <scp>TRIPOD</scp> statement. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 434-443.	2.3	62
1184	A systematic review of the cost-effectiveness of non-surgical obesity interventions in men. Obesity Research and Clinical Practice, 2015, 9, 310-327.	1.8	11
1185	Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement. BMC Medicine, 2015, 13, 1.	5.5	1,273
1186	Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement. European Urology, 2015, 67, 1142-1151.	1.9	299
1187	Epidemiology of Blood Lipids and Lipoproteins. Contemporary Endocrinology, 2015, , 13-24.	0.1	1
1188	Risk Prediction and Risk Classification. , 2015, , 205-216.		0
1189	Cardiovascular risk assessment: a global perspective. Nature Reviews Cardiology, 2015, 12, 301-311.	13.7	94
1190	Arterial Disorders. , 2015, , .		2
1191	Economics of Team-based Care in Controlling Blood Pressure. American Journal of Preventive Medicine, 2015, 49, 772-783.	3.0	34
1192	Is the â€œHeart Ageâ€•Concept Helpful or Harmful Compared to Absolute Cardiovascular Disease Risk? An Experimental Study. Medical Decision Making, 2015, 35, 967-978.	2.4	32
1193	Are different vascular risk scores calculated at midlife uniformly associated with subsequent poor cognitive performance?. Atherosclerosis, 2015, 243, 286-292.	0.8	6
1194	Low prevalence of peripheral arterial disease in a cross-sectional study of Danish HIV-infected patients. Infectious Diseases, 2015, 47, 776-782.	2.8	15

#	Article	IF	Citations
1195	Losing Heart? The Effect of Job Displacement on Health. ILR Review, 2015, 68, 833-861.	2.3	94
1196	Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. British Journal of Cancer, 2015, 112, 251-259.	6.4	752
1197	Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Annals of Internal Medicine, 2015, 162, W1-W73.	3.9	3,068
1198	Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (<scp>TRIPOD</scp>): the <scp>TRIPOD</scp> Statement. Diabetic Medicine, 2015, 32, 146-154.	2.3	14
1199	Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (<scp>TRIPOD</scp>): the <scp>TRIPOD S</scp>tatement. European Journal of Clinical Investigation, 2015, 45, 204-214.	3.4	38
1200	Assessment of arterial elasticity among <scp>HIV</scp>â€positive participants with high <scp>CD4</scp> cell counts: a substudy of the <scp>INSIGHT</scp> Strategic Timing of AntiRetroviral Treatment (<scp>START</scp>) trial. HIV Medicine, 2015, 16, 109-118.	2.2	10
1201	Estimating the yield of NHS Health Checks in England: a population-based cohort study. Journal of Public Health, 2015, 37, 234-240.	1.8	28
1202	Effects of probiotics consumption on lowering lipids and CVD risk factors: A systematic review and meta-analysis of randomized controlled trials. Annals of Medicine, 2015, 47, 430-440.	3.8	144
1203	Designing machine-to-machine (M2M) system in health-cure modeling for cardiovascular disease patients: Initial study. , 2015, , .		5
1204	Bariatricâ€“metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, The, 2015, 386, 964-973.	13.7	998
1205	The Future Burden of CKD in the United States: A Simulation Model for the CDC CKD Initiative. American Journal of Kidney Diseases, 2015, 65, 403-411.	1.9	241
1206	Implications of lower risk thresholds for statin treatment in primary prevention: Analysis of CPRD and simulation modelling of annual cholesterol monitoring. Preventive Medicine, 2015, 70, 14-16.	3.4	5
1207	Concurrent hypermulticolor monitoring of CD31, CD34, CD45 and CD146 endothelial progenitor cell markers for acute myocardial infarction. Analytica Chimica Acta, 2015, 853, 501-507.	5.4	17
1208	A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology, 2015, 22, 920-930.	1.8	136
1209	Biomaterials for Cardiac Regeneration. , 2015, , .		5
1210	Prognostic value of coronary computed tomography angiography in stroke patients. Atherosclerosis, 2015, 238, 271-277.	0.8	25
1211	Urinary Albumin Excretion Reflects Cardiovascular Risk in Postmenopausal Women without Diabetes: The 2011 to 2013 Korean National Health and Nutrition Examination Survey. Endocrinology and Metabolism, 2016, 31, 537.	3.0	4
1212	Analysis of Serum Homocysteine and Risk of Coronary Heart Disease in Patients with Pseudoexfoliation Syndrome. Journal of Korean Ophthalmological Society, 2016, 57, 461.	0.2	0

#	Article	IF	Citations
1213	Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial. Open Forum Infectious Diseases, 2016, 3, ofw213.	0.9	15
1214	Cohort profile: Womenâ€™s Healthy Ageing Project (WHAP)Â- a longitudinal prospective study of Australian women since 1990. Women's Midlife Health, 2016, 2, 5.	1.5	17
1215	Microbiota-Dependent Marker TMAO is Not Associated With Decreased Myocardial Perfusion in Well-Treated HIV-Infected Patients as Assessed by 82Rubidium PET/CT. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e83-e85.	2.1	10
1216	Joint models for multiple longitudinal processes and time-to-event outcome. Journal of Statistical Computation and Simulation, 2016, 86, 3682-3700.	1.2	14
1217	Prediction of 10â€year vascular risk in patients with diabetes: the <scp>ADâ€ON</scp> risk score. Diabetes, Obesity and Metabolism, 2016, 18, 289-294.	4.4	21
1218	Impact of cardiovascular risk factors and disease on length of stay and mortality in patients with acute coronary syndromes. International Journal of Cardiology, 2016, 220, 745-749.	1.7	10
1219	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. Circulation, 2016, 134, 1918-1930.	1.6	148
1220	Targeted case finding in the prevention of cardiovascular disease: a stepped wedge cluster randomised controlled trial. British Journal of General Practice, 2016, 66, e758-e767.	1.4	16
1221	Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study. Journal of Clinical Lipidology, 2016, 10, 1379-1388.	1.5	2
1222	Cardiovascular risk assessment among rural population: findings from a cohort study in a peripheral region of Bangladesh. Public Health, 2016, 137, 73-80.	2.9	7
1223	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37, 2315-2381.	2.2	5,370
1224	Maximizing Patient Recruitment and Retention in a Secondary Stroke Prevention Clinical Trial: Lessons Learned from the STAND FIRM Study. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1371-1380.	1.6	5
1225	Chemerin as an independent predictor of cardiovascular event risk. Therapeutic Advances in Endocrinology and Metabolism, 2016, 7, 57-68.	3.2	36
1226	Predicting cardiovascular disease. BMJ, The, 2016, 353, i2621.	6.0	4
1227	Incremental prognostic value of computed tomography in stroke: rationale and design of the IMPACTS study. International Journal of Cardiovascular Imaging, 2016, 32, 83-89.	1.5	1
1229	Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. Cmaj, 2016, 188, 1004-1011.	2.0	38
1230	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. American Heart Journal, 2016, 180, 22-28.	2.7	25
1231	Changes in cardiovascular disease risk and behavioural risk factors before the introduction of a health check programme in England. Preventive Medicine, 2016, 91, 158-163.	3.4	11

#	Article	IF	Citations
1232	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.8	415
1233	Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. Clinical Infectious Diseases, 2016, 63, 1508-1516.	5.8	103
1234	Estimated Glucose Disposal Rate (eGDR) â€“ A Marker for the Assessment of Insulin Resistance in Type 1 Diabetes Mellitus. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2016, 23, 177-182.	0.3	4
1235	Contributions of the Framingham Heart Study to the Epidemiology of Coronary Heart Disease. JAMA Cardiology, 2016, 1, 825.	6.1	50
1236	â€˜Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?â€™ No, but we can improve risk communication metrics. European Heart Journal, 2017, 38, ehw322.	2.2	10
1237	A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. American Journal of Cardiovascular Drugs, 2016, 16, 285-295.	2.2	1
1238	Ensuring Cardiac Rehabilitation Access for the Majority of Those in Need: A Call to Action for Canada. Canadian Journal of Cardiology, 2016, 32, S358-S364.	1.7	40
1239	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2016, 35, 537.	3.3	4
1240	The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model. American Journal of Epidemiology, 2016, 184, 681-689.	3.4	31
1241	Data-Driven Markov Decision Process Approximations for Personalized Hypertension Treatment Planning. MDM Policy and Practice, 2016, 1, 238146831667421.	0.9	13
1242	Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ, The, 2016, 353, i2416.	6.0	543
1243	External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges. BMJ, The, 2016, 353, i3140.	6.0	327
1244	Impact of socioeconomic deprivation on screening for cardiovascular disease risk in a primary prevention population: a cross-sectional study. BMJ Open, 2016, 6, e009984.	1.9	31
1245	PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment. BMJ Open Diabetes Research and Care, 2016, 4, e000216.	2.8	3
1246	Impact of clinical input variable uncertainties on ten-year atherosclerotic cardiovascular disease risk using new pooled cohort equations. BMC Cardiovascular Disorders, 2016, 16, 165.	1.7	3
1247	The response to receiving phenotypic and genetic coronary heart disease risk scores and lifestyle advice â€“ a qualitative study. BMC Public Health, 2016, 16, 1221.	2.9	12
1248	Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature. European Journal of Health Economics, 2016, 17, 1041-1053.	2.8	8
1251	Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: Findings from a pragmatic randomised controlled trial. European Journal of Preventive Cardiology, 2016, 23, 1537-1545.	1.8	12

#	Article	IF	Citations
1252	Cardiovascular risk models for South Asian populations: a systematic review. International Journal of Public Health, 2016, 61, 525-534.	2.3	20
1253	Field Synopsis of the Role of Sex in Stroke Prediction Models. Journal of the American Heart Association, 2016, 5, .	3.7	11
1254	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	1.8	683
1255	Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a025098.	6.2	33
1256	Indications for Carotid Endarterectomy in Patients with Asymptomatic and Symptomatic Carotid Stenosis. , 2016, , 1181-1191.		0
1257	Utility of the Framingham Risk Score in predicting secondary events in patients following percutaneous coronary intervention: A time-trend analysis. American Heart Journal, 2016, 172, 115-128.	2.7	13
1258	Assessment of cardiovascular risk in low resource settings â€œSo much to do - So little doneâ€• Indian Heart Journal, 2016, 68, 260-262.	0.5	3
1259	Genetics of Lipid Disorders. , 2016, , 159-193.		0
1260	Predictors of the Home-Clinic Blood Pressure Difference: A Systematic Review and Meta-Analysis. American Journal of Hypertension, 2016, 29, 614-625.	2.0	52
1261	Framingham Risk Scores for coronary heart disease in a cohort of Saudi Arabian men and women with spinal cord injury. Acta Neurologica Belgica, 2016, 116, 179-184.	1.1	2
1262	Risk assessment in the prevention of cardiovascular disease in low-resource settings. Indian Heart Journal, 2016, 68, 391-398.	0.5	30
1263	Outdoor air pollution improves the validity of a screening scale for cardiovascular disease (CVD) in clinical settings. Clinical Epidemiology and Global Health, 2016, 4, 109-114.	1.9	0
1264	Metabolism and health effects of phyto-estrogens. Critical Reviews in Food Science and Nutrition, 2017, 57, 2432-2454.	10.3	28
1265	Developing and validating a cardiovascular risk score for patients in the community with prior cardiovascular disease. Heart, 2017, 103, 891.1-892.	2.9	22
1266	Reagent-free simultaneous determination of glucose and cholesterol in whole blood by FTIR-ATR. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2017, 178, 192-197.	3.9	11
1267	Putting polypills into practice: challenges and lessons learned. Lancet, The, 2017, 389, 1066-1074.	13.7	68
1268	Markov Decision Processes in Practice. Profiles in Operations Research, 2017, , .	0.4	40
1269	Cardiovascular disease prevalence and insulin resistance in the Kyushuâ€“Okinawa Population Study and the Framingham Offspring Study. Journal of Clinical Lipidology, 2017, 11, 348-356.	1.5	12

#	Article	IF	Citations
1270	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 747 T 6, 22-30.	1.1	22
1271	Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. Medical Decision Making, 2017, 37, 802-814.	2.4	24
1272	Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIVâ€Positive Participants in the START (Strategic Timing of Antiretroviral) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.7	50
1273	Visualization and Inhibition of Mitochondria-Nuclear Translocation of Apoptosis Inducing Factor by a Graphene Oxide-DNA Nanosensor. Analytical Chemistry, 2017, 89, 4642-4647.	6.5	13
1274	Cost-effectiveness of Maintaining Daily Intake of Oat Î²-Glucan for Coronary Heart Disease Primary Prevention. Clinical Therapeutics, 2017, 39, 804-818.e3.	2.5	12
1275	Cost Effectiveness of Subsidizing Fruit and Vegetable Purchases Through the Supplemental Nutrition Assistance Program. American Journal of Preventive Medicine, 2017, 52, e147-e155.	3.0	67
1276	Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. Journal of the Saudi Heart Association, 2017, 29, 235-243.	0.4	82
1277	Estrogen Neuroprotective Activity After Stroke and Spinal Cord Injury. , 2017, , 243-255.		0
1278	Markov Decision Processes for Screening and Treatment of Chronic Diseases. Profiles in Operations Research, 2017, , 189-222.	0.4	36
1279	Severity of nonalcoholic fatty liver disease on sonography and risk of coronary heart disease. Journal of Clinical Ultrasound, 2017, 45, 391-399.	0.8	15
1281	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 537-547.	3.3	18
1282	Systematic Review of Health Economic Impact Evaluations of Risk Prediction Models: Stop Developing, Start Evaluating. Value in Health, 2017, 20, 718-726.	0.3	22
1283	2016 European Guidelines on cardiovascular disease prevention in clinical practice. International Journal of Behavioral Medicine, 2017, 24, 321-419.	1.7	84
1284	Perceived Cognition after Percutaneous Coronary Intervention: Association with Quality of Life, Mood and Fatigue in the THORESCI Study. International Journal of Behavioral Medicine, 2017, 24, 552-562.	1.7	11
1285	Costâ€effectiveness of elbasvir/grazoprevir use in treatmentâ€naive and treatmentâ€experienced patients with hepatitis CÂvirus genotype 1 infection and chronic kidney disease in the United States. Journal of Viral Hepatitis, 2017, 24, 268-279.	2.0	19
1286	An evaluation of the performance of SCORE Sweden 2015 in estimating cardiovascular risk. European Journal of Preventive Cardiology, 2017, 24, 103-110.	1.8	28
1287	Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. European Heart Journal Quality of Care & Clinical Outcomes, 2017, 3, 281-288.	4.0	2
1288	Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset. International Journal of Cardiology, 2017, 249, 443-447.	1.7	4

#	Article	IF	Citations
1289	Development and validation of a risk prediction model for work disability: multicohort study. Scientific Reports, 2017, 7, 13578.	3.3	26
1290	Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: A randomized trial: The PreFord-Study. European Journal of Preventive Cardiology, 2017, 24, 1544-1554.	1.8	22
1291	Validation and recalibration of the Framingham cardiovascular disease risk models in an Australian Indigenous cohort. European Journal of Preventive Cardiology, 2017, 24, 1660-1669.	1.8	34
1292	Model for endâ€stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease. Hepatology Communications, 2017, 1, 429-438.	4.3	9
1293	Evidence on the Validity of a Comprehensive Health Risk Index and Implications for Ambulatory Care and Population Health Management. Journal of Ambulatory Care Management, 2017, 40, 297-304.	1.1	1
1294	Relationship between estimated cardiovascular disease risk and insulin resistance in a black African population living with HIV: a cross-sectional study from Cameroon. BMJ Open, 2017, 7, e016835.	1.9	9
1295	Screening Strategies for Patients on the Kidney Transplant Waiting List. Operations Research, 2017, 65, 1131-1146.	1.9	11
1296	Evaluating FINDRISC as a screening tool for type 2 diabetes among overweight adults in the PREVIEW:NZ cohort. Primary Care Diabetes, 2017, 11, 561-569.	1.8	15
1297	Classification Rule for 5-year Cardiovascular Diseases Risk using decision tree in Primary Care Chinese Patients with Type 2 Diabetes Mellitus. Scientific Reports, 2017, 7, 15238.	3.3	4
1298	Exercise in the Therapy of Diabetes Mellitus. , 2017, , 857-880.		0
1299	A sudden death risk score specifically for hypertension. Journal of Hypertension, 2017, 35, 2178-2184.	0.5	5
1300	Statistical evaluation of adding multiple risk factors improves Framingham stroke risk score. BMC Medical Research Methodology, 2017, 17, 58.	3.1	5
1301	CHA2DS2-VASc-HSF score â€“ New predictor of severity of coronary artery disease in 2976 patients. International Journal of Cardiology, 2017, 228, 1002-1006.	1.7	19
1302	Perceptions of risks for diabetesâ€related complications in Type 2 diabetes populations: a systematic review. Diabetic Medicine, 2017, 34, 467-477.	2.3	41
1303	Plasma and blood viscosity in the prediction of cardiovascular disease and mortality in the Scottish Heart Health Extended Cohort Study. European Journal of Preventive Cardiology, 2017, 24, 161-167.	1.8	57
1304	Utility of genetic and non-genetic risk factors in predicting coronary heart disease in Singaporean Chinese. European Journal of Preventive Cardiology, 2017, 24, 153-160.	1.8	11
1305	Bus operatorsâ€™ responses to job strain: An experimental test of the job demandâ€“control model.. Journal of Occupational Health Psychology, 2017, 22, 518-527.	3.3	26
1306	Atherogenic index of plasma and 10-year risk of cardiovascular disease in adult Africans living with HIV infection: A cross-sectional study from YaoundÃ©, Cameroon. JRSM Cardiovascular Disease, 2017, 6, 204800401774047.	0.7	8

#	Article	IF	Citations
1307	Can traditional risk factors explain the higher risk of cardiovascular disease in South Asians compared to Europeans in Norway and New Zealand? Two cohort studies. BMJ Open, 2017, 7, e016819.	1.9	10
1308	Development of scoring system for risk stratification in clinical medicine: a step-by-step tutorial. Annals of Translational Medicine, 2017, 5, 436-436.	1.7	59
1309	Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. Obesity Facts, 2017, 10, 261-272.	3.4	20
1310	Comparison of the Peripheral Reactive Hyperemia Index with Myocardial Perfusion Reserve by 82Rb PET/CT in HIV-Infected Patients. Diagnostics, 2017, 7, 31.	2.6	6
1311	Predictive Analytics and Population Health. , 2017, , 217-225.		0
1312	Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PLoS ONE, 2017, 12, e0182625.	2.5	19
1313	Better Indigenous Risk stratification for Cardiac Health study (BIRCH) protocol: rationale and design of a cross-sectional and prospective cohort study to identify novel cardiovascular risk indicators in Aboriginal Australian and Torres Strait Islander adults. BMC Cardiovascular Disorders, 2017, 17, 228.	1.7	4
1314	Cost-utility analysis of bariatric surgery compared with conventional medical management in Germany: a decision analytic modeling. BMC Surgery, 2017, 17, 87.	1.3	20
1315	Nurse health and lifestyle modification versus standard care in 40 to 70 year old regional adults: study protocol of the Management to Optimise Diabetes and mEtabolic syndrome Risk reduction via Nurse-led intervention (MODERN) randomized controlled trial. BMC Health Services Research, 2017, 17, 813.	2.2	7
1316	Assessment of the agreement between the Framingham and DAD risk equations for estimating cardiovascular risk in adult Africans living with HIV infection: a cross-sectional study. Tropical Diseases, Travel Medicine and Vaccines, 2017, 3, 12.	2.2	10
1317	Evaluation of the National Guard Health Promotion Program for Chronic Diseases and Comorbid Conditions Among Military Personnel in Jeddah City, Saudi Arabia, 2016. Military Medicine, 2017, 182, e1973-e1980.	0.8	9
1318	Should information about sexual health be included in education directed toward men with cardiovascular diseases?. Aging Male, 2018, 21, 243-250.	1.9	13
1319	Persistence of socioeconomic inequalities in the knowledge of cardiovascular risk factors five years after coronary angiography. European Journal of Cardiovascular Nursing, 2018, 17, 136-147.	0.9	12
1320	Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viremia. Scientific Reports, 2018, 8, 6113.	3.3	11
1321	Sagittal abdominal diameter and Framingham risk score in non-dialysis chronic kidney disease patients. International Urology and Nephrology, 2018, 50, 1679-1685.	1.4	3
1322	Costâ€“utility analysis of bariatric surgery. British Journal of Surgery, 2018, 105, 1328-1337.	0.3	35
1323	Using survival analysis to improve pre-emptive fire engine allocation for emergency response. Fire Safety Journal, 2018, 97, 76-84.	3.1	8
1324	Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004171.	2.2	22

#	Article	IF	Citations
1325	Identification, risk assessment, and management of patients with atrial fibrillation in a large primary care cohort. International Journal of Cardiology, 2018, 254, 119-124.	1.7	12
1326	Systematic review of predictive risk models for adverse drug events in hospitalized patients. British Journal of Clinical Pharmacology, 2018, 84, 846-864.	2.4	52
1328	No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. Aids, 2018, 32, 985-997.	2.2	15
1329	Heuristics and biases in cardiovascular disease prevention: How can we improve communication about risk, benefits and harms?. Patient Education and Counseling, 2018, 101, 843-853.	2.2	19
1330	Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. Journal of Medical Economics, 2018, 21, 365-373.	2.1	17
1331	Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis. Alcohol, 2018, 69, 63-67.	1.7	16
1332	Patterns and trends of potentially inappropriate high-density lipoprotein cholesterol testing in Australian adults at high risk of cardiovascular disease from 2008 to 2014: analysis of linked individual patient data from the Australian Medicare Benefits Schedule and Pharmaceutical Benefits Scheme. BMJ Open, 2018, 8, e019041.	1.9	5
1333	Association Between Workâ€Related Stress and Coronary Heart Disease: A Review of Prospective Studies Through the Job Strain, Effortâ€Reward Balance, and Organizational Justice Models. Journal of the American Heart Association, 2018, 7, .	3.7	125
1334	Cardiovascular disease risk prediction equations in 400â€˙000 primary care patients in New Zealand: a derivation and validation study. Lancet, The, 2018, 391, 1897-1907.	13.7	173
1335	Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study. BMJ Open, 2018, 8, e017723.	1.9	17
1336	Diuretic therapy in hypertension. Journal of Cardiovascular Medicine, 2018, 19, e123-e125.	1.5	0
1337	Population estimates and characteristics of Australians potentially eligible for bariatric surgery: findings from the 2011â€“13 Australian Health Survey. Australian Health Review, 2018, 42, 429.	1.1	10
1338	Development of a cardiovascular diseases risk prediction model and tools for <scp>C</scp>hinese patients with type 2 diabetes mellitus: <scp>A</scp> populationâ€based retrospective cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 309-318.	4.4	26
1339	Cost-Effectiveness and Value of Information Analysis of Brief Interventions to Promote Physical Activity in Primary Care. Value in Health, 2018, 21, 18-26.	0.3	17
1340	Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 305-314.	1.4	8
1341	Predicting Out-of-Office Blood Pressure in the Clinic for the Diagnosis of Hypertension in Primary Care. Hypertension, 2018, 71, 250-261.	2.7	14
1342	Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe. Pharmacoeconomics, 2018, 36, 205-213.	3.3	15
1344	Prediction of Heart Diseases Using Data Mining Techniques. International Journal of Big Data and Analytics in Healthcare, 2018, 3, 1-9.	0.7	16

#	Article	IF	Citations
1345	Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. The Cochrane Library, 2018, 2018, CD005061.	2.8	25
1346	Speaker Abstracts. Journal of the International AIDS Society, 2018, 21, e25093.	3.0	2
1347	Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study. PLoS ONE, 2018, 13, e0207110.	2.5	7
1348	Predictive Value of Prothrombin Time for All-cause Mortality in Acute Myocardial Infarction Patients*. , 2018, 2018, 5366-5369.		3
1349	Improving Young Stroke Prediction by Learning with Active Data Augmenter in a Large-Scale Electronic Medical Claims Database. , 2018, 2018, 5362-5365.		7
1350	Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women. Journal of the American Heart Association, 2018, 7, e007514.	3.7	20
1351	Perspective: DNA Copy Number Variations in Cardiovascular Diseases. Epigenetics Insights, 2018, 11, 251686571881883.	2.0	3
1352	Optimization of Sequential Decision Making for Chronic Diseases: From Data to Decisions. , 2018, , 316-348.		8
1353	Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G. Open Forum Infectious Diseases, 2018, 5, ofy205.	0.9	10
1354	Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels. JAMA Network Open, 2018, 1, e182008.	5.9	7
1355	Targeted afferent renal denervation reduces arterial pressure but not renal inflammation in established DOCA-salt hypertension in the rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2018, 314, R883-R891.	1.8	31
1356	Future Health and Economic Impact of Comprehensive Tobacco Control in DoD: A Microsimulation Approach. Military Medicine, 2018, 183, e104-e112.	0.8	3
1357	HealthNavigator: a mobile application for chronic disease screening and linkage to services at an urban Primary Health Network. Australian Journal of Primary Health, 2018, 24, 116.	0.9	4
1358	A New Framework for the Integrative Analytics of Intravascular Ultrasound and Optical Coherence Tomography Images. IEEE Access, 2018, 6, 36408-36419.	4.2	18
1359	A Survey on the Roles of Communication Technologies in IoT-Based Personalized Healthcare Applications. IEEE Access, 2018, 6, 36611-36631.	4.2	191
1360	Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy. JAMA - Journal of the American Medical Association, 2018, 319, 2507.	7.4	36
1361	Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?. PLoS ONE, 2018, 13, e0199299.	2.5	4
1362	Future biomarkers in cardiology: my favourites. European Heart Journal Supplements, 2018, 20, G37-G44.	0.1	25

#	Article	IF	Citations
1363	Clinical Assessment of Coronary Heart Disease. , 2018, , 13-24.		0
1364	Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment. JAMA - Journal of the American Medical Association, 2018, 320, 281.	7.4	126
1365	Performance of a Framingham cardiovascular risk model among Indians and Europeans in New Zealand and the role of body mass index and social deprivation. Open Heart, 2018, 5, e000821.	2.3	13
1366	Interventions for improving modifiable risk factor control in the secondary prevention of stroke. The Cochrane Library, 2022, 2022, CD009103.	2.8	84
1367	An Overview of Indigenous Australian Disadvantage in Terms of Ischaemic Heart Disease. Heart Lung and Circulation, 2018, 27, 1274-1284.	0.4	13
1368	Prognostic impact of systolic blood pressure variability in people with diabetes. PLoS ONE, 2018, 13, e0194084.	2.5	15
1369	Targeted lung cancer screening selects individuals at high risk of cardiovascular disease. Lung Cancer, 2018, 124, 148-153.	2.0	27
1370	Clarifying questions about â€œrisk factorsâ€• predictors versus explanation. Emerging Themes in Epidemiology, 2018, 15, 10.	2.7	48
1371	Novel Phenoxazinones as potent agonist of PPAR-Î±: design, synthesis, molecular docking and in vivo studies. Lipids in Health and Disease, 2018, 17, 120.	3.0	12
1372	A retrospective review of great ape cardiovascular disease epidemiology and pathology. International Zoo Yearbook, 2018, 52, 113-125.	0.9	25
1373	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Medicine, 2018, 15, e1002538.	8.4	67
1374	Type 2 diabetes prevalence and its risk factors in HIV: A cross-sectional study. PLoS ONE, 2018, 13, e0194199.	2.5	83
1375	Optimal coinsurance rates for a heterogeneous population under inequality and resource constraints. IISE Transactions, 2019, 51, 74-91.	2.4	6
1376	Lifestyle Risk Association Aggregation. , 2019, , .		1
1378	Basic Knowledge, Strategies, and Procedures. , 2019, , 12-36.		0
1379	Built Environment Upgrading for AAL (BeuAAL). , 2019, , 37-73.		0
1380	Existing AAL Products. , 2019, , 74-103.		0
1381	Research and Development Projects for AAL Systems. , 2019, , 104-139.		0

#	Article	IF	Citations
1382	Future Trends and Developments. , 2019, , 140-147.		0
1385	Early Prediction of Cardiovascular Risk after Hematopoietic Cell Transplantation: Are We There Yet?. Biology of Blood and Marrow Transplantation, 2019, 25, e310-e316.	2.0	15
1386	Cardiovascular Predictive Value and Genetic Basis of Ventricular Repolarization Dynamics. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007549.	4.8	13
1387	Use of latent class analysis to identify multimorbidity patterns and associated factors in Korean adults aged 50 years and older. PLoS ONE, 2019, 14, e0216259.	2.5	42
1388	Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target. Frontiers in Pharmacology, 2019, 10, 1360.	3.5	213
1389	Computational models and neural nets: Fantastic modelsâ€"Where to find them and how to identify them. International Journal of Clinical Practice, 2019, 73, e13391.	1.7	1
1390	Predicting the risk of stroke among patients with type 2 diabetes: a systematic review and meta-analysis of C-statistics. BMJ Open, 2019, 9, e025579.	1.9	20
1391	Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk. BMC Public Health, 2019, 19, 1234.	2.9	14
1392	There is an association between body fat percentage and metabolic abnormality in normal weight subjects: Iranian large population. Translational Metabolic Syndrome Research, 2019, 2, 11-16.	0.8	10
1393	Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. Pharmacoeconomics, 2019, 37, 1451-1468.	3.3	24
1394	Application of a fuzzy unit hypercube in cardiovascular risk classification. Soft Computing, 2019, 23, 12521-12527.	3.6	3
1395	High-sensitivity troponin I for cardiovascular risk stratification in the general asymptomatic population: Perspectives from Asia-Pacific. International Journal of Cardiology, 2019, 282, 93-98.	1.7	8
1396	Value of genetic testing in the prevention of coronary heart disease events. PLoS ONE, 2019, 14, e0210010.	2.5	18
1397	Ten-second central SBP variability predicts first and recurrent cardiovascular events. Journal of Hypertension, 2019, 37, 530-537.	0.5	2
1398	The utility of long-term blood pressure variability for cardiovascular risk prediction in primary care. Journal of Hypertension, 2019, 37, 522-529.	0.5	8
1399	Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study . Drug Design, Development and Therapy, 2019, Volume 13, 1667-1685.	4.3	5
1400	Primary Absolute Cardiovascular Disease Risk and Prevention in Relation to Psychological Distress in the Australian Population: A Nationally Representative Cross-Sectional Study. Frontiers in Public Health, 2019, 7, 126.	2.7	5
1401	CT screening for lung cancer: Are we ready to implement in Europe?. Lung Cancer, 2019, 134, 25-33.	2.0	25

#	Article	IF	Citations
1402	Assessing the Impact of Lifestyle Interventions on Diabetes Prevention in China: A Modeling Approach. International Journal of Environmental Research and Public Health, 2019, 16, 1677.	2.6	9
1403	Using out-of-office blood pressure measurements in established cardiovascular risk scores: a secondary analysis of data from two blood pressure monitoring studies. British Journal of General Practice, 2019, 69, e381-e388.	1.4	3
1404	Cost-Effectiveness of Telemonitoring and Self-Monitoring of Blood Pressure for Antihypertensive Titration in Primary Care (TASMINH4). Hypertension, 2019, 73, 1231-1239.	2.7	73
1405	A novel clinical risk prediction model for myocardial infarction, coronary revascularization, and cardiac death according to clinical, exercise, and gated SPECT variables (VH-RS). European Heart Journal Cardiovascular Imaging, 2020, 21, 210-221.	1.2	5
1406	The powerâ€integrated discriminant improvement: An accurate measure of the incremental predictive value of additional biomarkers. Statistics in Medicine, 2019, 38, 2589-2604.	1.6	21
1407	Development of an intelligent decision support system for ischemic stroke risk assessment in a population-based electronic health record database. PLoS ONE, 2019, 14, e0213007.	2.5	22
1408	Cardiovascular Disease Incidence Projections in the TREAT Asia HIV Observational Database (TAHOD). Antiviral Therapy, 2019, 24, 271-279.	1.0	2
1409	Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. European Radiology, 2019, 29, 4593-4602.	4.5	15
1410	Cardiovascular Risk Prediction Models. , 2019, , .		2
1411	Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. Journal of Infection and Public Health, 2019, 12, 502-508.	4.1	1
1412	Wave reflections in hypertension. Journal of Hypertension, 2019, 37, 555-562.	0.5	4
1413	Health Consumer Usage Patterns in Management of CVD using Data Mining Techniques. , 2019, , .		1
1414	Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention. Annals of Internal Medicine, 2019, 171, 529.	3.9	16
1415	Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease. Annals of Internal Medicine, 2019, 170, 357.	3.9	23
1416	Predisposing factors to nonfatal cardiovascular events in women with systemic lupus erythematosus. An observational, cross-sectional, multicenter study in Spain from the risk/systemic lupus erythematosus thematic network. Medicine (United States), 2019, 98, e17489.	1.0	4
1417	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. American Heart Journal, 2019, 208, 81-90.	2.7	25
1418	Comparative Cost-Effectiveness of Clinic, Home, or Ambulatory Blood Pressure Measurement for Hypertension Diagnosis in US Adults. Hypertension, 2019, 73, 121-131.	2.7	45
1419	Prognostic tools for cardiovascular disease in patients with type 2 diabetes: A systematic review and meta-analysis of C-statistics. Journal of Diabetes and Its Complications, 2019, 33, 98-111.	2.3	37

#	Article	IF	Citations
1420	Minimum sample size for developing a multivariable prediction model: PART II â€•binary and timeâ€toâ€event outcomes. Statistics in Medicine, 2019, 38, 1276-1296.	1.6	480
1421	External validation of two Framingham cardiovascular risk equations and the Pooled Cohort equations: A nationwide registry analysis. International Journal of Cardiology, 2019, 283, 165-170.	1.7	14
1422	Pulse rate variability predicts atrial fibrillation and cerebrovascular events in a large, population-based cohort. International Journal of Cardiology, 2019, 275, 83-88.	1.7	8
1423	Epidemiologic Characterization of Risk for Cardiovascular Diseases. Contemporary Cardiology, 2019, , 3-20.	0.1	1
1424	Impact of the NHS Health Check on inequalities in cardiovascular disease risk: a difference-in-differences matching analysis. Journal of Epidemiology and Community Health, 2019, 73, 11-18.	3.7	18
1425	Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study. Journal of Clinical Lipidology, 2019, 13, 148-155.	1.5	2
1426	Cardiovascular risk prediction models with myocardial perfusion imaging in chronic kidney disease: ACCESSing digits or focusing on the patient?. Journal of Nuclear Cardiology, 2020, 27, 51-52.	2.1	3
1427	Association of upper airway surgery and improved cardiovascular biomarkers and risk in OSA. Laryngoscope, 2020, 130, 818-824.	2.0	11
1428	Physician Responses to Enhanced Prescription Drug Monitoring Program Profiles. Pain Medicine, 2020, 21, e9-e21.	1.9	12
1429	Development and Use of Prediction Models for Classification of Cardiovascular Risk of Remote Indigenous Australians. Heart Lung and Circulation, 2020, 29, 374-383.	0.4	5
1430	Pharmacistsâ€™ advice and clinical reasoning in relation to cardiovascular disease risk factors â€“ A vignette case study. Research in Social and Administrative Pharmacy, 2020, 16, 568-573.	3.0	2
1431	Redefining Blood Pressure Assessment â€” The Role of the Ambulatory Blood Pressure Monitoring Study for Drug Safety. Clinical Pharmacology and Therapeutics, 2020, 107, 147-153.	4.7	6
1432	Women and Cardiovascular Disease: Pregnancy, the Forgotten Risk Factor. Heart Lung and Circulation, 2020, 29, 662-667.	0.4	17
1433	Integrating pharmacists into Aboriginal Community Controlled Health Services (IPAC project): Protocol for an interventional, non-randomised study to improve chronic disease outcomes. Research in Social and Administrative Pharmacy, 2020, 16, 1431-1441.	3.0	4
1434	Cardiovascular Risk and Cognitive Function in Middle-Aged and Older Hispanics/Latinos: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Journal of Alzheimer's Disease, 2020, 73, 103-116.	2.6	28
1435	Effects of cardamom supplementation on lipid profile: A systematic review and metaâ€analysis of randomized controlled clinical trials. Phytotherapy Research, 2020, 34, 475-485.	5.8	13
1436	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovascular Diabetology, 2020, 19, 156.	6.8	25
1437	Is periodontitis a risk factor for ischaemic stroke, coronary artery disease and subclinical atherosclerosis? A Mendelian randomization study. Atherosclerosis, 2020, 313, 111-117.	0.8	22

#	Article	IF	Citations
1438	Evaluating risk of dementia in older people: a pathway to personalized prevention?. European Heart Journal, 2020, 41, 4034-4036.	2.2	7
1439	Cardiovascular disease risk perception in a Hungarian community sample: psychometric evaluation of the ABCD Risk Perception Questionnaire. BMJ Open, 2020, 10, e036028.	1.9	8
1440	Blood Pressure during Blood Collection and the Implication for Absolute Cardiovascular Risk Assessment. Pulse, 2020, 8, 40-46.	1.9	0
1441	Atherosclerosis in Rheumatology: Old and New Insights. , 0, , .		0
1442	Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 829-836.	1.4	6
1443	Prediction models for cardiovascular disease risk in the hypertensive population: a systematic review. Journal of Hypertension, 2020, 38, 1632-1639.	0.5	10
1444	Development and validation of risk prediction models for multiple cardiovascular diseases and Type 2 diabetes. PLoS ONE, 2020, 15, e0235758.	2.5	13
1445	The Journal of Cardiopulmonary Rehabilitation and Prevention at 40 yr and Its Role in Promoting Preventive Cardiology: Part 2. Journal of Cardiopulmonary Rehabilitation and Prevention, 2020, 40, 209-214.	2.1	11
1446	Arterial stiffness in black adults from Angola and Brazil. Journal of Clinical Hypertension, 2020, 22, 1469-1475.	2.0	1
1448	Dietary intake of total, animal and plant proteins and the risk of coronary heart disease and hypertension: a systematic review and dose-response meta-analysis of prospective cohort studies. Critical Reviews in Food Science and Nutrition, 2022, 62, 1336-1349.	10.3	8
1449	Association between Carotid Artery Calcification and Periodontal Disease Progression in Japanese Men and Women: A Cross-Sectional Study. Journal of Clinical Medicine, 2020, 9, 3365.	2.4	8
1450	Understanding Vascular Age: Are Clinical scoring systems useful for Early Vascular Aging Syndrome Prediction ?. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 569-577.	2.2	1
1451	Arterial calcification at multiple sites: sex-specific cardiovascular risk profiles and mortality riskâ€"the Rotterdam Study. BMC Medicine, 2020, 18, 263.	5.5	24
1452	Performance of cardiovascular risk prediction equations in Indigenous Australians. Heart, 2020, 106, 1252-1260.	2.9	3
1453	A 10-year trend in income disparity of cardiovascular health among older adults in South Korea. SSM - Population Health, 2020, 12, 100682.	2.7	2
1454	Re-estimation improved the performance of two Framingham cardiovascular risk equations and the Pooled Cohort equations: A nationwide registry analysis. Scientific Reports, 2020, 10, 8140.	3.3	10
1455	Association between unrealistic comparative optimism and selfâ€management in individuals with type 2 diabetes: Results from a crossâ€sectional, populationâ€based study. Health Science Reports, 2020, 3, e157.	1.5	4
1456	Text messages for primary prevention of cardiovascular disease: the TextMe2 randomised controlled trial protocol. BMJ Open, 2020, 10, e036767.	1.9	5

#	Article	IF	Citations
1457	A vascular-liver chip for sensitive detection of nutraceutical metabolites from human pluripotent stem cell derivatives. Biomicrofluidics, 2020, 14, 034108.	2.4	12
1458	ImpediBands: Body Coupled Bio-Impedance Patches for Physiological Sensing Proof of Concept. IEEE Transactions on Biomedical Circuits and Systems, 2020, 14, 757-774.	4.0	23
1459	Cardiovascular disease risk assessment for Aboriginal and Torres Strait Islander adults aged under 35 years: a consensus statement. Medical Journal of Australia, 2020, 212, 422-427.	1.7	26
1460	Calculating the sample size required for developing a clinical prediction model. BMJ, The, 2020, 368, m441.	6.0	804
1461	Effect of Berberine on Atherosclerosis and Gut Microbiota Modulation and Their Correlation in High-Fat Diet-Fed ApoEâ^'/â^' Mice. Frontiers in Pharmacology, 2020, 11, 223.	3.5	129
1462	Prospective Evaluation of Cardiovascular, Cardiorespiratory, and Metabolic Risk of German Office Workers in Comparison to International Data. International Journal of Environmental Research and Public Health, 2020, 17, 1590.	2.6	13
1463	Biomarkers versus traditional risk factors to predict cardiovascular events in very old adults: cross-validated prospective cohort study. BMJ Open, 2020, 10, e035809.	1.9	5
1464	The impact of colectomy on the risk of cardiovascular disease among patients without colorectal cancer. Scientific Reports, 2020, 10, 2925.	3.3	6
1465	Cardiovascular risk assessment in the resource limited setting of Western Honduras: An epidemiological perspective. IJC Heart and Vasculature, 2020, 27, 100476.	1.1	6
1466	Predicting the Likelihood for Severe CAD and CABG Indication on Elective Patients: Comparison of Novel CHA2DS2-VASc-HSF with CHA2DS2 and CHA2DS2-VASc Score. IOP Conference Series: Earth and Environmental Science, 2020, 441, 012195.	0.3	0
1467	Cost-effectiveness of intensive interventions compared to standard care in individuals with type 2 diabetes: A systematic review and critical appraisal of decision-analytic models. Diabetes Research and Clinical Practice, 2020, 161, 108073.	2.8	3
1469	OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions. Obesity Facts, 2020, 13, 1-28.	3.4	15
1470	Costâ€"benefit Analysis in Health Care: The Case of Bariatric Surgery Compared With Diet. Clinical Therapeutics, 2020, 42, 60-75.e7.	2.5	8
1471	Deep learning approach for diabetes prediction using PIMA Indian dataset. Journal of Diabetes and Metabolic Disorders, 2020, 19, 391-403.	1.9	144
1472	Operationalization of Utilitarian and Egalitarian Objectives for Optimal Allocation of Health Care Resources. Decision Sciences, 2020, , .	4.5	5
1473	Diabetes and Cardiovascular Disease: Insights from the Framingham Heart Study. Global Heart, 2013, 8, 43.	2.3	33
1474	Lipids and Vascular Disease: A Framingham Perspective. Global Heart, 2013, 8, 25.	2.3	11
1475	Risk scoring for the primary prevention of cardiovascular disease. The Cochrane Library, 2021, 2021, CD006887.	2.8	70

#	Article	IF	Citations
1476	Selection of variables for multivariable models: Opportunities and limitations in quantifying model stability by resampling. Statistics in Medicine, 2021, 40, 369-381.	1.6	8
1477	Time-to-Treatment and Its Association With Complications and Mortality Rate in Patients With Acute Myocardial Infarction: A Prospective Cohort Study. Journal of Emergency Nursing, 2021, 47, 288-298.e4.	1.0	6
1478	Network analytics and machine learning for predictive risk modelling of cardiovascular disease in patients with type 2 diabetes. Expert Systems With Applications, 2021, 164, 113918.	7.6	46
1479	Development and validation of the Adverse Inpatient Medication Event model (AIME). British Journal of Clinical Pharmacology, 2021, 87, 1512-1524.	2.4	12
1480	Dietary fat and alcohol in the prediction of indices of vascular health among young adults. Nutrition, 2021, 84, 111120.	2.4	5
1481	Time-to-pregnancy and risk of cardiovascular disease among men and women. European Journal of Epidemiology, 2021, 36, 383-391.	5.7	15
1482	Strategies for diseases prevention: the role of the general practitioner and primary health care. Profilakticheskaya Meditsina, 2021, 24, 7.	0.6	5
1483	Prediction of COVID-19 Possibilities using KNearest Neighbour Classification Algorithm. International Journal of Current Research and Review (discontinued), 2021, , 156-164.	0.1	13
1484	Acceptable Risk of Sudden Incapacitation Among Safety Critical Transportation Workers. Journal of Occupational and Environmental Medicine, 2021, 63, 329-342.	1.7	1
1485	Data Mining for Cardiovascular Disease Prediction. Journal of Medical Systems, 2021, 45, 6.	3.6	36
1486	Should We Target Global Risk or Risk Factors?. Current Atherosclerosis Reports, 2021, 23, 2.	4.8	2
1487	Innovative Mobile Device for Human Health Monitoring. Lecture Notes in Networks and Systems, 2021, , 3-15.	0.7	0
1488	Data linkages in epidemiology. , 2021, , 95-117.		0
1489	Exercise capacity, cardiovascular and metabolic risk of the sample of German police officers in a descriptive international comparison. International Journal of Medical Sciences, 2021, 18, 2767-2775.	2.5	7
1490	Molecular modeling and molecular docking studies on the derivatives of 1,4-dihydropyridine towards Cytochrome P450 for structure based drug design. Materials Today: Proceedings, 2021, 47, 1798-1806.	1.8	0
1491	Optimal prediction of attacks and arterial stiffness effects on heart disease by hybrid machine learning algorithm. Journal of Ambient Intelligence and Humanized Computing, 0, , 1.	4.9	3
1492	Role of Serum High-Sensitivity C-Reactive Protein Level as Risk Factor in the Prediction of Coronary Artery Disease in Hyperglycemic Subjects. , 2021, , 123-134.		0
1493	An Improved Machine Learning Technique with Effective Heart Disease Prediction System. Computers, Materials and Continua, 2021, 69, 4169-4181.	1.9	0

#	Article	IF	Citations
1494	Progress in ASCVD Risk Assessment in African Americans and Hispanic Americans. Contemporary Cardiology, 2021, , 147-157.	0.1	0
1495	Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, The, 2021, 397, 293-304.	13.7	272
1496	Assessment of Knowledge with Regard to Cardiovascular Disease Risk Factors among College Students Using Heart Disease Fact Questionnaire. Journal of Evolution of Medical and Dental Sciences, 2021, 10, 347-351.	0.1	2
1497	Macrovascular Risk Equations Based on the CANVAS Program. Pharmacoeconomics, 2021, 39, 447-461.	3.3	4
1498	Assessment of Dietary Habits Using the Diet Quality Indexâ€"International in Cerebrovascular and Cardiovascular Disease Patients. Nutrients, 2021, 13, 542.	4.1	8
1499	Absolute risk assessment for guiding cardiovascular risk management in a chest pain clinic. Medical Journal of Australia, 2021, 214, 266-271.	1.7	8
1500	Heart disease and optimal prediction of attacks using hybrid machine learning algorithm: A survey. Materials Today: Proceedings, 2021, , .	1.8	4
1501	A systematic review of the status and methodological considerations for estimating risk of first ever stroke in the general population. Neurological Sciences, 2021, 42, 2235-2247.	1.9	6
1502	The Contribution of Material, Behavioral, Psychological, and Social-Relational Factors to Income-Related Disparities in Cardiovascular Risk Among Older Adults. Journal of Cardiovascular Nursing, 2021, Publish Ahead of Print, .	1.1	0
1503	Anthropometric cut-points for discriminating diabetes and the metabolic syndrome among Arabs and Asians: the Kuwait Diabetes Epidemiology Program. British Journal of Nutrition, 2022, 127, 92-102.	2.3	6
1504	Alterations in Metabolic and Cardiovascular Risk Factors During Critical Training in Wildland Firefighters. Journal of Occupational and Environmental Medicine, 2021, 63, 594-599.	1.7	4
1505	General practitioners maintain a focus on blood pressure management rather than absolute cardiovascular disease risk management. Journal of Evaluation in Clinical Practice, 2021, 27, 1353-1360.	1.8	7
1506	Risk Models and Scores of Cardiovascular Disease in Patients with Diabetes Mellitus. Current Pharmaceutical Design, 2021, 27, 1245-1253.	1.9	3
1508	The Prevalence and Risk Factors for Peripheral Arterial Disease in Adults Living With Human Immunodeficiency Virus. International Journal of Lower Extremity Wounds, 2023, 22, 332-338.	1.1	2
1510	Association of nut and legume consumption with Framingham 10 year risk of general cardiovascular disease in older adult men: A cross-sectional study. Clinical Nutrition ESPEN, 2021, 42, 373-380.	1.2	7
1511	An electronic decision supportâ€based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). Medical Journal of Australia, 2021, 214, 420-427.	1.7	7
1512	A genome-wide methylation study of body fat traits in the Norfolk Island isolate. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1556-1563.	2.6	4
1513	Cardiorespiratory Fitness Is Associated with a Reduced Cardiovascular Risk in Occupational Groups with Different Working Conditions: A Cross-Sectional Study among Police Officers and Office Workers. Journal of Clinical Medicine, 2021, 10, 2025.	2.4	5

#	Article	IF	Citations
1514	The cost-effectiveness of a two-step blood pressure screening programme in a dental health-care setting. PLoS ONE, 2021, 16, e0252037.	2.5	0
1515	Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight, 2021, 6, .	5.0	45
1516	Erectile Dysfunction Is a Hallmark of Cardiovascular Disease: Unavoidable Matter of Fact or Opportunity to Improve Menâ€™s Health?. Journal of Clinical Medicine, 2021, 10, 2221.	2.4	17
1517	Cardiovascular disease risk prediction in older people: a qualitative study. British Journal of General Practice, 2021, 71, e772-e779.	1.4	3
1518	Improved sleep efficiency is associated with reduced cardioâ€metabolic risk: Findings from the MODERN trial. Journal of Sleep Research, 2021, 30, e13389.	3.2	8
1519	Analysis and Management of COVID-19 Using Computational Intelligence Technologies. Journal of Medical Imaging and Health Informatics, 2021, 11, 1642-1648.	0.3	0
1520	Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study. Lancet, The, 2021, 397, 2264-2274.	13.7	29
1522	Comparison of Predicted Cardiovascular Risk Profiles by Different CVD Risk-Scoring Algorithms between HIV-1-Infected and Uninfected Adults: A Cross-Sectional Study in Tanzania. HIV/AIDS - Research and Palliative Care, 2021, Volume 13, 605-615.	0.8	4
1523	Decision models in type 2 diabetes mellitus: A systematic review. Acta Diabetologica, 2021, 58, 1451-1469.	2.5	13
1524	Systematic Coronary Risk Evaluation (SCORE). Journal of the American College of Cardiology, 2021, 77, 3046-3057.	2.8	25
1525	Cardiovascular risk factors associated with acute myocardial infarction and stroke in the MADIABETES cohort. Scientific Reports, 2021, 11, 15245.	3.3	6
1526	Validation and comparison of 28 risk prediction models for coronary artery disease. European Journal of Preventive Cardiology, 2022, 29, 666-674.	1.8	10
1527	Improvement in the Prediction of Coronary Heart Disease Risk by Using Artificial Neural Networks. Quality Management in Health Care, 2021, 30, 244-250.	0.8	5
1528	Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. Expert Review of Hematology, 2021, 14, 831-840.	2.2	4
1529	Change in cardiovascular risk assessment tool and updated Norwegian guidelines for cardiovascular disease in primary prevention increase the population proportion at risk: the TromsÃ¸ Study 2015â€“2016. Open Heart, 2021, 8, e001777.	2.3	2
1530	Self-help behaviors partially mediate the relationship between personalized depression risk disclosure and psychological distress: A mediation analysis using data from a randomized controlled trial. Journal of Psychiatric Research, 2021, 140, 7-14.	3.1	0
1531	Obstructive sleep apnea predicts 10-year cardiovascular diseaseâ€“related mortality in the Sleep Heart Health Study: a machine learning approach. Journal of Clinical Sleep Medicine, 2022, 18, 497-504.	2.6	10
1532	Atrial fibrillation risk prediction from the 12-lead electrocardiogram using digital biomarkers and deep representation learning. European Heart Journal Digital Health, 2021, 2, 576-585.	1.7	28

#	Article	IF	Citations
1533	Estimation of vascular risk: Time and place matter. Revista Clínica Espanõla, 2021, 221, 596-597.	0.5	0
1534	Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart, 2021, 8, e001735.	2.3	14
1535	Blood Lead Levels and Cardiovascular Disease Risk: Results from the Korean National Health and Nutrition Examination Survey. International Journal of Environmental Research and Public Health, 2021, 18, 10315.	2.6	4
1536	2021 Consensus Pathway of the TaiwanÂSociety of Cardiology on NovelÂTherapyÂfor Type 2 Diabetes. JACC Asia, 2021, 1, 129-146.	1.5	1
1537	Cost-effectiveness of a Community-based Hypertension Improvement Project (ComHIP) in Ghana: results from a modelling study. BMJ Open, 2021, 11, e039594.	1.9	3
1538	Associations Between Cardiorespiratory Fitness, Cardiovascular Risk, and Cognition Are Mediated by Structural Brain Health in Midlife. Journal of the American Heart Association, 2021, 10, e020688.	3.7	18
1539	Text messages for primary prevention of cardiovascular disease: The TextMe2 randomized clinical trial. American Heart Journal, 2021, 242, 33-44.	2.7	12
1540	Association between Speech Recognition in Noise and Risk Factors of Cardiovascular Disease. Audiology and Neuro-Otology, 2021, 26, 368-377.	1.3	8
1542	Critical Inquiries on Technology Utilization. , 2005, , 133-146.		1
1543	Information-Theoretic Causal Power. , 2009, , 231-265.		5
1544	Application of Metabolomics to Renal and Cardiometabolic Diseases. Methods in Molecular Biology, 2020, 2104, 401-417.	0.9	2
1545	From Vulnerable Plaque to Vulnerable Patient. , 2011, , 13-38.		4
1546	Is It Possible to Predict Cardiac Death?. IFMBE Proceedings, 2020, , 847-854.	0.3	15
1547	Ontology Based Personalized Modeling for Chronic Disease Risk Analysis: An Integrated Approach. Lecture Notes in Computer Science, 2009, , 1204-1210.	1.3	8
1549	An Overview of the Beneficial Effects of Exercise on Health and Performance. Advances in Experimental Medicine and Biology, 2020, 1228, 3-22.	1.6	44
1550	Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet, The, 2005, 365, 434-441.	13.7	283
1552	Aspirin for primary prevention: yes or no?. Journal of Primary Health Care, 2010, 2, 92.	0.6	6
1553	Does Your Heart Forecast help practitioner understanding and confidence with cardiovascular disease risk communication?. Journal of Primary Health Care, 2011, 3, 4.	0.6	12

#	Article	IF	Citations
1554	Blood pressure and the burden of coronary heart disease. , 2005, , 152-173.		3
1555	EFFICACY, SAFETY AND PATIENT ACCEPTANCE OF SILDENAFIL CITRATE AS TREATMENT FOR ERECTILE DYSFUNCTION. Journal of Urology, 2000, , 1192-1196.	0.4	7
1556	Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation, 2002, 73, 901-906.	1.0	297
1558	COVID-19 Future Forecasting Using Supervised Machine Learning Models. IEEE Access, 2020, 8, 101489-101499.	4.2	350
1559	Strategies for reducing coronary risk factors in primary care: which is most cost effective?. BMJ: British Medical Journal, 1995, 310, 1109-1112.	2.3	72
1560	Interventions in OXCHECK study waste resources. BMJ: British Medical Journal, 1995, 311, 260-260.	2.3	6
1561	Ratio of waist circumference to height may be better indicator of need for weight management. BMJ: British Medical Journal, 1996, 312, 377-377.	2.3	188
1562	The number needed to treat: a clinically useful nomogram in its proper context. BMJ: British Medical Journal, 1996, 312, 426-429.	2.3	173
1563	Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ: British Medical Journal, 2000, 320, 680-685.	2.3	46
1564	Optimal age for starting lipid lowering treatment. BMJ: British Medical Journal, 2000, 321, 637-637.	2.3	5
1565	Aspirin in type 2 diabetes: is there any evidence base?. BMJ: British Medical Journal, 2008, 337, a1902-a1902.	2.3	8
1566	Blood pressure self monitoring: questions and answers from a national conference. BMJ: British Medical Journal, 2008, 337, a2732-a2732.	2.3	31
1567	Evaluating cardiovascular risk assessment for asymptomatic people. BMJ: British Medical Journal, 2009, 338, a2844-a2844.	2.3	15
1568	Continuous Health Interface Event Retrieval. , 2020, , .		2
1569	Coronary Risk Estimation and Treatment of Hypercholesterolemia. Circulation, 1997, 96, 2449-2452.	1.6	39
1570	Ethnic differences in total and HDL cholesterol concentrations: Caucasians compared with predominantly Punjabi Sikh Indo-Asians. Annals of Clinical Biochemistry, 2002, 39, 609-611.	1.6	9
1571	Application of the Updated Framingham Risk Score to Japanese Men.. Hypertension Research, 2001, 24, 685-689.	2.7	33
1572	Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels. HIV Clinical Trials, 2009, 10, 1-12.	2.0	33

#	Article	IF	Citations
1573	Guideline-Driven Assessment of Cardiovascular Disease and Related Risks After Spinal Cord Injury. Topics in Spinal Cord Injury Rehabilitation, 2009, 14, 32-45.	1.8	12
1574	Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age. PLoS ONE, 2011, 6, e18742.	2.5	95
1575	A Comparative Assessment of Non-Laboratory-Based versus Commonly Used Laboratory-Based Cardiovascular Disease Risk Scores in the NHANES III Population. PLoS ONE, 2011, 6, e20416.	2.5	51
1576	Which Interventions Offer Best Value for Money in Primary Prevention of Cardiovascular Disease?. PLoS ONE, 2012, 7, e41842.	2.5	66
1577	Prediction of Risk Factors for Coronary Heart Disease Using Framingham Risk Score in Korean Men. PLoS ONE, 2012, 7, e45030.	2.5	11
1578	The Utility of Liver Function Tests for Mortality Prediction within One Year in Primary Care Using the Algorithm for Liver Function Investigations (ALFI). PLoS ONE, 2012, 7, e50965.	2.5	12
1579	Risk Models to Predict Hypertension: A Systematic Review. PLoS ONE, 2013, 8, e67370.	2.5	106
1580	Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study. PLoS ONE, 2013, 8, e67611.	2.5	59
1581	Characterization of Vascular Disease Risk in Postmenopausal Women and Its Association with Cognitive Performance. PLoS ONE, 2013, 8, e68741.	2.5	16
1582	Obesity as Assessed by Body Adiposity Index and Multivariable Cardiovascular Disease Risk. PLoS ONE, 2014, 9, e94560.	2.5	29
1583	Aortic Unfolding Determined Using Non-Contrast Cardiac Computed Tomography: Correlations with Age and Coronary Artery Calcium Score. PLoS ONE, 2014, 9, e95887.	2.5	7
1584	Accounting for eXentricities: Analysis of the X Chromosome in GWAS Reveals X-Linked Genes Implicated in Autoimmune Diseases. PLoS ONE, 2014, 9, e113684.	2.5	100
1585	Tailoring the Implementation of New Biomarkers Based on Their Added Predictive Value in Subgroups of Individuals. PLoS ONE, 2015, 10, e0114020.	2.5	4
1586	Health Risks and Changes in Self-Efficacy Following Community Health Screening of Adults with Serious Mental Illnesses. PLoS ONE, 2015, 10, e0123552.	2.5	18
1587	Costs and Cost-Effectiveness of Hypertension Screening and Treatment in Adults with Hypertension in Rural Nigeria in the Context of a Health Insurance Program. PLoS ONE, 2016, 11, e0157925.	2.5	26
1588	The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus. PLoS ONE, 2016, 11, e0162441.	2.5	10
1589	Clinical and Economic Impact of a Digital, Remotely-Delivered Intensive Behavioral Counseling Program on Medicare Beneficiaries at Risk for Diabetes and Cardiovascular Disease. PLoS ONE, 2016, 11, e0163627.	2.5	41
1590	Equity in healthcare for coronary heart disease, Wales (UK) 2004â€“2010: A population-based electronic cohort study. PLoS ONE, 2017, 12, e0172618.	2.5	6

#	Article	IF	Citations
1591	Crossover effect of spouse weekly working hours on estimated 10-years risk of cardiovascular disease. PLoS ONE, 2017, 12, e0182010.	2.5	8
1592	Genetic loci associated with prevalent and incident myocardial infarction and coronary heart disease in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. PLoS ONE, 2020, 15, e0230035.	2.5	5
1593	Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations. PLoS ONE, 2020, 15, e0244675.	2.5	3
1595	Noninvasive detection of coronary artery disease: challenges for prevention of disease and clinical events. Clinics, 2005, 60, 415-428.	1.5	7
1597	Combination of Ezetimibe and Garlic Reduces Serum Lipids and Intestinal Niemann-Pick C1-like 1 Expression More Effectively in Hypercholesterolemic Mice. Avicenna Journal of Medical Biochemistry, 2015, 3, .	0.3	3
1598	Overview of Risk-Estimation Tools for Primary Prevention of Cardiovascular Diseases in European Populations. Central European Journal of Public Health, 2015, 23, 91-99.	1.1	8
1600	Recalibration of the Framingham Equations in the Thai Population. SSRN Electronic Journal, 0, , .	0.4	1
1601	Cardiovascular prevention in general practice. Acta Cardiologica, 2004, 59, 598-605.	0.9	6
1602	Cardiovascular risk assessment and management in developing countries. Vascular Health and Risk Management, 2005, 1, 15-18.	2.3	32
1603	Methodological issues in cardiovascular epidemiology: the risk of determining absolute risk through statistical models. Vascular Health and Risk Management, 2006, 2, 309-315.	2.3	12
1604	Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians. Vascular Health and Risk Management, 2008, 4, 199-211.	2.3	56
1605	Management of Measurable Variable Cardiovascular Disease' Risk Factors. Current Cardiology Reviews, 2018, 14, 153-163.	1.5	199
1606	Paracrine Mechanisms Involved in Mesenchymal Stem Cell Differentiation into Cardiomyocytes. Current Stem Cell Research and Therapy, 2019, 14, 9-13.	1.3	30
1607	Charts Based on Body Mass Index and Waist-to-Height Ratio to Assess the Health Risks of Obesity: A Review. The Open Obesity Journal, 2011, 3, 78-84.	0.1	54
1608	An Electronic Clinical Decision Support Tool to Assist Primary Care Providers in Cardiovascular Disease Risk Management: Development and Mixed Methods Evaluation. Journal of Medical Internet Research, 2009, 11, e51.	4.3	59
1609	I Don't Believe It, But I'd Better Do Something About It: Patient Experiences of Online Heart Age Risk Calculators. Journal of Medical Internet Research, 2014, 16, e120.	4.3	52
1610	Are People With Chronic Diseases Interested in Using Telehealth? A Cross-Sectional Postal Survey. Journal of Medical Internet Research, 2014, 16, e123.	4.3	103
1611	A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technology Assessment, 2007, 11, 1-160, iii-iv.	2.8	311

#	Article	IF	Citations
1612	Continuous positive airway pressure devices for the treatment of obstructive sleep apnoeaâ€“hypopnoea syndrome: a systematic review and economic analysis. Health Technology Assessment, 2009, 13, iii-iv, xi-xiv, 1-119, 143-274.	2.8	172
1613	Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis. Health Technology Assessment, 2009, 13, iii-iv, ix-xi, 1-90.	2.8	42
1614	Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technology Assessment, 2009, 13, iii-iv, ix-xi, 1-134.	2.8	54
1615	The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technology Assessment, 2009, 13, 1-190, 215-357, iii-iv.	2.8	789
1616	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technology Assessment, 2015, 19, 1-402.	2.8	30
1617	A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT. Health Technology Assessment, 2015, 19, 1-188.	2.8	46
1618	A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults. Health Technology Assessment, 2015, 19, 1-378.	2.8	40
1619	Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT. Health Technology Assessment, 2019, 23, 1-144.	2.8	17
1620	An evidence-based approach to the use of telehealth in long-term health conditions: development of an intervention and evaluation through pragmatic randomised controlled trials in patients with depression or raised cardiovascular risk. Programme Grants for Applied Research, 2017, 5, 1-468.	1.0	4
1621	Football Fans in Training (FFIT): a randomised controlled trial of a gender-sensitised weight loss and healthy living programme for men â€“ end of study report. Public Health Research, 2015, 3, 1-130.	1.3	64
1622	Prognostic Value of Coronary CT Angiography for Predicting Poor Cardiac Outcome in Stroke Patients without Known Cardiac Disease or Chest Pain: The Assessment of Coronary Artery Disease in Stroke Patients Study. Korean Journal of Radiology, 2020, 21, 1055.	3.4	11
1623	The Potential Benefit of Monitoring Oxidative Stress and Inflammation in the Prevention of Non-Communicable Diseases (NCDs). Antioxidants, 2021, 10, 15.	5.1	36
1624	Zero end-digit preference in recorded blood pressure and its impact on classification of patients for pharmacologic management in primary care â€” PREDICT-CVDâ€“6. British Journal of General Practice, 2007, 57, 897-903.	1.4	27
1625	Cost-Benefit Model System of Chronic Diseases in Australia to Assess and Rank Prevention and Treatment Options. , 2010, 4, 57-70.		2
1626	Novel CHA2DS2-VASc-HSF is Superior to CHADS2 and CHA2DS2-VASc Score to Predict the Risk of Severe Coronary Artery Disease. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 451-456.	0.2	2
1627	Self-monitoring of blood glucose improved glycemic control and the 10-year coronary heart disease risk profile of female type 2 diabetes patients in Trinidad and Tobago. Nigerian Journal of Clinical Practice, 2011, 14, 1.	0.6	11
1628	Comparison consequences of Jackson-Pratt drain versus chest tube after coronary artery bypass grafting: A randomized controlled clinical trial. Journal of Research in Medical Sciences, 2017, 22, 134.	0.9	2
1629	Assessing 10-year coronary heart disease risk in people with Type 2 diabetes mellitus: Framingham versus United Kingdom Prospective Diabetes Study. Journal of Diabetes Mellitus, 2014, 04, 12-18.	0.3	6

#	Article	IF	Citations
1630	Is reversal of endothelial dysfunction still an attractive target in modern cardiology?. World Journal of Cardiology, 2014, 6, 824.	1.5	19
1631	Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project. Kardiologia Polska, 2013, 71, 702-711.	0.6	6
1632	Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting. Kardiologia Polska, 2015, 73, 768-780.	0.6	9
1633	Exercise Effects on Risk of Cardiovascular Disease among Iranian Women. Asian Journal of Sports Medicine, 2011, 2, 37-43.	0.3	16
1634	Non-Alcoholic Fatty Liver Disease: Diagnosis and Evaluation of Disease Severity. â€â€«â€¬â€Thrita Journal of Medical Sciences, 2013, 2, 43-51.	0.2	6
1635	The 30-year cardiovascular risk profile of South Africans with diagnosed diabetes, undiagnosed diabetes, pre-diabetes or normoglycaemia : the Bellville, South Africa pilot study. Cardiovascular Journal of Africa, 2012, 23, 5-11.	0.4	47
1636	The ADVANCE cardiovascular risk model and current strategies for cardiovascular disease risk evaluation in people with diabetes. Cardiovascular Journal of Africa, 2013, 24, 376-381.	0.4	23
1637	Cardiovascular risk evaluation of HIV-positive patients in a case-control study: comparison of the D:A:D and Framingham equations. Journal of the International AIDS Society, 2014, 17, 19515.	3.0	10
1638	Biochemical Studies on the Amelioration of Petroleum Product Intoxication with Indigenous Plants. International Journal of Biochemistry Research & Review, 2012, 2, 87-97.	0.1	8
1639	A detailed analysis of Covid-19 using supervised machine learning models. AIP Conference Proceedings, 2021, , .	0.4	0
1640	Estimating the cost-effectiveness of the Sodium Reduction in Communities Program. Public Health Nutrition, 2022, 25, 1050-1060.	2.2	1
1641	Assessment of plasma ceramides as predictor for subclinical atherosclerosis. Atherosclerosis Plus, 2021, 45, 25-31.	0.7	3
1642	Cardiovascular Risk Calculators and their Applicability to South Asians. Current Diabetes Reviews, 2021, 17, e100120186497.	1.3	2
1643	Arterielle Hypertonie. , 2000, , 259-268.		0
1644	Weitere kardiovaskulÃre Risikofaktoren. , 2000, , 269-291.		0
1645	Fettstoffwechsel, Ãœbergewicht und ErnÃhrung, Diabetes. , 2000, , 239-257.		0
1646	Absolute, attributable, and relative risk in the management of coronary heart disease. Heart, 2001, 85, 491-492.	2.9	1
1647	Methods for the prediction of coronary heart disease risk. Heart, 2001, 85, 489-490.	2.9	0

#	Article	IF	Citations
1648	Menopause Therapy. , 2002, , 299-312.		0
1649	New score is needed to predict risk of coronary heart disease. BMJ: British Medical Journal, 2002, 324, 1217-1217.	2.3	2
1650	The Potential Impact of CardioVision 2020 and Three Other Risk Factor Scenarios on Population Rates of Coronary Heart and Cardiovascular Disease: A Call to Action. Progress in Experimental Cardiology, 2003, , 495-505.	0.0	0
1651	Information Mastery: Practical Evidence-Based Family Medicine. , 2003, , 577-591.		0
1652	SexualitÃt. , 2004, , 259-298.		0
1653	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. , 2004, , 159-181.		0
1654	Sexual Activity As a Trigger of Myocardial Infarction/Ischemia. , 2004, , 251-260.		0
1655	Risk scores for management and prevention of cardiovascular disease. , 2005, , 669-687.		1
1656	Clinical Evidence Review: Best Practices Diabetes Mellitus Update. , 2006, , .		0
1657	Cerebrovascular prevention by angiotensin II receptor antagonists. , 2006, , 173-188.		0
1658	Estimating the value of information in strategies for identifying patients at high risk of cardiovascular disease. Journal of Innovation in Health Informatics, 2006, 14, 85-92.	0.9	6
1659	Are guidelines on cardiovascular risk prevention comprehensive enough? Focus on the 2005 Joint British Societies? Guidelines. Therapy: Open Access in Clinical Medicine, 2006, 3, 687-690.	0.2	0
1660	Erectile Dysfunction and Cardiovascular Disease. , 2007, , 2791-2801.		0
1661	Cardiovascular Disease Risk Prevention Across Europe. European Cardiology Review, 2007, 3, 14.	2.2	1
1662	Comparison between the Stroke Risk Score Calculated from Annual Health Check Data and the Intakes of Dietary Constituents. The Japanese Journal of Nutrition and Dietetics, 2008, 66, 69-76.	0.1	0
1664	Aortic and Carotid Function as a Predictor of Cardiovascular Outcomes. , 2008, , 71-77.		0
1665	NHG-Standaard Cardiovasculair risicomanagement. , 2009, , 106-152.		4
1666	Exercise in the Therapy of Diabetes Mellitus. , 2010, , 687-708.		0

#	Article	IF	Citations
1667	Noninvasive Ultrasound Imaging of Carotid Intima Thickness. , 2011, , 285-318.		0
1668	Cardiovascular Epidemiology and Characterization of Atherosclerotic Disease Risk Factors. , 2011, , 3-24.		0
1669	Association of Coronary Artery Calcium Scores with Cadiovascular Disease Risk Factors in an Asymptomatic Adults. The Journal of the Korea Contents Association, 2010, 10, 268-275.	0.1	1
1670	Clinical evaluation of factors that influence blood pressure ratios among various sites in the arm. Nihon Toseki Igakkai Zasshi, 2011, 44, 623-628.	0.1	0
1672	Exercise Effects on Risk of Cardiovascular Disease among Iranian Women. Asian Journal of Sports Medicine, 2011, 2, .	0.3	7
1673	Corelationship Study between Hwa-Byung and Coronary Heart Disease, by using Framingham Coronary Risk Score. Journal of Oriental Neuropsychiatry, 2011, 22, 13-22.	0.1	1
1677	The Methodology of Human Diseases Risk Prediction Tools. International Journal of Statistics in Medical Research, 0, , .	1.0	0
1678	The Association between Serum Gamma-glutamyltransferase within Normal Range and Risk Factors of Cardiovascular Diseases: Based on the Framingham Risk Score. The Korean Journal of Obesity, 2013, 22, 21.	0.2	3
1679	Risk Factor Analysis for Incidence of Major Adverse Cardiac Events after Percutaneous Coronary Intervention Treatment. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2014, 40, 278-284.	0.1	0
1680	Triggering of myocardial infarction by physical activity, emotional stress and sexual activity. Developments in Cardiovascular Medicine, 1996, , 71-80.	0.1	1
1682	Triggers of Acute Coronary Syndromes. Contemporary Cardiology, 1999, , 57-85.	0.1	0
1683	Economic Evaluation of the Use of HMG-CoA Reductase Inhibitors (Statins for the Primary Prevention) Tj ETQq1 1 0.784314 rgBT /Ov	0.0	0
1684	Screening for Type 2 Diabetes. JAMA - Journal of the American Medical Association, 1999, 281, 1986-1988.	7.4	1
1685	Is the Framingham risk function valid for northern European populations?. Heart, 1999, 82, 114-115.	2.9	0
1686	Effects on the Risk of Cardiovascular Disease in Breast Cancer Patients Received Postoperative Adjuvant Anticancer Therapy. Journal of the Korea Academia-Industrial Cooperation Society, 2014, 15, 2971-2980.	0.1	0
1688	Growth Factor Delivery Matrices for Cardiovascular Regeneration. , 2015, , 159-214.		0
1689	Neurosurgery for Extracranial Carotid Disease. , 2015, , 2719-2738.		0
1691	Arterial Alterations in Hypertension. , 2015, , 285-297.		0

#	Article	IF	Citations
1692	The Comparison of the Impact of Physical Activity on Cardiovascular Health-Related Behaviors in Male and Female High School Students, Based on the Perceived Benefits and Barriers. International Journal of School Health, 2015, 2, .	0.2	0
1693	Exercise in the Therapy of Diabetes Mellitus. , 2016, , 1-24.		0
1694	Characteristics of Young Korean Metabolically Healthy Obese Patient: Based on Retrospective Analysis of Republic of Korea Navy Soldiers' Medical Examination. Journal of Lipid and Atherosclerosis, 2016, 5, 155.	3.5	0
1695	Exercise in the Therapy of Diabetes Mellitus. , 2016, , 1-24.		0
1696	â€œA Study of the Cardiovascular Risk Factors and Cardiovascular Complications in Systemic Hypertensionâ€•. International Journal of Medical Science and Clinical Invention, 0, , .	0.1	0
1697	Traumatismo CranioencefÃ¡lico e Modelos PrognÃ³sticos. Jbnc - Jornal Brasileiro De Neurocirurgia, 2018, 26, 57-67.	0.0	3
1698	Comparison of ChitoHem Powder and Sand Bag for Controlling Bleeding After Femoral Angiography. Jundishapur Journal of Chronic Disease Care, 2018, 7, .	0.3	2
1700	Belirlenen Hedeflere UlaÅŸamayan Kilo Verdirici Diyet GiriÅŸimlerinin KardiyovaskÃ¼ler Risk Ãœzerine Etkisi. Turkish Journal of Family Medicine & Primary Care, 2018, 12, 156-161.	0.6	0
1701	Predictive Performance of Ultrasound-Determined Non-Alcoholic Fatty Pancreas Disease Severity for Intermediate and High Risk of Coronary Heart Disease. Journal of the Korean Society of Radiology, 2019, 80, 1190.	0.2	1
1705	Early Prediction of Non-communicable Diseases Using Soft Computing Methodology. Learning and Analytics in Intelligent Systems, 2020, , 696-703.	0.6	0
1706	Role of machine learning algorithms over heart diseases prediction. AIP Conference Proceedings, 2020, , .	0.4	16
1708	Isolation and characterization of chemical constituents, cytotoxicity, antibacterial and antioxidant activity of the isolates, crude extract from Hornstedtia scyphifera var leaf. GSC Biological and Pharmaceutical Sciences, 2020, 10, 070-098.	0.3	0
1709	Characterization of Chemical Constituent and Evaluation of Antioxidant, Cytotoxicity, Potential of Selenicereus hamatus Crude Extract. Asian Journal of Biochemistry, 2020, 15, 50-59.	0.5	1
1711	Lysophospholipids as Predictive Markers of ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI). Metabolites, 2021, 11, 25.	2.9	8
1712	Involvement of Epigenetic Control and Non-coding RNAs in Cardiovascular System. Advances in Experimental Medicine and Biology, 2020, 1229, 121-132.	1.6	0
1713	Cinnamic Acid from Barringtonia asiatica Stem-Bark Extract. Its Cytotoxicity, Antioxidant and Bioactive Potentials on Some Selected Pathogens. International Journal of Recent Biotechnology, 2020, 8, 35-46.	0.0	0
1714	Developing and evaluating packages to support implementation of quality indicators in general practice: the ASPIRE research programme, including two cluster RCTs. Programme Grants for Applied Research, 2020, 8, 1-96.	1.0	7
1716	Cardiovascular Chronobiology: Do You Know What Time It Is?. Progress in Cardiovascular Nursing, 2001, 16, 65-79.	0.4	1

#	Article	IF	Citations
1717	Epidemiology of Hypertension in the Older Patient. , 2005, , 53-67.		0
1718	Current treatment strategies for obesity. Therapy: Open Access in Clinical Medicine, 2005, 2, 955-967.	0.2	0
1719	Changes to the Statin Prescribing Policy in Belgium. American Journal of Cardiovascular Drugs, 2012, 12, 225-232.	2.2	3
1720	Prospective associations between ECG abnormalities and death or myocardial infarction in a cohort of 980 employed, middle-aged Swedish men. Egyptian Heart Journal, 2020, 72, 75.	1.2	2
1722	Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used. BMJ: British Medical Journal, 2000, 321, 637; author reply 638.	2.3	0
1723	End points for predicting coronary risk must be clarified. BMJ: British Medical Journal, 2001, 323, 396-7.	2.3	0
1724	New score is needed to predict risk of coronary heart disease. BMJ, The, 2002, 324, 1217.	6.0	1
1725	Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. Cmaj, 1999, 160, 1449-55.	2.0	8
1726	Estimation of cardiovascular risk in hypertensive patients in primary care. British Journal of General Practice, 2000, 50, 127-8.	1.4	46
1727	Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable. British Journal of General Practice, 2000, 50, 693-5.	1.4	1
1728	The primary prevention of coronary heart disease with statins: practice headache or public health?. British Journal of General Practice, 2000, 50, 695-7.	1.4	3
1729	Management of UTI in general practice: a cost effective analysis. A commentary to facilitate an understanding of economic evaluation. British Journal of General Practice, 2000, 50, 697-8.	1.4	0
1730	A factorial randomised controlled trial of decision analysis and an information video plus leaflet for newly diagnosed hypertensive patients. British Journal of General Practice, 2003, 53, 446-53.	1.4	74
1731	Predictors for the white coat effect in general practice patients with suspected and treated hypertension. British Journal of General Practice, 2003, 53, 790-3.	1.4	17
1732	Three-year follow-up of a factorial randomised controlled trial of two decision aids for newly diagnosed hypertensive patients. British Journal of General Practice, 2005, 55, 551-3.	1.4	25
1733	Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Heart Health Surveys Research Group. Cmaj, 1992, 146, 1997-2005.	2.0	44
1734	Multiple cardiovascular disease risk factors in Canadian adults. Canadian Heart Health Surveys Research Group. Cmaj, 1992, 146, 2021-9.	2.0	21
1735	The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. British Journal of General Practice, 2005, 55, 838-45.	1.4	93

#	Article	IF	Citations
1736	The use of cardiovascular risk factor information in practice databases: making the best of patient data. British Journal of General Practice, 2006, 56, 600-5.	1.4	7
1737	New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003. Clinical Biochemist Reviews, 2007, 28, 19-29.	3.3	8
1738	Impact on hypertension control of a patient-held guideline: a randomised controlled trial. British Journal of General Practice, 2006, 56, 842-7.	1.4	15
1739	Optimal blood pressure level and best measurement procedure in hemodialysis patients. Vascular Health and Risk Management, 2005, 1, 235-44.	2.3	11
1740	Multivariate risk assessment and risk score cards in hypertension. Vascular Health and Risk Management, 2007, 3, 313-20.	2.3	4
1741	Modeling the local dynamics of cardiovascular health: risk factors, context, and capacity. Preventing Chronic Disease, 2008, 5, A63.	3.4	33
1743	Simulating and evaluating local interventions to improve cardiovascular health. Preventing Chronic Disease, 2010, 7, A18.	3.4	35
1744	Primary prevention of CVD: treating dyslipidaemia. Clinical Evidence, 2008, 2008, .	0.2	4
1745	Diabetes mellitus update. , 2006, 10, 29-34.		0
1747	Primary prevention of CVD: treating dyslipidaemia. Clinical Evidence, 2010, 2010, .	0.2	2
1748	Exercise Effects on Risk of Cardiovascular Disease among Iranian Women. Asian Journal of Sports Medicine, 2011, 2, 37-43.	0.3	8
1749	Accuracy of self-perception of cardiovascular risk in the community. Journal of Vascular and Interventional Neurology, 2008, 1, 106-12.	1.1	6
1750	Low-density lipoprotein apheresis: an evidence-based analysis. Ontario Health Technology Assessment Series, 2007, 7, 1-101.	1.8	4
1751	Cardiac risk is not associated with hypertension treatment intensification. American Journal of Managed Care, 2012, 18, 414-20.	1.1	1
1752	Plasma acetylcholinesterase activity correlates with intracerebral Î²-amyloid load. Current Alzheimer Research, 2013, 10, 48-56.	1.4	24
1753	Involvement of microRNA-133 and -29 in cardiac disturbances in diabetic ovariectomized rats. Iranian Journal of Basic Medical Sciences, 2016, 19, 1177-1185.	1.0	19
1754	Effects of the Health Belief Model (HBM)-Based Educational Program on the Nutritional Knowledge and Behaviors ofÂCABGÂPatients. The Journal of Tehran Heart Center, 2016, 11, 181-186.	0.3	12
1756	HYPERTENSION IN RELATION TO IMMUNE SYSTEM AND WAY OF LIFE ALONG WITH TREATMENT. International Journal of Current Pharmaceutical Research, 0, , 1-10.	0.2	1

#	Article	IF	Citations
1757	The Impact of Exercise on Telomere Length, DNA Methylation and Metabolic Footprints. Cells, 2022, 11, 153.	4.1	5
1758	Cardiovascular health is associated with the epigenetic clock in the Berlin Aging Study II (BASE-II). Mechanisms of Ageing and Development, 2022, 201, 111616.	4.6	9
1759	In vivo therapeutic genome editing via CRISPR/Cas9 magnetoplexes for myocardial infarction. Biomaterials, 2022, 281, 121327.	11.4	10
1760	Using clinical prediction models to personalise lifestyle interventions for cardiovascular disease prevention: A systematic literature review. Preventive Medicine Reports, 2022, 25, 101672.	1.8	0
1762	An explainable XGBoostâ€“based approach towards assessing the risk of cardiovascular disease in patients with Type 2 Diabetes Mellitus. , 2020, , .		23
1763	COVID â€“ 19 Future forecasting using Time Series Model. , 2021, , .		0
1764	The importance of blood pressure thresholds versus predicted cardiovascular risk on subsequent rates of cardiovascular disease: a cohort study in English primary care. The Lancet Healthy Longevity, 2022, 3, e22-e30.	4.6	3
1765	Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. Diabetologia, 2022, 65, 644-656.	6.3	41
1766	COVID-19 Future Predictions Using 4 Supervised Machine Learning Models. International Journal of Advanced Research in Science, Communication and Technology, 0, , 61-66.	0.0	0
1767	Prediction of Cardiovascular and All-Cause Mortality After Myocardial Infarction in US Veterans. American Journal of Cardiology, 2022, 169, 10-17.	1.6	4
1768	Evaluating community-driven cardiovascular health policy changes in the United States using agent-based modeling. Journal of Public Health Policy, 2022, 43, 40-53.	2.0	1
1769	Inclusion of Smoking Data in Cardiovascular Disease Risk Estimation. JAMA Cardiology, 2022, 7, 195.	6.1	11
1772	New Insights into Polyphenols in Plants as Potential Modulators of Atherosclerosis by Acting on Lipoprotein Lipase: In Silico Molecular Docking and In Vitro Studies. ACS Food Science & Technology, 2022, 2, 476-483.	2.7	0
1773	Cardiac CT motion artifact grading via semi-automatic labeling and vessel tracking using synthetic image-augmented training data. Journal of X-Ray Science and Technology, 2022, 30, 433-445.	1.0	3
1774	Generalizability of Cardiovascular Disease Clinical Prediction Models: 158 Independent External Validations of 104 Unique Models. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, 101161CIRCOUTCOMES121008487.	2.2	21
1775	Noninvasive Voice Biomarker Is Associated With Incident Coronary Artery Disease Events at Follow-up. Mayo Clinic Proceedings, 2022, 97, 835-846.	3.0	10
1776	Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: a cohort-based cross-sectional study. BMC Cardiovascular Disorders, 2022, 22, 162.	1.7	8
1778	Incorporating Insulin Growth Factor-1 into Regenerative and Personalized Medicine for Cardiovascular Disease: A Systematic Review. Current Stem Cell Research and Therapy, 2023, 18, 202-215.	1.3	2

#	Article	IF	Citations
1779	Use of coronary computed tomography or polygenic risk scores to prompt action to reduce coronary artery disease risk: the CAPAR-CAD trial. American Heart Journal, 2022, 248, 97-107.	2.7	2
1780	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. American Journal of Preventive Cardiology, 2022, 10, 100335.	3.0	58
1781	Dedicated Wearable Sensitive Strain Sensor, Based on Carbon Nanotubes, for Monitoring the Rat Respiration Rate. , 2021, 10, .		0
1782	Comparing the Predictive Power of Heart Failure Hospitalisation Risk Scores in the Diabetic Outpatient Clinic and Primary Care Settings. , 2021, , .		1
1783	A mental models approach for defining explainable artificial intelligence. BMC Medical Informatics and Decision Making, 2021, 21, 344.	3.0	10
1784	Logistic regression models for patient-level prediction based on massive observational data: Do we need all data?. International Journal of Medical Informatics, 2022, 163, 104762.	3.3	5
1789	Carotid intima-media thickness and carotid and/or iliofemoral plaques: comparison of two markers of cardiovascular risk in hypertensive patients. Journal of Hypertension, 2003, 21, 739-46.	0.5	7
1790	Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK. Quality and Safety in Health Care, 2004, 13, 191-197.	2.5	32
1791	Predicted cardiovascular disease risk and prescribing of antihypertensive therapy among patients with hypertension in Australia using MedicineInsight. Journal of Human Hypertension, 2023, 37, 370-378.	2.2	5
1792	Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. Frontiers in Medicine, 2022, 9, .	2.6	5
1793	Risk Assessment of CHD Using Retinal Images with Machine Learning Approaches for People with Cardiometabolic Disorders. Journal of Clinical Medicine, 2022, 11, 2687.	2.4	4
1794	A Mobile App for Prevention of Cardiovascular Disease and Type 2 Diabetes Mellitus: Development and Usability Study. JMIR Human Factors, 2022, 9, e35065.	2.0	10
1795	More visible greenspace, stronger heart? Evidence from ischaemic heart disease emergency department visits by middle-aged and older adults in Hubei, China. Landscape and Urban Planning, 2022, 224, 104444.	7.5	13
1797	Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial. Antiviral Therapy, 2008, 13, 177-188.	1.0	191
1799	Cardiovascular/Stroke Risk Assessment in Patients with Erectile Dysfunctionâ€"A Role of Carotid Wall Arterial Imaging and Plaque Tissue Characterization Using Artificial Intelligence Paradigm: A Narrative Review. Diagnostics, 2022, 12, 1249.	2.6	5
1800	Associations of Cannabis Use across Adolescence and Early Adulthood With Health and Psychosocial Adjustment in Early Adulthood and Midadulthood in Men. Substance Abuse: Research and Treatment, 2022, 16, 117822182210961.	0.9	1
1801	The effects of sesame, canola, and sesameâ€"canola oils on cardiometabolic markers in patients with type 2 diabetes: a triple-blind three-way randomized crossover clinical trial. European Journal of Nutrition, 2022, 61, 3499-3516.	3.9	2
1802	A Machine Learning-Based Approach for Cardiovascular Diseases Prediction. , 2022, , .		0

#	Article	IF	Citations
1803	Precision prognostics for the development of complications in diabetes. Diabetologia, 2022, 65, 1867-1882.	6.3	21
1804	Development and internal validation of the Edmonton Obesity Staging System-2 Risk screening Tool (EOSS-2 Risk Tool) for weight-related health complications: a case-control study in a representative sample of Australian adults with overweight and obesity. BMJ Open, 2022, 12, e061251.	1.9	0
1805	Direct oral anticoagulants and peripheral arterial disease. , 2022, 1, 76-79.		0
1807	Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe Obesity. Pharmacoeconomics, 0, , .	3.3	0
1808	Disease heterogeneity of adult diabetes based on routine clinical variables at diagnosis: Results from the German/Austrian Diabetes Followâ€up Registry. Diabetes, Obesity and Metabolism, 2022, 24, 2253-2262.	4.4	1
1809	Remotely Conducted App-Based Intervention for Cardiovascular Disease and Diabetes Risk Awareness and Prevention: Single-Group Feasibility Trial. JMIR Human Factors, 2022, 9, e38469.	2.0	3
1810	Healthy Eating Index-2015 and Predicted 10-Year Cardiovascular Disease Risk, as Well as Heart Age. Frontiers in Nutrition, 0, 9, .	3.7	6
1812	Comparison of Three Cardiovascular Risk Scores among HIV-Infected Patients in Korea: The Korea HIV/AIDS Cohort Study. Infection and Chemotherapy, 2022, 54, 409.	2.3	1
1813	PPG-Based Cardiovascular Disease Predictor Using Artificial Intelligence. Advances in Medical Technologies and Clinical Practice Book Series, 2022, , 218-239.	0.3	1
1814	Recognition and Investigation of Covid-19 with Artificial Intelligence and Deep Learning Approaches. International Journal of Advanced Research in Science, Communication and Technology, 0, , 78-84.	0.0	0
1815	Side effects of labor market policies*. Scandinavian Journal of Economics, 2023, 125, 339-375.	1.4	1
1816	Advances in child abuse and neglect research and practice. Child Abuse and Neglect, 2022, 134, 105875.	2.6	1
1817	Providing guideline-recommended preventive cardiovascular care to Aboriginal and Torres Strait Islander women: exploring gender differences with a medical record review in primary health care. Australian Journal of Primary Health, 2022, 28, 498-507.	0.9	1
1818	Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. Cardiovascular Diabetology, 2022, 21, .	6.8	3
1819	MonEco: a Novel Health Monitoring Ecosystem to Predict Respiratory and Cardiovascular Disorders. Irbm, 2023, 44, 100736.	5.6	1
1820	Using Transfer Learning to Train a Binary Classifier for Lorrca Ektacytometery Microscopic Images of Sickle Cells and Healthy Red Blood Cells. Data, 2022, 7, 126.	2.3	0
1821	Do Patients with Atrial Fibrillation and a History of Ischemic Stroke Overuse Reduced Doses of NOACs?â€"Results of the Polish Atrial Fibrillation (POL-AF) Registry. International Journal of Environmental Research and Public Health, 2022, 19, 11939.	2.6	0
1822	Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Translation in to Russian. Digital Diagnostics, 2022, 3, 232-322.	0.6	1

#	Article	IF	Citations
1823	Prediction of COVID-19 Severity Using Patientâ€™s PHR. Smart Innovation, Systems and Technologies, 2023, , 49-56.	0.6	0
1824	Machine learning and automatic ARIMA/Prophet models-based forecasting of COVID-19: methodology, evaluation, and case study in SAARC countries. Stochastic Environmental Research and Risk Assessment, 2023, 37, 345-359.	4.0	15
1827	nn-TransUNet: An Automatic Deep Learning Pipeline for Heart MRI Segmentation. Life, 2022, 12, 1570.	2.4	6
1828	Cardiorespiratory Benefits of Exercise. , 0, , .		1
1829	Role of medicinal plants and their bioactive compounds in obesity, hypertension, and cardiovascular diseases. , 2023, , 469-515.		1
1830	Unexpected high prevalence of metabolic disorders and chronic disease among young male draftees - the Swiss Army XXI experience. Swiss Medical Weekly, 0, , .	1.6	6
1831	Physicians' estimates of the 10 year cardiovascular risk in hypertensive patients: An evaluation in primary care physicians in training. Swiss Medical Weekly, 0, , .	1.6	1
1832	AutoScore-Ordinal: an interpretable machine learning framework for generating scoring models for ordinal outcomes. BMC Medical Research Methodology, 2022, 22, .	3.1	2
1833	Risky business: a single-centre cross-sectional analysis of calculated cardiovascular risk in patients with primary aldosteronism and essential hypertension. BMJ Open, 2022, 12, e062406.	1.9	1
1834	Development and validation of a cardiovascular diseases risk prediction model for Chinese males (CVDMCM). Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
1838	Association between inflammatory biomarker profiles and cardiovascular risk in individuals with and without HIV. Aids, 2023, 37, 595-603.	2.2	5
1839	Framingham Risk Score Inadequately Predicts Cardiac Risk in Young Patients Presenting with a First Myocardial Infarction. Annals of the Academy of Medicine, Singapore, 2010, 39, 163-167.	0.4	28
1840	Drug good registration management to ensure the universal health coverage. Profilakticheskaya Meditsina, 2022, 25, 7.	0.6	0
1841	The association between denture use and cardiovascular diseases. The United States National Health and Nutrition Examination Survey 2009â€“2018. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
1842	Modeling sequential context effects in judgment analysis: A time series approach. Judgment and Decision Making, 2008, 3, 570-584.	1.4	7
1843	Possibilities of Prediction of COVID 19 using K-Nearest Neighbour Algorithm. , 2022, , .		0
1844	Fuzzy AHP point factored inference system for detection of cardiovascular disease. Journal of Intelligent and Fuzzy Systems, 2023, 44, 6655-6684.	1.4	6
1845	â€˜Some of my patients only come to renew their prescriptions. They are not interested in any additional advice or supportâ€™. Physiciansâ€™ perceptions on their roles in cardiovascular diseases risk reduction and management in Fiji. Primary Health Care Research and Development, 2023, 24, .	1.2	0

#	Article	IF	Citations
1846	The Hypertriglyceridemic Waist Phenotype Is Associated with Several Cardiovascular Risk Factors in Women with Rheumatoid Arthritis. Healthcare (Switzerland), 2023, 11, 405.	2.0	0
1847	Multimodal deep learning of fundus abnormalities and traditional risk factors for cardiovascular risk prediction. Npj Digital Medicine, 2023, 6, .	10.9	10
1848	Monitoring Cardiovascular Problems in Heart Patients Using Machine Learning. Journal of Healthcare Engineering, 2023, 2023, 1-15.	1.9	9
1849	The collective vibrational modes of dihydropyridine in nifedipine studied by terahertz spectroscopy. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2023, 292, 122404.	3.9	1
1850	Prediction of complications in health economic models of type 2 diabetes: a review of methods used. Acta Diabetologica, 2023, 60, 861-879.	2.5	2
1852	Spectrophotometric, chromatographic and bioanalysis of selected recently approved drugs from 2015â€“2020 to treat cardiovascular diseases: an analytical review. Bulletin of the National Research Centre, 2023, 47, .	1.8	1
1853	One Heartbeat Away from a Prediction Model for Cardiovascular Diseases in Patients with Chronic Kidney Disease: A Systematic Review. CardioRenal Medicine, 2023, , 109-142.	1.9	0
1854	Critical periods for cognitive reserve building activities for late life global cognition and cognitive decline: the Sydney memory and aging cohort study. Aging, Neuropsychology, and Cognition, 2024, 31, 387-403.	1.3	3
1855	Performance of HIV Infection Prediction Models in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis. Archives of Sexual Behavior, 2023, 52, 2011-2023.	1.9	2
1856	Prognostic models for heart failure in patients with type 2 diabetes: a systematic review and meta-analysis. Heart, 2023, 109, 1436-1442.	2.9	0
1857	Outcomes of ST Segment Elevation Myocardial Infarction without Standard Modifiable Cardiovascular Risk Factors â€“ Newer Insights from a Prospective Registry in India. Global Heart, 2023, 18, .	2.3	0
1858	Reactive Oxygen Species-Responsive Compounds: Properties, Design, and Applications. ACS Symposium Series, 0, , 181-201.	0.5	0
1859	Regression discontinuity design to evaluate the effect of statins on myocardial infarction in electronic health records. European Journal of Epidemiology, 2023, 38, 393-402.	5.7	0
1860	Nightmares: An Independent Risk Factor for Cardiovascular Disease?. Sleep, 0, , .	1.1	4
1861	Breast Cancer Diagnosis Using a Machine Learning Model and Swarm Intelligence Approach. , 2023, , .		1
1863	Overcoming cohort heterogeneity for the prediction of subclinical cardiovascular disease risk. IScience, 2023, 26, 106633.	4.1	1
1864	THE COSTâ€EFFECTIVENESS OF DOXAZOSIN FOR THE TREATMENT OF HYPERTENSION IN TYPE II DIABETIC PATIENTS IN THE UK AND ITALY. International Journal of Clinical Practice, 2001, 55, 84-92.	1.7	3
1865	Discovering Biological Mechanisms of Exceptional Human Health Span and Life Span. Cold Spring Harbor Perspectives in Medicine, 2023, 13, a041204.	6.2	1

#	Article	IF	Citations
1866	Association Between Chronic Hypertension and the Risk of 12 Cardiovascular Diseases Among Parous Women: The Role of Adverse Pregnancy Outcomes. Hypertension, 2023, 80, 1427-1438.	2.7	1
1867	Estrogen Neuroprotective Activity After Stroke and Spinal Cord Injury. Contemporary Clinical Neuroscience, 2023, , 319-332.	0.3	0
1868	Cardiovascular disease (CVD) outcomes and associated risk factors in a medicare population without prior CVD history: an analysis using statistical and machine learning algorithms. Internal and Emergency Medicine, 0, , .	2.0	0
1869	Reference distributions of aortic calcification and association with Framingham risk score. Scientific Reports, 2023, 13, .	3.3	0
1870	Cardiovascular risk in myositis patients compared with the general population. Rheumatology, 2024, 63, 715-724.	1.9	0
1871	Biomarkers of ageing: Current stateâ€ofâ€art, challenges, and opportunities. , 2023, 2, .		6
1872	Cost-utility analysis of diagnostic methods for arterial hypertension in primary care for Brazil: ABPM vs. OBPM vs. HBPM. Blood Pressure Monitoring, 0, Publish Ahead of Print, .	0.8	0
1873	SEXUAL ACTIVITY CARDIOLOGICAL SURVEY ON MEMBERS OF THE ISRAEL HEART SOCIETY. International Journal of Clinical Practice, 2003, 57, 285-288.	1.7	0
1874	Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and Elaboration. Translation into Russian. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 2023, 22, 109-187.	0.4	0
1875	â€˜Inequalities in prevalence of hypertension, prehypertension, anti-hypertensive coverage, awareness, and effective treatment in 429 districts of Iran; a population-based STEPS 2016 small area spatial estimation modelâ€™. Journal of Diabetes and Metabolic Disorders, 0, , .	1.9	0
1876	Major Adverse Cardiovascular Event Risk Prediction in Asian Patients After Myocardial Infarction: A Novel, Dynamic, Machine-learning Approach. , 0, 2, .		0
1877	The Gut-Heart Axis: Updated Review for The Roles of Microbiome in Cardiovascular Health. Korean Circulation Journal, 0, 53, .	1.9	3
1878	Forecasting of COVID-19 Cases Using AI and Real-Time DataSet. Internet of Things, 2023, , 97-110.	1.7	0
1879	Evidence supporting the choice of a new cardiovascular risk equation for Australia. Medical Journal of Australia, 2023, 219, 173-186.	1.7	0
1880	Analysis of quantile graphs in EGC data from elderly and young individuals using machine learning and deep learning. Journal of Complex Networks, 2023, 11, .	1.8	0
1881	Longitudinal Changes in Arterial Stiffness Associated with Physical Activity Intensity: The Toon Health Study. Journal of Atherosclerosis and Thrombosis, 2023, , .	2.0	1
1882	An intelligent hybrid classification model for heart disease detection using imbalanced electrocardiogram signals. Journal of Supercomputing, 2024, 80, 4286-4308.	3.6	1
1883	Development of methodological approaches to the formation of a risk-based model to minimize the prevalence of adverse reactions in drug application in medical organizations of Moscow. Farmakoekonomika, 2023, 16, 248-257.	1.2	0

#	Article	IF	Citations
1885	Derivation and Internal Validation of a <scp>Diseaseâ€Specific</scp> Cardiovascular Risk Prediction Model for Patients With Psoriatic Arthritis and Psoriasis. Arthritis and Rheumatology, 2024, 76, 238-246.	5.6	1
1886	Exhaustion and cardiovascular risk factors: the role of vagally-mediated heart rate variability. Annals of Epidemiology, 2023, 87, 93-99.e2.	1.9	1
1887	Value of Hcy combined with Framingham score for predicting macrovascular disease in elderly patients with type 2 diabetes. Medicine (United States), 2023, 102, e35401.	1.0	0
1889	A Resampling Approach for Causal Inference on Novel Two-Point Time-Series with Application to Identify Risk Factors for Type-2 Diabetes and Cardiovascular Disease. Statistics in Biosciences, 0, , .	1.2	0
1890	Vall dâ€™Hebron Risk Score II for myocardial infarction and cardiac death. Open Heart, 2023, 10, e002431.	2.3	0
1891	Validity of the models predicting 10-year risk of cardiovascular diseases in Asia: A systematic review and prediction model meta-analysis. PLoS ONE, 2023, 18, e0292396.	2.5	0
1892	SCORE and SCORE2 in East AsianÂPopulation. JACC Asia, 2024, 4, 265-274.	1.5	0
1893	Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes. Circulation Research, 2024, 134, 189-202.	4.5	1
1894	Research trends in contemporary health economics: a scientometric analysis on collective content of specialty journals. Health Economics Review, 2024, 14, .	2.0	0
1895	Recalibration of Framingham risk for a local population of Sri Lanka. BMC Public Health, 2024, 24, .	2.9	0
1896	Genetics of Lipid Disorders. , 2023, , 163-195.		0
1897	A Stacked Meta Classifier Approach for Predicting Cardiovascular Diseases. , 2023, , .		0
1898	Major Limitations of Cardiovascular Risk Scores. Cardiovascular Therapeutics, 2024, 2024, 1-6.	2.5	0
1899	Comparing screening based on the NHS Health Check and Polypill Prevention Programmes in the primary prevention of heart attacks and strokes. Journal of Medical Screening, 0, , .	2.3	0
1900	Imaging Biomarkers: Carotid Intima-Media Thickness and Aortic Stiffness as Predictors of Cardiovascular Disease. , 2024, , 323-342.		0